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SUMMARY
Nitric oxide (NO) is a highly reactive signaling molecule that plays diverse and 
important bioregulatory roles. In endothelial cells, NO is synthesized by eNOS, a 
member of the NO synthase (NOS) family, whose activity is tightly regulated at the 
posttranslational level by acylation, phosphorylation, S-nitrosylation and protein-protein 
interactions. The biological actions of NO arise as a direct consequence of chemical 
reactions between NO, or NO-derived species, and protein targets. S-nitrosylation of 
specific cysteine residues in target proteins is emerging as an important mechanism of 
NO signaling. Although eNOS is known to undergo a complex pattern of trafficking 
within endothelial cells, the distinct activities, modes of regulation, and protein targets of 
NO at eNOS-containing organelles are largely unexplored. We hypothesize that eNOS is 
differentially regulated at alternative subcellular loci and NO is preferentially transferred 
to protein acceptors that neighbor NO synthases. To test these hypotheses, we sought to 
develop a conditional heterodimerization approach that can target eNOS, on-demand, to 
discrete subcellular loci (via specific targeting sequences e.g. nuclear, mitochondrial, 
Golgi and cell membrane) and assess the consequences for eNOS activity, regulation and 
protein S-nitrosylation patterns. Furthermore, we sought to devise a proteomic strategy 
for unbiased identification of S-nitrosylation sites on proteins that mediate NO 
bioactivities. Use of these new tools should enable the resolution of controversies 
regarding the role of diffusion in NO biology, as well as the identification of novel 
protein targets and mechanism that regulate NO biosynthesis at distinct loci within 
endothelial cells. In this thesis research, I describe the development and application of 
“eNOS CID” and “SNOSID” as powerful new tools to address the impact of eNOS 
compartmentalization on NO signalling in endothelial cells.
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CHAPTER 1 
MODULATION OF NITRIC OXIDE BIOACTIVITY 
BY THE FAMILY OF NITRIC OXIDE SYNTHASES
1.1 A New Principle: Nitric Oxide
Nitric oxide (NO) is one of the simplest compounds in nature. Discovered by 
Joseph Priestley in 1772, NO is a colorless, highly reactive gas and normally exists for 
only a few seconds inside the body before combining with oxygen to form nitrate. 
Possessing an unpaired electron, it is a highly reactive free radical and was generally 
dismissed as an environmental pollutant throughout the eighteenth, nineteenth and most 
of the twentieth centuries. Its inherent toxicity gave no clues that it might play a crucial 
role as an endogenous mediator of body function. NO is now recognized as a key 
biological mediator with diverse roles in both physiological and pathophysiological 
settings.
Over a quarter of a century ago, a groundbreaking study by Furchgott and 
colleagues revealed that relaxation of blood vessels in response to acetylcholine required 
an intact endothelium (Furchgott & Zawadzki, 1980). Moreover, they concluded that 
acetylcholine, acting via muscarinic receptors on endothelial cells, causes the release of a 
labile substance (or substances) that mediates vascular smooth muscle cell relaxation 
(Furchgott & Zawadzki, 1980). Later this substance was given the name “endothelial- 
derived relaxing factor” (EDRF) (Cherry et a l, 1982). EDRF was found to increase 
levels of cyclic GMP in vascular smooth muscle (Holzmann, 1982), activate guanylate 
cyclase (Forstermann et a l, 1986) and inhibit platelet aggregation (Azuma et a l, 1986). 
Soon after, two gioups simultaneously showed that levels of NO, or an NO precursor,
1
accounted for the biological activities of EDRF (Ignarro et a l, 1987; Palmer et a l, 1987). 
This evidence, coupled with the fact that both NO and EDRF relax vascular smooth 
muscle and are quenched to a similar degree by hemoglobin or superoxide, led to the 
seminal finding that EDRF was NO or a very closely related compounds (Ignarro et a l, 
1987; Palmer et a l, 1987).
Initially, a role for NO in biology was not readily accepted, predominantly due to 
the lack of an identifiable enzymatic pathway for its biosynthesis in mammals. At that 
time, studies involving nitrogen oxides focused primarily on the role of nitrites (NOz ) 
and nitrates (NO3") in the formation of A-nitroso compounds, and their role in cancer 
etiology. The potential reaction of NO2', derived from NO3", with endogenous or 
exogenous amines to form carcinogenic nitiosoamines, raised interest in the origin of 
excreted nitrite and niti'ate. Several groups had observed that humans fed on a low 
protein diet excreted more urinary NO3 than was ingested (Green et a l, 1981; 
Tannenbaum et a l, 1978). Early studies suggested that the excess urinary NO3' secretion 
in mammals was a result of denitrification reactions involving enteric bacteria (Green et 
a l, 1981). However, in studies comparing germ-ffee and conventional rats. Green and 
colleagues precluded the role of intestinal microflora and concluded that NO3' 
biosynthesis was via a mammalian pathway (Green et a l, 1981). Interestingly, mice 
treated with Escherichia coli-derived lipopolysaccharide (LPS), revealed an approximate 
10-fold increase in urinary NO3' and further investigations identified macrophages as the 
major source (Stuelir & Marietta, 1985; Wagner et a l, 1983).
Cytotoxin-activated macrophages were implicated in the metabolic inhibition of 
tumor target cells via an L-arginine-dependent effector mechanism. Moreover, the 
findings revealed L-arginine as the precursor for NOs'/NOz' biosynthesis in macrophages
(Hibbs et a l, 1987). These findings, coupled with stable isotope studies showing that the 
nitrogen atoms of nitiogen oxides were derived from one of the equivalent guanido 
nitrogens of L-arginine and resulted in L-citrulline as a co-product, helped identify a 
metabolic pathway for NO synthesis (Iyengar et a l, 1987). Signal transmission by a gas, 
produced by one cell, which penetrates membranes and regulates the function of other 
cells, was an entirely new principle for signaling in mammalian organisms. Evidence 
now demonstrates the involvement of NO in a wide array of fundamental processes 
including regulation of vascular tone (Furchgott, 1988; Ignarro et ah, 1987; Palmer et ah,
1987), platelet aggregation (Azuma et a l, 1986), penile erection (Argiolas, 1994), host 
defense (Hibbs et a l, 1987; Hibbs et a l, 1987; Iyengar et a l, 1987; Marietta et a l,
1988), inflammation (Harbrecht et a l, 1995; Tiao et a l, 1994), neurotransmission (Bredt 
et a l, 1990) and hormone release (Rettori et a l, 1993; Seilicovich et a l, 1995). 
Dysregulation of NO synthesis has also been implicated in several disease states such as 
septic shock (Wolfe & Dasta, 1995), diabetes (Williams et a l, 1996), Parkinson’s and 
Alzheimer’s diseases (Beal, 1998; Canals et a l, 2003; Kuiper et a l, 1994) and 
atherosclerosis (Wilcox et a l, 1997). The dichotomous nature of NO is thus dependent 
on numerous factors such as NO concentration, duration of production and the 
composition of the surrounding microenvironment.
In a little over 20 years, scientists from several different fields combined their 
efforts to study a common pathway and proved that NO is a unique biomolecule essential 
in the regulation of cellular function. This discovery was recognized in 1998 with the 
Nobel Prize in Physiology or Medicine to Drs. Furchgott, Ignairo and Murad.
1.2 Nitric Oxide Synthases
Nitric oxide is synthesized in mammalian cells by a family of three NO synthases 
(NOSs) which all utilize the cofactor NADPH, and the cosubstrates arginine and O .^ 
Mammalian NOSs comprise three isoforms that are 50-60% homologous and are the 
product of distinct genes. Each isoform is distinguished from its sister isoform by its 
structure, function, mode of regulation and intracellular localization (Table 1.1) (for 
review see (Stuehr, 1999)). All tliree aie functionally categorized by whether their 
expression is constitutive or inducible.
Two of the three isoforms are constitutively expressed (cNOSs) in specific cell 
types where their activity is tightly regulated by changing levels of intracellular calcium, 
although in some cases, such as that observed in response to hemodynamic shear stress, 
the activity is independent of the intracellulai* calcium concentration (Fleming et al., 
1998). The constitutive enzymes are termed endothelial NOS (eNOS ~130kDa) and 
neuronal NOS (nNOS --'IbOkDa), reflecting the tissue from which they were originally 
isolated, bovine endothelial cells and rat neurons, respectively. The activity of cNOSs is 
dependent on the transient binding of calcium/cahnodulin (Ca"^/CaM) subsequent to an 
agonist-induced increase in intracellular calcium levels. The pulsatile production of NO 
attributed to these isoforms, suits their signaling role in cells and tissue.
The third isoform, inducible NOS (iNOS ^130kDa) is constitutively expressed 
only in select tissues, for example lung epithelium, and is more typically induced in
Table 1.1. Nitric Oxide Synthase Family of Enzymes. Table summarizes the 
protein-protein interactions, subcellular distribution, transcriptional and post- 
translational regulation of the NOS family of enzymes. eNOS and nNOS are 
constitutively expressed in response to rising calcium tiansients whereas iNOS is 
induced in response to inflammatory cytokines.
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response to inflammatory or proinflammatory mediators. Unlike the cNOSs, iNOS 
contains tightly bound calmodulin which allows the enzyme to be active at all levels of 
intracellular calcium (Cho et al., 1992). The activity of iNOS is regulated by protein 
degradation and substrate/cofactor availability. The constant high output production of 
NO by iNOS plays an important role in host-defense and modulating the immune 
response, but its expression has also been linked to a number of inflammatory diseases.
Despite these differences, all three proteins share the same basic overall structure. 
The NOSs are divided into distinct reductase and oxygenase domains (Fig. 1.1). Between 
these domains, there is an approximate 30 amino acid recognition sequence for the 
calcium binding protein, calmodulin (CaM). The oxygenase domain (amino acids 1-491 
in murine iNOS) binds heme, zinc, the cofactor tetrahydrobiopterin (BHJ, L-aiginine, and 
forms the active site where NO synthesis occurs. The reductase domain (amino acids 512- 
1205 in iNOS) binds FAD, FMN and NADPH. During NO synthesis the reductase flavins 
acquire electrons from NADPH and channel them to the heme group, where NO 
production from L-arginine is catalyzed. The binding of CaM to its binding site (amino 
acids 492-512 in iNOS) enables the electron transfer from the reductase domain to the 
oxygenase domain, thus activating NO synthesis.
NOSs are obligate homodimers and electron transfer occurs in a trans manner 
between the flavin and heme of opposite subunits of the dimer. All three NOSs have 
important biochemical characteristics in common -  they catalyze a five-electron oxidation 
of one of the equivalent guanido nitrogens of L-arginine to form an NO radical and L- 
citrulline (Nathan & Xie, 1994). One catalytic turnover requires 1.0 molecule of dioxygen 
and 1.5 molecules of NADPH (Fig. 1.2).
C aM  domain Reductase domain COOH
^  — >* (DS  Q.
NH,
1
,1 BH4 1 Heme I Arginine r CaM up1 499 518
. j Heme 1 Arginine r CaM
COOH eNOS
221 724 757
15 742
949 980
1153
j -  COOH nNOS 
1433
NH Heme Arginine CaM COOH iNOS
504 537 687 716 1203
Figure 1.1. Domain Structures of Human Nitric Oxide Synthases. The diagram shows the division of 
NOSs into distinct oxygenase and reductase domains. The numbered amino acids denote the start and end of 
each domain. Comparison of the eNOS and nNOS structures reveals lack of homology at the N-terminus. 
The PDZ domain of nNOS contains a GLGF repeat and eNOS contains acylation sites that are critical in the 
subcellular localization and thus function of the enzyme. Abbreviations: myr, myristoylation; palm, 
palmitoylation; NH2 , amino terminus; COOH, carboxyl terminus.
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1.3 NOS Catalysis: Role of Cofactors and Prosthetic Groups
Reductase Domain Flavins
The role of flavins in NOS catalysis has been well established. Much like the 
cytochrome P450 family of enzymes, FAD and FMN are tightly bound within the 
reductase domain of NOS and serve to store and channel NADPH-derived electrons to 
the heme group within the oxygenase domain active site. In turn, the heme has an 
essential redox role in the activation of molecular oxygen to generate the ultimate oxidant 
(Fig. 1.3).
Heme
NOSs contain a ferric heme iron that is ligated axially with a cysteine thiolate 
(Stuehr & Ikeda-Saito, 1992). In enzymatic assays where the heme-binding agents CO, 
NO, KCN and miconazole were used, the L-citiulline-producing ability of NOSs was 
significantly diminished (-80%) (Klatt et a l, 1992; McMillan et a l, 1992; Stuelir & 
Ikeda-Saito, 1992; Wliite & Marietta, 1992).
Figure 2.1 describes the two-stage mono-oxygenase reaction catalyzed by the 
NOSs. Obseiwations made independently by Feldman et ah and Pufahl and Marietta, 
showed that the NOS heme catalyzed the N-hydroxylation of L-arginine to N“-hydroxy 
L-arginine (NOHA) at the expense of two electrons donated by NADPH {step I) 
(Feldman et a l, 1993; Pufahl & Marietta, 1993). In step II NADPH contributes one 
electron to the three-electron oxidation of NOHA to fonn citrulline and NO. Step I  
represents a simple hydroxylation reaction characteristic of P450 catalyzed oxidation 
reactions, however, step II  appears to be a unique chemistry carried out by the NO
10
synthases (Griffith & Stuehr, 1995). Studies have emphasized the importance of the 
protoporphrin IX heme group in NOS catalysis.
(6R)~5,6,7,8-tetrahydro-L-biopterin (BH4)
NOSs are unique amongst flavoheme proteins as they contain tightly bound BH4, 
a required cofactor for NOS catalysis (Hevel & Marietta, 1993; Kwon et al, 1989; Mayer 
et a l,  1991). Initially, BH4 was anticipated to flmction in a mamier analogous to the 
hydi'oxylations catalyzed by the aromatic amino acid hydroxylases. Tryptophan, tyrosine 
and phenylalanine hydroxylases each utilize BH4 as an electron source and prior to the 
discovery of a heme cofactor in NOSs, this utilization also seemed plausible for NOSs 
(reviewed in (Griffith & Stuehr, 1995)). Instead it was suggested that BH4 is more likely 
to support an allosteric or structure-stabilizing role during NOS catalysis (Giovanelli et 
al,  1991).
The structural role for BH4 was evident in a study where the co factor was shown 
to facilitate iNOS dimer assembly (Ghosh & Stuehr, 1995). Despite these observations, 
the finding that recombinant NOS’s can be purified as dimers in the absence of BH4 
precluded an essential role for the cofactor in dimerization (Klatt et al,  1995; Rodriguez- 
Crespo et a l,  1996). Even so, BH4 contributes significantly to the stmctural stabilization 
of active homodimers of iNOS, nNOS and, to a lesser extent, eNOS (Klatt et al, 1995). 
Consistent with an allosteric role, BH4 binding increases NOS’s affinity for arginine or 
its structural analogs (Klatt et al, 1994; Liu & Gross, 1996).
Elucidation of the crystal structures for eNOS (Fischmann et a l,  1999; Raman et 
al,  1998), nNOS (Raman et a l,  2000) and iNOS (Crane et a l,  1998) (Fig. 1.4)
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Arginine + O Citruiiine + NO
NADPH FAD FMN
Reductase Domain Oxygenase Domain
Figure 1.3. Schematic representation of the reaction catalyzed by NOS. NOSs are obligate 
homodimers. Electrons are channeled in trans from the reductase domain of one subunit to the 
oxygenase domain of the companion sub-unit of the NOS homodimer.
1?
oxygenase domains revealed an almost identical mode of BH4 binding and substrate 
recognition. The relatively remote location of BH4 from the nitrogen in arginine that 
undergoes hydroxylation within NOS’s active site excluded a role for BH4 in the 2-step 
mono-oxygenase reaction. However, structurally the pyrimidine ring of BH4 couples 
with a heme carboxylate enabling electron transfer from BH4 to the heme iron by virtue 
of hydrogen bonds (Fig, 1.5) (Gross et a l, 2000). The redox role of BH4 was further 
supported by experiments showing that dihydropterin and redox-null tetrahydiopterins do 
not support NOS catalysis (Presta et a l,  1998). Also noteworthy was the key finding that 
BH4-deficient NOSs produce superoxide (O2 ) rather than NO (Vasquez-Vivar et a l, 
1998). The functional role of BH4 is slowly coming into focus fueled by recent studies 
suggesting a dual redox role for the cofactor. Results suggest, that BH4 acts as an 
electron donor for the oxidation of L-arginine and NOHA (in two sequential steps), the 
resulting BH4+* could in turn act as an electron acceptor and be reduced by the NOS 
flavins (Equation 1). These events would ensure the release of NO and not nitroxyl (NO' 
) (Hurshman et al., 1999; Wei et a l, 2003; Wei et a l, 2003).
Equation 1.
N G H A  N O H A
H4B
O2 l A
— F |6 ----------- ► —Fje"'— ---^ — ►
s S
N O H A 2-
0o' F a s fF|8"'
s
i n t e r m e d i a t e s
H 4 B *  H 4 B  +  c i t r u l l i n e  +  N O
S U .  "
s
1.4 Protein S-nitrosylation as a Mediator of NO Actions
The contribution of NO to an airay of cellular functions has captured our 
imagination and sparked immense interest from scientists. The dogmatic view has been
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that NO travels down concentration gradients to exert its effects (Lancaster, 1994; 
Stamler, 1996). Kinetically, this suggests that NO travels to extracellular targets much 
faster than it can react with targets proximal to the source of NO within a cell. NO- 
mediated vasodilation depends principally on nitrosylation of the heme-iron in soluble 
guanylate cyclase (sGC), resulting in enzyme activation and intracellular cGMP 
accumulation. However, unlike vasorelaxation, which is substantially blocked by sGC 
inhibitors and stimulated by non-hydrolyzable cGMP analogs (8-bromocGMP), many 
of the other vascular (and non-vascular) effects of NO are independent of sGC (Stamler 
et a l, 1997). Indeed, many biological actions of NO involve the formation of protein 
nitrosothiols (SNOs), a process termed S-nitrosation or S~nitrosylation. NO also 
readily reacts with transition metals to form metal nitiosyl adducts (MNO). Both SNO 
and MNO modifications provide a mechanism for targeted NO delivery to both remote 
and contiguous targets.
S-niti’osylation of cysteine (Cys) residues in target proteins was first recognized 
in 1992, when micromolar levels of SNO-albumin were reported to circulate in blood 
(Stamler et a l, 1992). Since then, important physiological roles have been ascribed to 
S-nitrosylation (for an extensive review see (Martinez-Ruiz & Lamas, 2004; Stamler et 
a l, 2001)). The list of NO targets includes, ion-channels, transporters, structural 
proteins, kinases, phosphatases, metabolic enzymes, signaling proteins, respiratory 
proteins, transcription factors and redox enzymes (Stamler et a l,  2001). Once formed, 
the nitroso-moiety of the nitrosothiol can be transferred to other thiols through a 
process termed transnitrosylation. Transniti'osylation allows for NO groups to be 
transferred from protein to protein, in addition to low molecular weight thiols (e.g.
1A
glutathione) before undergoing terminal oxidation to b io logica lly  inert N O 2 ' and N O 3 '.
1.4.1 ^-Nitrosylation and O-Phosphorylation: Analogous Modifications 
Tête-à-tête
S-nitrosylation of Cys residues in protein targets is emerging as a 
posttranslational control mechanism for many proteins, akin to 0-phosphorylation (see 
(Lane et ah, 2001)). Serine, tlireonine and tyrosine residues in proteins are modified by 
the covalent addition of a phosphoryl group (PO3) during phosphorylation reactions. 
Analogous to this, during S-nitrosylation (or trans-nitrosylation), proteins are modified 
by covalent linkage of NO to Cys residues or metals. Both phosphorylation and S- 
nitrosylation are spatially and temporally controlled events, ensuring tight regulation of 
signaling pathways that impact cellular fonction. However, first appearances can be 
misleading. Whereas phosphorylation and dephosphorylation are tightly regulated by 
enzyme-catalyzed reactions that require an intimate relationship between substiate and 
enzyme, S-nitrosylation and denitiosylation are modifications that occur in solution 
phase via chemical reactions involving diffiisible molecules (Pawloski et ah, 2001). In 
fact, it is precisely the ability of S-nitrosylation to occur in solution-phase that provides 
an extra level of control via intracellular redox mechanisms, not extended to 
phosphorylation (Lane et a l, 2001).
S-NO Environment and S-NO M otif
Primary amino acid sequences of proteins often reveal traits or motifs that suggest 
potential posttranslational modifications (e.g., glycosylation, prénylation and
17
phosphorylation). If we consider phosphorylation, there are amino acids that flank 
serine, threonine and tyrosine residues that identifies them as sites of phosphorylation and 
dephosphorylation to an ever-growing family of protein kinases and phosphatases. The 
same may be true for S-nitrosylation. Indeed, in a comprehensive review, Stamler and 
colleagues identify an acid/base consensus sequence (X(K,R,H)C(D,E)), based on 
proteins where the modified cysteine is known (Stamler et a l, 1997). The most 
significant feature of this motif is an acidic amino acid (aspartate or glutamate) directly 
following the target cysteine (Stamler et a l, 1997) that catalyzes S-nitrosylation (Fig. 
1.6). In cases where known NO-modified cysteines do not fit the acid/base mould, it has 
been suggested that the microenvironment of the cysteine within the folded protein 
structure, may make the cysteine susceptible to S-nitrosylation (Lane et a l, 2001).
1.5 Neuronal Nitric Oxide Synthase (nNOS)
Neuronal NO synthase (nNOS, NOSI) was isolated as a Ca'^VCalmodulin- 
requiring enzyme from rat cerebellum (Bredt et a l, 1990; Bredt & Snyder, 1990), where 
NO apparently mediates synaptic signaling, plasticity, learning and memory (Bredt & 
Snyder, 1994). Non-neuronal nNOS has also been identified in skeletal muscle 
(Brenman et a l, 1995), cardiac myocytes (Xu et a l, 1999) and the adventitia of a subset 
of neuronal blood vessels (Nozaki et a l, 1993). The diverse distribution of nNOS in 
mammals can be explained by the identification of posttranscriptional nNOS mRNA 
splice variants that lead to four distinct peptides named nNOSa, nNOSp, nNOSy and 
nNOSp (Fig. 1.7) (Wang et a l, 1999). Each splice isoform has distinct tissue and 
subcellular distribution and may engage in unique complex physical interactions with a
18
Deiiitrosylatioii
His
Nitrosylation
Figure 1.6. Add-Base Catalysis of S-nitrosylation and Denitrosylation of 
Hemoglobin Cys-^93. Transnitrosylation of Cys-|393 in human hemoglobin by the 
intermediary nitrosothiol, R-S-NO, is catalytically assisted by neighboring Histidine and 
Aspartate residues acting as base and acid, respectively.
IQ
range of cellular proteins.
1.5.1 Protein-protein Interactions
Unlike eNOS and iNOS, nNOS has an extended N-terminus (300 amino acids) 
and residues 18-97 encode a PDZ (post synaptic density protein-95/93, disc-large ZO-1) 
domain (Hendriks, 1995) whose interaction dictates the confinement of nNOS to discrete 
spatial regions within a cell, restricting protein-protein interactions, A survey of 
recognized protein-protein interactions involving nNOS is provided in Figures 1.8 and 
1.9 and discussion below.
Dystrophin
In skeletal muscle, nNOSp-derived NO targets sGC in the smooth muscle layer of 
adjacent blood vessels leading to vessel relaxation (Persson et a l, 1990). NO derived 
from this pathway serves to regulate the active muscle’s need for oxygen/nutrients by 
controlling local blood flow.
The PDZ domain anchors nNOS p. to integral cytoskeletal and membrane proteins 
in skeletal muscle. Genetic approaches revealed that, at the sarcolemma, nNOSp 
interacts with the dystrophin glycoprotein complex, a family of proteins known to be 
mutated in Duchenne’s and other inherited dystrophies (Bonnemann et a l, 1996; 
Campbell, 1995). Within the dystrophin complex, the nNOSp PDZ-domain specifically 
interacts with ai-syntrophin, an association that is vital for membrane association of
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nNOSp and regulation of muscle contraction (Brenman et a l, 1996).
A dismpted dystrophin complex observed in muscular dystrophies results in a 
selective loss of nNOSp in skeletal muscle tissue that impairs local blood flow (Grange et 
a l, 2001). Evidence suggests that while the absence of nNOSp (and thus NO) at the 
sarcolemma does not itself lead to symptoms of muscular dystiophy, the presence of 
nNOSp in muscular dystrophies appears to ameliorate muscle pathophysiology (Chao et 
a l, 1996; Chao et a l, 1998; Crosbie et a l, 1998; Grady et a l, 1999). These findings 
suggest potential therapeutic avenues to treat pathophysiological symptoms of muscular 
dystrophies using tissue specific NO-donors.
Caveolin~3
The association of caveolin-3 with the dystrophin complex at the sarcolemma of 
skeletal muscle hinted that an interaction between nNOS and caveolin-3 may occur (Song 
et a l, 1996). In 1997, Venema and colleagues provided the first evidence for a direct 
physical interaction between caveolin-3 and nNOS (Venema et a l, 1997). The interaction 
of nNOS with caveolin-3 appears to be independent of its association with ai-syntrophin, 
but does involve the two scaffolding domains of caveolin-3 -  one on the N- and one on the 
C-terminus (Venema et a l, 1997). Furthermore, the intimate relationship between nNOS 
and caveolin-3 at the sai’colemma appears to attenuate nNOS activity (Venema et a l, 
1997).
Phosphofructokinase-M
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Direct interaction between the nNOS PDZ-domain and the muscle isoform of 
phosphofmctokinase (PFK-M), the rate-limiting enzyme in glycolysis, was demonstrated 
in both skeletal muscle and neurons (Firestein & Bredt, 1999). At the cellular level, 
neurons expressing nNOS additionally co-express PFK-M. In tissues, PFK and nNOS are 
highly associated in the cytosol (skeletal muscle) and synaptic vesicles of neuronal cells 
(Firestein & Bredt, 1999). In neurons, the nNOS-PFK-M complex regulates intracellular 
levels of the glycolytic intermediate, fructose-1,6-bisphosphate, which has been shown to 
have neuroprotective properties (Sola et a l, 1996).
Carboxy-terminal PDZ Ligand o f  nNOS (CAPON) and the NMD A Receptor
In neurons, direct PDZ-PDZ interactions between nNOS and the postsynaptic 
density 95 protein (PSD95) and the related protein PSD93, localize nNOS to complexes 
containing the N-methyl-D-Aspartate (NMDA) glutamate receptor. The presence of 
nNOS at the post-synaptic density and the indirect association of nNOS with the NMDA 
receptor, presumably allows NMDA receptor channel-derived Ca"^ entry to efficiently 
trigger nNOS activation and NO release. NO released at the post-synaptic density acts as 
a retrograde messenger and signals via activation of sGC on the presynaptic terminal 
(Boulton et a l, 1994; Boulton et a l, 1995; Haley et a l, 1992; Shibuki & Okada, 1991). 
The regulation of membrane-anchored nNOS is multifaceted and appears to be mediated 
by several protein-protein interactions.
Using a yeast two-hybrid screen designed to identify nNOS-binding partners, 
Jaffi'ey and colleagues identified CAPON (carboxy-tenninal PDZ ligand of «NOS), an 
adaptor protein that competes with PSD95 for binding to the PDZ domain of nNOS
91
(Jaffrey et al., 1998). Studies suggest that CAPON binding to the PDZ domain, moves 
nNOS away from the vicinity of the NMDA receptor and thus attenuates nNOS activity by 
limiting access to fluxes of C a^  (Jaffrey et al., 1998). A secondary role for CAPON, 
involves its N-terminal phosphotyrosine-binding (PTB) domain. CAPON interacts with 
synapsin I via its PTB and the ternary complex formed between nNOS-CAPON-synapsin 
I, seiwes to target nNOS to the presynaptic membrane. This indicates that the precise 
targeting of NO to specific presynaptic compartments selectively regulates the function of 
the synapsin family of proteins (Jaffrey et a l, 2002).
Protein Inhibitor o f  nNOS (PIN-1)
Protein inhibitor of nNOS (PIN-1) is an approximately 8 kDa dynein light chain 
protein discovered using a yeast two-hybrid screen of a rat hippocampal cDNA library 
(Jaffrey & Snyder, 1996). PIN-1 selectively inhibits iiNOS by disrupting the catalytically 
essential nNOS dimer (Jaffrey & Snyder, 1996). The specificity of PIN-1 for nNOS 
derives from its binding to the N-terminal Met 228 -  His 244, a region absent in eNOS 
and iNOS (Fan et a l, 1998). In contrast to the findings of Jaffrey and Snyder, one study 
demonstrated that the association of PIN-1 with nNOS does not interact at the nNOS 
monomer-monomer interface and does not affect nNOS catalytic activity (Rodriguez- 
Crespo et al., 1998). However, a recent study confirmed that PIN-1 not only attenuates 
iiNOS-derived NO, but also nNOS-derived superoxide (O2 ), independent of nNOS dimer 
decomposition (Xia et a l, 2006). These discrepancies suggest that nNOS regulation by 
PIN-1 is complicated and additional details are required to elucidate the precise 
mechanism.
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Adapted from Mungrue and Bredt, 2004
Figure 1.9. nNOS distribution and function in cardiac myocytes. nNOS is thought to associate 
with the ryanodine receptor at the sarcoplasmic reticulum where NO production acts to enhance 
calcium release and cardiac contractility. Abbreviations: LCC, L-type calcium channel; RyR, 
ryanodine receptor; SERCA, sarcoplasmic reticulum Ca^^-ATPasc.
Ryanodine Receptor
An interaction between nNOSp, and the lyanodine receptor has been suggested in 
cardiac myocytes (Sears et ah, 2003). nNOS plays a key, yet complex, role in cardiac 
myocytes and has been shown to regulate calcium dynamics via NO-induced activation of 
the ryanodine receptor, inhibition of L-type calcium channels and inhibition of 
sarcoplasmic reticulmn Ca^-ATPase (SERCA) (Sears et a l, 2003). In a clinical setting, 
patients suffering from many of the muscular dystrophies often present cardiac 
complications (Emery, 2002) and this has been linked to decreased levels of cardiac nNOS 
(Bia et a l, 1999). Although its exact role remains undefined, it is evident that the 
presence of nNOS in cardiac tissue has significant clinical implications and warrants 
detailed investigation.
1.5.2 Posttranslational Modifications
nNOS Mediated S-nitrosylation o f the NMDA Receptor and Dexrasl
As mentioned above, nNOS-derived NO synthesis in neurons is coupled to 
calcium release by the NMDA receptor (Bredt & Snyder, 1989; Garthwaite & Boulton, 
1995). NMDA receptors are located at the postsynaptic density (PSD) of excitatory 
synapses and are essential in long-term potentiation (LTP) (Moriyoshi et a l, 1991). The 
association of nNOS with the NMDA receptor is via the scaffold-protein PSD95 and 
occurs through interactions of each protein with a distinct PDZ domain of PSD95 (Fig. 
1.10) (Brenman et a l, 1996; Christopherson et a l, 1999). The NMDA-PSD95-nNOS 
ternary complex ensures efficient signal transduction by nNOS, following a transient 
increase in intracellular calcium arising from NMDA receptor activation (i.e. channel
97
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Figure 1.10. PDZ signaling complexes that define activation and targeting of 
nNOS-derived NO. The figure shows the fate of NO produced in response to 
NMDA reeeptor aetivation. NO diffuses to presynaptie nerve terminals and 
nitrosylates both the NMDA receptor and Dexrasl associated with CAPON. 
Abbreviations: Arg, arginine; CaM, calmodulin; GK, guanylate kinase domain.
opening). Interestingly, in this setting, nNOS-derived NO has been shown to S-nitrosylate 
Cys399 on the NMDA receptor, a modification that renders the channel inactive (Choi et 
a l, 2000; Lipton et a l, 1993). Mechanistically, S-nitrosylation of this site is thought to be 
an important mediator of receptor desensitization.
Analysis of the structure of CAPON revealed an N-terminal PTB domain. The 
PTB domain has been shown to associate with the monomeric G-protein, Dexrasl 
(Wehling et a l, 2001) and further investigations revealed that NO can activate Dexrasl 
via S-nitrosylation of a single cysteine residue at position 11 (C ysll) (Fang et a l, 2000; 
Jaffrey et a l, 2002). C ysll is located within the N-terminal domain but the functional 
significance of this domain is, as yet, unknown. Conceivably, modification via S- 
nitrosylation induces a confoimational change within the protein Üiat promotes the 
dissociation of GDP and favor binding of GTP, thus activation Dexras (Jaffrey et a l, 
2002). The physiological implications of Dexrasl S-nitrosylation are apparent in nNOS 
null mice (nNOS-/-), where there is a selective decrease in Dexrasl activation. Notably, 
other members of the Ras family were not affected by nNOS gene knockout (Fang et a l, 
2000). These observations, coupled to the NMDA receptor studies described above, 
suggest that the assembly of nNOS signaling complexes determine the activation and 
targeting of NO and are essential for the physiological regulation of specific signaling 
proteins, such as Dexrasl (Fig. 1.10).
1.6 Inducible Nitric Oxide Synthase (iNOS)
1.6.1 Innate Immune System
9Q
The innate immune system is an ancient form of an organism’s host defense that 
most likely appeared early in evolution. Innate immunity is the body’s first line of 
defense to pathogenic invasion. The cells of the innate immune system have evolved 
pattem-recognition receptors on their surface to identify pathogen-associated structures, 
such as bacterial lipopolysacharides. During infection, many of the important effector 
cells of the imiate immune system, such as macrophages, neutrophils, dendritic cells and 
B-cells, compile a host response by releasing mediators (e.g. chemokines and cytokines) 
that rapidly perform their effector functions (i.e. host-defense). NO is an important 
effector molecule of the imiate immune system and is released by macrophages during 
pathogenic invasion.
1.6.2 YES to NO as an Anti-microbial Effector
Akin to oxygen and its reactive intermediates, there are five cardinal hallmarks that 
classify NO as a macrophage-derived anti-microbial effector (Nathan, 1983). Thus studies 
in mice establish that {1) resistance of the host to microbial infection is concomitant with 
increased iNOS expression, {2) infection is enhanced by treatment with iNOS inhibitors, 
{3) anti-microbial effects are elicited by exogenous NO administration, {4) host resistance 
to infection is decreased in iNOS-/- mice, and (5) infection is enhanced by microbial 
overexpression of proteins that protect against NO toxicity. Together, these five 
observations reveal a seminal role for NO in host-defense.
1.6.3 Regulation of INOS and The Immune Response
in
Inducible NOS (iNOS, NOSII) is the enzyme isofomi that releases large amounts 
of NO for host defense (for review see (Lowenstein & Padalko, 2004)). Notably, iNOS 
protein has been localized to lung epithelial cells, vascular smooth muscle cells, pancreatic 
(3-cells, hepatocytes and most importantly, macrophages. iNOS sustains NO production 
for a time-span ranging from a few hours to many days (MacMicking et ah, 1997). The 
prolonged NO release contiibutes to the destruction of both pathogens and host cells. The 
high-output of NO by iNOS is a hallmark feature of this isoform.
Resting cells of the innate immune system do not express iNOS constitutively. An 
immune reaction is mounted in response to extracellular insults such as lipopolysaccharide 
(LPS) (the cell wall component of Gram-negative bacteria), or proinflammatory cytokines 
such as interferon-y (IFN-y), tumor necrosis factor-ct (TNF-a) and interleukins 1 and 2 
(IL-1/-2) (for review see (MacMicking et a l,  1997)). These stimuli then initiate signaling 
events that ultimately result in iNOS induction and NO release. Some cells, such as 
normal human lung epithelial cells, may express iNOS constitutively given their constant 
exposure to LPS, ozone and other potential proinflammatory stimuli (Guo et a l, 1995).
Signaling Pathways: The Players
The pathway of LPS-induced iNOS expression has been well characterized and 
involves several key players. Upon entry into the circulation, LPS is rapidly bound to a 
serum protein, LPS-binding protein (LBP), which transfers the LPS to CD 14 on the 
surface of mononuclear cells (macrophages and B-cells) (Schumann et a l, 1990). The 
LPS-CD14 complex is then recognized by the toll-like receptor 4 (TLR4), with the aid of
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the small adapter protein, MD2 (myeloid differentiation protein-2) (Shimazu et a l, 1999). 
The association of CD 14, TLR4 and MD2 initiates an intracellular cascade via IRAK 
(interleukin-1 associated kinase) and myeloid differentiation factor-88 (Myd88) (Muzio et 
a l , 1998). Subsequent signaling pathways, via either the mitogen activated protein kinase 
(MAPK) (Kristof et a l, 2001) or the nuclear factor kB (NF-kB) pathway (Xie et a l, 
1994), lead to transcriptional activation of iNOS (Fig. 1.11). Concomitantly, cytokines 
like interferon-y can bind to interferon-1 and interferon-2 receptors and initiate iNOS 
transcription independently, via the janus kinase-signal transducer and activator of 
transcription (Jak/STAT) pathway (Fig. 1.11) (Darnell et a l, 1994). Even though the 
Jak/STAT and NF-KB pathways appear to be the central players targeted by many iNOS- 
inducing compounds, several other signaling molecules can activate or attenuate iNOS 
expression including NO itself, protein kinase A (PKA), protein kinase C (PKC), protein 
kinase G (PKG), phospholipase Az (PLA2), poly(ADP-ribose) polymerase-1 (PARP-1) 
and phosphatidylinositol 3 kinase (PI-3K) (reviewed by (Bogdan, 2001; Coleman, 2001)).
Transcriptional Regulation: A Multifaceted Affair
Regulation of iNOS expression was extensively reviewed by Kleinert and 
colleagues (Kleinert et a l, 2003). The complex structure of the mouse iNOS enhancer- 
promoter sequence hinted towards a convoluted regulation by numerous transcription 
factors. As described above, several prominent cytokines (e.g. TNF-a, IL-1 and IFN-y), 
as well as endotoxins (e.g. LPS), initiate distinct signaling pathways, either individually or 
synergistically, that converge and induce iNOS transcription. Interestingly, in vitro
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studies demonstrated that iNOS expression is upregulated when cells are subjected to 
multiple stimuli rather than a single extracellular stimulus.
Analysis of the primary sequence of the iNOS promoter revealed consensus- 
binding sites for several transcription factors that are known to be regulated by the 
LPS/cytokine pathway. These include, activating protein-1 (AP-1), NF-kB, interferon 
regulatory factor-1 (IRF-1), signal transducer and activator of transcription (STAT-la), 
cAMP-responsive element binding protein (CREB), peroxisome proliferator-activated 
receptor (PPAR), hypoxia inducible factor-la (HIF-la), octamer factor (Oct) and non­
histone high mobility group protein I(Y) (HMG-I(Y)) (reviewed by (Kleinert et a l, 
2004)). It is important to note that the tianscription factors mentioned have each been 
shown to regulate human, rat or murine iNOS promoter activity in different cell systems. 
Once expressed, iNOS releases NO immediately, unless substrate is unavailable, and 
enzymatic activity is sustained until the protein is degraded. Targets of iNOS-derived NO 
are discussed below.
1.6.4 Fate of iNOS-Derived NO
Anti-Microbial Effects o f  NO: Menace or Mai'vel?
At 30 Da, NO is certainly one of the smallest and simplest biosynthetic molecules 
found in nature. NO, compared to other free radicals, is relatively inert. However the 
reaction of NO with O2 or 0%, leads to the formation of higher, and in some cases more 
reactive oxides of nitrogen such as nitrogen dioxide (N02), dinitrogen trioxide (N2O3) and 
peroxynitrite (ONOO ). NO can react with thiol gioups (SH) to form an RSNO molecule 
that releases an electron-deficient nitrosonium ion (NO^. These intermediate species
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account for the oxidative, nitrosative and nitrative properties often attributed to NO. For 
simplicity, in this thesis the term “NO” refers to nitric oxide and any of its derived species.
The role of NO in the pathogenesis of infection has been intensively studied over 
the past 20 years. During septic shock, the excessive NO produced following cytokine- 
induced iNOS expression leads to vasodilation, hypotension, vascular collapse, multiple 
organ failure and ultimately death. Conversely, the microvascular, immunoregulatory and 
anti-microbial properties of iNOS-derived NO have a protective role in host defense. The 
anti-microbial properties of NO differ depending on the invading pathogen.
Bacteria
As an anti-bacterial agent, NO targets ribonucleotide reductase, inhibiting DNA 
synthesis and thus bacterial replication. Additionally, NO modifies reactive cysteine 
thiols in bacterial proteins (S-nitrosylation), oxidizes lipid membranes, causes double- 
stianded breaks in DNA and interacts with heme dinitrosyl-iron complexes in protein 
catalytic centers (reviewed by (Fang, 1997)). NO also binds to protein iron-sulfurs in the 
Ki'eb’s Cycle and respiratory chain, subsequently blocking metabolism and aerobic 
respiration. When NO combines with superoxide (O2 ') it forms ONOO', which has been 
implicated in bacterial lipid peroxidation, protein oxidation, double stranded breaks in 
DNA and protein nitration (Woodmansee & Imlay, 2003). Protein nitration can disrupt 
pathways involving tyrosine phosphorylation and therefore, protein function.
Vh'uses
3S
NO has important anti-viral effects. iNOS induction by viral infection is mediated 
predominantly by proinflammatory cytokines. Primarily NO targets viral pro teases that 
cleave large viral polyproteins to smaller polypeptides, an essential step in viral 
propagation. NO has been shown to inhibit picomavirus, herpesvirus, flavivirus and 
coronavirus replication. As is the case for coxsackievirus, NO S-nitrosylates a critical 
cysteine in viral protease activities, inliibiting replication.
Tumors
The insidious nature of tumor cells requires extracellular killing, as opposed to 
intracellular killing as is the case for infecting pathogens. The ready diffusion of NO 
makes it highly accessible as a tumoricidal effector. Some major targets of iNOS-derived 
NO in tumor cells include cü-aconitase, ribonucleotide reductase (the rate limiting 
enzyme in DNA synthesis) and complexes I and II in the mitochondrial electron transport 
chain (for review see (Nathan, 1992)). Modification of these tumor cell proteins can 
ultimately result in apoptotic death.
Reciprocally, at low concentrations the actions of NO can be pro-tumorogenic. 
NO has growth factor properties and mediates tumor vascularization, either directly or via 
activation of vascular endothelial growth factor (VEGF) (Jenkins et a l, 1995). These 
proangiogenic effects are essential in supplying blood to growing tumors. The 
dichotomous nature of NO in tumor pathophysiology was extensively discussed in a 
review by Lechner et al (Lechner et al., 2005).
Fighting Back
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Despite the extensive targets of NO (and NO congeners) in microbes and tumors, 
invading organisms are not defenseless to NO-attack. Bacteria have developed systems 
that are sensitive to oxidative stresses, and which are expressed upon exposure to NO and 
its higher oxides. As a defense mechanism, the bacterial transcription factors OxyR, 
SoxRS and Fur activate a set of antioxidant genes that leads to expression of catalase 
(CAT), alkyl-hydroperoxidase-1 (AHP-1) and superoxide dismutase (SOD) (Bryk et a l, 
2000; Hausladen et a l, 1996; Zheng et a l, 1999). Together, these proteins mount a 
‘counter-attack’ to NO and protect bacteria from oxidative and nitrosative damage. In 
tumors, tumor-derived suppressor agents such as tumor growth factor-(3 (TGF-|3) inhibit 
iNOS gene transcription (Vodovotz & Bogdan, 1994). Additionally, there is evidence that 
some tumors produce high levels of arginase, an enzyme that degiades L-arginine, the 
NOS substrate (Wei et a l, 2000). Substrate consumption provides a mechanism by which 
tumors defend themselves against NO-induced damage.
1.6.5 Protein-Protein Interactions and Posttranslational Modifications
Calmodulin
As discussed earlier, iNOS tightly binds calmodulin and is active at extremely low 
levels of Ca^^, when compared to eNOS and nNOS. The canonical CaM-binding domain 
of iNOS is located between amino acid residues 503-532 (mouse iNOS) and tightly binds 
CaM at ambient levels of intracellular Ca"^. This unique feature of iNOS amongst the 
three NOS isoforms, means that as iNOS is translated, it becomes catalytically active even 
at the lowest levels of free intracellular Ca^ .^ However, based on studies of chimeric 
nNOS and iNOS, it appears that even though the CaM-binding site is important, it is not
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sufficient for maximal Ca*^-independent iNOS activity (Ruan et a l, 1996). Amino acid 
residues 484-726, in addition to contributing the CaM-binding domain, contain amino 
acids that are integral for iNOS’s Ca^^ independence (Ruan et a l, 1996).
Racl andRac2
The Rho GTPases, Racl and Rac2, were identified as iNOS-interacting proteins in 
a yeast two-hybrid screen and in vitro studies showed that Rac2 interacts with the iNOS 
oxygenase domain specifically (Kuncewicz et a l, 2001). The Racl and Rac2 isoforms 
regulate NADPH oxidase activity during cellular homeostasis and phagocytosis. The 
physical interaction between iNOS and Rac2 suggests a tight and complex regulation of 
both iNOS mediated NO release and Rac2-driven NADPH oxidase activity. Transfection 
of RAW 264.7 macrophages with a cDNA encoding Rac2 and subsequent treatment with 
LPS, potentiated iNOS activity and NO production (Kuncewicz et a l, 2001). Both Racl 
and Rac2 were shown to induce cellular redistribution of iNOS in LPS treated 
macrophages, suggesting that spatial cornpartmentalization of iNOS is pivotal for ensuring 
optimal microbial killing (Kuncewicz et a l, 2001). These key observations suggest that 
iNOS activity is not solely under transcriptional control but that posttranslational 
mechanisms also play a vital role in iNOS regulation. The impact of the iN0S-Rac2 
complex on NADPH oxidase function remains to be determined.
Kalirin
Using iNOS (amino acids 1-70) as bait and a hippocampal cDNA library as prey, a 
yeast-two hybrid screen identified kalirin, a neuron-specific cytosolic protein (Ratovitski
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et a l, 1999). The interaction between iNOS and kalirin was further conflimed in vivo in 
brains of LPS-stimulated wild-type mice but was not detected in brains of iNOS knockout 
mice (Ratovitski et a l, 1999).
Cells expressing a truncated kalirin mutant, kalirin-(447-1124), showed a marked 
decrease in iNOS catalytic activity. Mechanistically, kalirin-binding to the N-terminal 70 
amino acids of iNOS disrupts homodimerization and prevents iNOS frinction (Ratovitski 
et a l, 1999). The presence of iNOS in the nervous system is associated with 
inflammatory states leading to neurotoxicity, dysregulation of hormone secretion and 
neuronal apoptosis. Kalirin may serve as a key neuroprotective effector that opposes 
iNOS-induced neuronal damage.
MAPI 10
Mouse macrophages express NOS-associated protein-110 (NAP 110) and both in 
vitro and in vivo experiments confirmed that iNOS monomers physically interact with 
NAP 110 (Ratovitski et a l, 1999). The iNOS-NAPl 10 heterodimer attenuated iNOS 
activity by ~90% (Ratovitski et a l, 1999). The NAP 110 binding domain was mapped to 
the first 70 amino acids of iNOS, similar to the iNOS-kalirin complex (Ratovitski et a l, 
1999). Even though the mechanism of NAP 110 inhibition of iNOS is not fully understood 
it appears that, like kalirin, NAPllO disrupts iNOS homodimer assembly. Since 
mammalian NOSs only make NO when homodimeric, NAPllO may serve to protect 
iNOS-expressing macrophages from cytotoxic levels of NO.
EBP50
3Q
Solute transport in polarized epithelial cells is regulated in part by iNOS-derived 
NO. Ezrin-radixin-moesin-binding phosphoprotein 50 (EBP-50) is a PDZ domain- 
containing protein localized to the apical microvilli and actin cytoskeleton of epithelial 
cells (Reczek et a l, 1997). In epithelial cells, iNOS associates with a submembranous 
protein complex and interacts specifically with EBP-50’s three C-terminal amino acids, 
Serine-Alanine-Leucine (SAL) (Glynne et a l, 2001). Furthermore, the iNOS-EBP-50 
interaction is stabilized by the presence of additional unknown accessory proteins. Given 
the random distribution of ion and acid-base transporters within apical membranes of 
epithelial cells, compartmentalization of iNOS would allow delivery of NO to its proximal 
molecular targets (Glynne et a l, 2001).
Caveolin-I
Caveolin-1 has been shown to associate with iNOS in human colon carcinoma 
cells in response to inflammatory cytokines (Felley-Bosco et a l, 2000). Localization of 
the iNOS-caveolin-1 complex was isolated to the detergent insoluble membrane fractions 
and the interaction predisposes iNOS to degradation via the proteosome pathway (Felley- 
Bosco et a l, 2000). The intimate relationship between iNOS and caveolin-1 is suggestive 
of a defense mechanism against iNOS-mediated genotoxicity and tumor progression.
Tyrosine Phosphorylation
Using phosphotyrosine antibodies. Pan and colleagues demonstrated that iNOS is 
post-translationally phosphorylated on tyrosine residues in response to LPS/IFN-y (Pan et 
a l, 1996). Treatment of macrophages with the tyrosine phosphatase inhibitor, vanadate.
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protected iNOS against dephosphorylation and significantly increased levels of detectable 
phospho-iNOS. Conversely, treatment with PMA (a PKC activator) or okadaic acid (a 
serine/threonine phosphatase inhibitor) did not mimic the increase in iNOS 
phosphorylation observed with vanadate (Pan et a l, 1996). Vanadate treatment of 
macrophages additionally increased iNOS catalytic activity with no significant change in 
total iNOS protein (Pan et a l, 1996). The tyrosine kinases and phosphatases involved 
remain elusive, but a recent study suggests that tyi*osine-151 (Y151) of iNOS may be 
modified by the family of Src tyrosine kinases (Hansel et a l, 2006). Interestingly, iNOS 
phosphorylation was also shown to occur via an FKBP-rapamycin dependant pathway in 
RAW 264.7 macrophages (Salh et a l, 1998).
1.7 Endothelial Nitric Oxide Synthase (eNOS)
Endothelium-derived NO is a key mediator of cardiovascular homeostasis. 
Endothelial NO synthase (eNOS, NOS III) was isolated as a particulate Ca^VCalmodulin- 
regulated enzyme. Initially, it was believed that eNOS was solely a Ca^/Calmodulin- 
dependent protein, yet numerous studies in the last decade have shed light on its complex 
control. Regulation of eNOS by phosphorylation, acylation, subcellular localization and 
protein-protein interactions (summarized in Figme 1.11), allow for moment-to-moment 
control of vascular tone, as well as regulation of other aspects of the cardiovascular 
system.
1.7.1 Transcriptional Regulation of eNOS
Regulation of eNOS gene expression has emerged as an important event in both
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physiological and pathophysiological settings. Analysis of the eNOS promoter sequence 
reveals the lack of a TATA box and the presence of the proximal promoter elements, Spl 
and GATA motifs (Zhang et a l, 1995). These characteristics are in keeping with a so- 
called constitutively expressed protein. Furthermore, in addition to SPl and GATA, the 
promoter region contains binding sites for several other transcription factors, nuclear 
factors (NF-1), shear stress-, c AMP-response-, and sterol-regulatory cis elements 
(reviewed by (Forstermann et a l, 1998)). The functional properties of these binding sites 
have not all been well studied, but mutation of the Spl binding consensus at position 103 
resulted in a dramatic knockdown (-80%) in eNOS promoter activity (Zhang et a l, 1995). 
Conversely, several shear stress response element binding motifs have been identified 
within the eNOS promoter and shown to be necessary for upregulation of eNOS gene 
expression by shear (Sessa et a l, 1992; Sessa et a l, 1994).
1.7.2 Posttranslational Modifications
Modification o f eNOS by Acylation
Integral membrane proteins are processed by the classic ER-Golgi pathway and 
anchored to the plasma membrane by hydrophobic stretches of amino acids comprising 
transmembrane domains. In contrast, non-integral membrane proteins, such as G-proteins 
and Src family members are targeted to the plasma membrane by co-translational N- 
myristoylation, posttranslational thiopalmitoylation or prénylation. Correct targeting to 
membrane microdomains is recognized to be critical for conect cellular trafficking and the 
fidelity of signal transduction events. Endothelial NOS is unique among the three NOS 
isoforms in that it is dually acylated by the saturated fatty acids myristate and palmitate
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(Robinson et a l, 1996). Myristoylation is an irreversible co-translational lipid 
modification that is catalyzed by A-myristoyltiansferase and occurs on a glycine at the N- 
terminus (Liu & Sessa, 1994). 7V-myristoylation of eNOS is critical for membrane 
association and for subsequent cysteine palmitoylation. Palmitoylation occurs 
postti’anslationally and involves the reversible formation of a fatty-acyl thioester bond 
between palmitoyl-CoA and the thiol group of cysteine residues 15 and/or 26 within 
eNOS (Liu et a l, 1995). Palmitoylation can occur in response to extracellular stimuli, 
providing a mechanism for the dynamic regulation of protein localization (James & Olson, 
1989). The combined hydrophobic interactions, of iV-myristoylation and 
thiopalmitoylation, play a key role in the anchoring and subcellular targeting of eNOS to 
the endothelial plasma and cw-Golgi membranes.
In in vivo site-directed mutagenesis studies where myristic acid incorporation has 
been hindered, eNOS becomes predominantly cytosolic, with very little effect on enzyme 
activity. This demonstrates that the incorporation of a myristoyl moiety at Gly2 (Glyl 
after Met removal) is an absolute requirement for eNOS membrane association (Sessa et 
a l, 1993). Mutation of the palmitoylation sites of eNOS does not affect its overall 
hydrophobic and in vitro kinetic properties when compared to WT eNOS. However, when 
the palmitoylation-deficient enzyme is tiansfected into cells, its ability to release NO is 
impaired, indicating that correct subcellular targeting is necessary to bring eNOS into 
close proximity with its substrates and perhaps other signaling proteins that allow for 
efficient activation by external stimuli (Liu et a l, 1996). Recently, an elegant study 
identified five Asp-His-His-Cys (DHHC) acyl transferases (DHHC-2, -3, -7, -8 and -21) 
that enlianced incorporation of [^H]-palmitate into eNOS (Femandez-Hemando et a l,
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2006). Closer investigation revealed that all DHHCs colocalize and associate with eNOS 
both at the cytoplasmic face of the Golgi complex and the plasma membrane (Femandez- 
Hemando et a l, 2006). Interestingly, targeted disruption of DHHC-21 mRNA levels by 
siRNA, resulted in mislocalization of eNOS and attenuated agonist-stimulated eNOS 
activity. Reciprocally, studies dismpting DHHC-3 expression had no impact on eNOS 
activity (Femandez-Hemando et a l, 2006). This finding exemplifies the functional 
importance of eNOS targeting to discrete subcellular structures.
Agonists such as bradykinin have been shown to promote depalmitoylation of 
eNOS, paralleled by disassociation of eNOS from the plasma membrane (Robinson & 
Michel, 1995). Depalmitoylation is driven by acyl-protein thioesterase 1 (APTl) and 
potentiated by the binding of calcium-calmodulin (Yeh et a l, 1999). The idea that 
bradykinin may induce eNOS depalmitoylation was challenged by Liu and colleagues in a 
study showing that NO releasing agonists do not promote enzyme depalmitoylation (Liu et 
a l, 1995).
eNOS Phosphorylation
eNOS is subjected to negative and positive regulation by phosphorylation of 
serine, threonine, and tyrosine residues at multiple sites that have been identified (Fig. 
1.13). Among the numerous potential phosphorylation sites in eNOS, perhaps the most 
important and best studied is Seri 177 in the reductase domain and Thr495 in the CaM- 
binding domain (sequence designation is relative to human eNOS). The phosphoregulation 
of eNOS is complex and our understanding is clearly incomplete, as yet (for review see 
(Fulton et a l, 2001)).
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Unstimulated cultured endothelial cells reveal a lack of phosphorylation at 
Seri 177 of eNOS. Phosphorylation and subsequent activation occurs rapidly in response 
to stimuli such as fluid shear-stress (Dimmeler et a l, 1999; Gallis et a l,  1999), estrogen 
(Lantin-Hermoso et a l, 1997), insulin (Kim et a l, 2001), bradykinin (Fleming et a l,
2001) and vascular endothelial growth factor (VEGF) (Dimmeler et a l, 1999; Michell et 
a l,  2001). The phosphorylation of eNOS at Seri 177 is primarily, but not solely, mediated 
by the serine/threonine kinase Akt/PKB in vivo. Akt is an important regulator of cell 
survival and glucose metabolism, stimuli such as increased mechanical stress, insulin and 
VEGF result in phospho-activation of Akt via the phosphatidylinositol-3-OH kinase 
(PI(3)K) pathway. Activated Akt can further phosphorylate several cellular targets, 
including Seri 177 on eNOS. The net effect of Seri 177 phosphoiylation is a two- to three­
fold increase in NO production when compared to basal eNOS activity (Dimmeler et a l, 
1999; Fulton et a l, 1999). The PI(3)K inhibitors, LY294002 and Wortmannin, attenuate 
shear-, VEGF- and insulin-induced phosphorylation and activation of eNOS (Dimmeler et 
a l, 1999; Fulton et a l, 1999). Additionally, activation of eNOS by phosphorylation at 
Seri 177 apparently allows eNOS to be active at low basal levels of intracellular calcium 
(Fulton et a l, 1999). An added complexity to understanding the cellular regulation of 
Seri 177 phosphorylation is the finding that AMP-dependent protein kinase (AMPK) 
(Chen et a l, 1999), protein kinase A (PKA) (Boo et a l, 2002), protein kinase G (PKG) 
(Butt et a l, 2000) and CaM II Protein kinase (Fleming et a l, 2001) also phosphorylate 
eNOS on Seri 177. The identities of the kinases involved in the phosphorylation of 
Seri 177 are dependent on the stimuli applied. A fundamental finding is that upon
phosphorylation of Seri 177, eNOS activity increases to above basal levels as a 
consequence of accelerated electron flux from the reductase to the oxygenase domain.
Thr^^
eNOS is basally phosphorylated on Thr495 in quiescent endothelial cells in most 
settings, resulting in attenuated enzyme activity. The location of this site within the CaM- 
binding domain of eNOS suggests that phosphorylation interferes with CaM binding. 
Upon stimulation of endothelial cells with Ca^^-elevating agents, such as histamine, 
ionophore and bradykinin, Tlir495 becomes dephosphorylated allowing substantially more 
CaM binding to eNOS. The kinase required for phosphorylation at Thr495 was identified 
as a phorbol-ester sensitive iso form of protein kinase C (PKC) (Fleming et a l, 2001), 
confirming earlier observations that PKC-driven phosphorylation dampens eNOS activity 
(Davda et a l, 1994; Hirata et a l, 1995; Tsukahara et a l, 1993). Moreover, the PKC 
inhibitor Ro 31-8220 attenuated basal PKC-mediated phosphorylation of Thr495 and 
increased eNOS activity. Treatment with calyculin A, which inliibits protein phosphatase 
1 (PPl) and protein phosphatase 2A (PP2A), rendered eNOS unresponsive to stimuli such 
as bradykinin (Fleming et a l, 2001). The observation that calyculin A also increases 
phosphorylation of Seri 177, but has no effect on eNOS activity, suggests tight regulation 
of eNOS whereby dephosphorylation of Tlir495 and phosphorylation of Seri 177 must 
occur in tandem to allow for effective eNOS activation.
Ser^^
Ser633 resides in the autoinhibitory loop of eNOS within the FMN-binding
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domain. The autoinhibitory loop is a 45 amino acid stretch found within eNOS that may 
dock with the CaM-binding site and impede enzymatic activation by CaM (Nishida & 
Ortiz de Montellano, 1999; Salerno et ah, 1997). Based on this model, it is reasonable to 
speculate that phosphorylation of Ser633 leads to a structural rearrangement that alters 
CaM-binding and eNOS activity. Lane and Gross proposed that phosphorylation of 
Ser633 activates eNOS by disinhibition of the autoinhibitory control loop, thus removing a 
banier to electron flux and permitting Ca^^/CaM to bind eNOS (Lane & Gross, 2002). 
Phosphorylation of Ser633 is mediated by PKA and occurs in response to shear stress, 
VEGF and 8-bromocAMP (8BRcAMP) (Boo et a l,  2002; Michell et a l, 2002). Several 
lines of evidence suggest that phosphorylation of Ser633 is involved in maintaining basal 
NO levels in a Ca^/CaM-independent manner (Boo et a l, 2003). The functional 
significance of phosphoiylation at this site is, as yet, undefined.
Phosphorylation of Serb 15 was identified by phosphopeptide mapping and matrix- 
assisted laser desorption ionization time of flight (MALDI-TOF) spectrometry (Michell et 
a l, 2002). Stimuli such as VEGF, bradykinin and ATP evoke phosphorylation of Ser615 
by Akt and increase the Ca^^-independent activity of eNOS (Michell et a l, 2002). The 
role of Ser615 phosphorylation in eNOS regulation has not been fully established. Most 
likely dual phosphorylation of Serb 15 and Seri 177 plays a pivotal role in the regulation of 
the enzyme in response to mechanical stress.
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Phosphoiylation at Seri 14 was first described in a study aiming to identify flow- 
dependent eNOS phosphorylation sites (Gallis et a l, 1999). It has been proposed that 
dephosphorylation of Seri 14 leads to activation of eNOS and occurs in response to VEGF 
(Kou et a l, 2002). In vitro assays revealed that VEGF activates the Ca^VCaM-dependent 
phosphatase, calcineurin (PP2B). When cyclosporin-A (an inhibitor of calcineurin) was 
added, both VEGF mediated dephosphorylation of Seri 14 and eNOS activity were 
attenuated. These findings provide a mechanism for cyclosporin-A-mediated 
hypertension: when administered as an immunosuppressive dmg, cyclosporine-A leads to 
hypertension, resulting from reduced eNOS activity via a calcineurin-sensitive mechanism 
(Kou et a l , 2002).
T y / ‘
Phosphorylation of eNOS at tyrosine residues has been poorly studied. Some of 
the first evidence hinting that tyrosine phosphorylation of eNOS may contribute to 
regulation, was provided by Garcia-Cardena and colleagues in 1996 (Garcia-Cardena et 
a l, 1996). They reported that the tyrosine phosphatase inhibitor, sodium ortho vanadate, 
and the oxidant, H2 O2 , both stimulated tyi'osine phosphorylation of eNOS in endothelial 
cells and increased the association of eNOS with caveolin-1 in caveolae (Garcia-Cardena 
et a l, 1996). Several other groups additionally suggested roles for tyiosine 
phosphoiylation in the regulation of eNOS function (Ayajiki et a l, 1996; Corson et a l, 
1996; Fleming et a l, 1998; Takenouchi et a l, 2004). A more recent study revealed that in 
endothelial cells eNOS and the Src kinase, c-Src, coimmunoprecipitate, suggesting a
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possible role for c-Src mediated phosphorylation of eNOS (Fulton et a l, 2005). The 
salient finding was that tyrosine 83 (Tyr83) (relative to bovine eNOS) is the site of 
phosphorylation, as confirmed by domain mapping and site-directed mutagenesis studies 
(Fulton et a l, 2005). Furthermore, when cells were co-transfected with exogenous eNOS 
and the active form of c-Src, v-Src, there was a 3-fold increase in basal NO production, an 
observation that was absent in parallel studies where the dominant-negative-Src (DN-Src) 
was substituted for v-Src (Fulton et a l, 2005). Phosphoiylation of eNOS at Tyr83 adds an 
additional level of complexity to an already convoluted regulation.
eNOS S-nitf’osylation
As described already, eNOS is precisely regulated by a complex pattern of post- 
tianslational modifications. Each serves to regulate eNOS function so that NO is 
produced when and where required. Molecular assembly of eNOS into signaling 
complexes compartmentalizes the source of NO allowing for S-nitrosylation of key 
proteins within a complex. It is therefore no surprise that eNOS function itself, is also 
regulated by S-nitrosylation of key cysteine residues. In recent studies, Erwin and 
colleagues demonstiated that eNOS is S-nitrosylated in quiescent bovine aortic endothelial 
cells (Eiwin et a l, 2005). Interestingly, upon VEGF stimulation there is a rapid transient 
denitrosylation of eNOS, concomitant with an increase in Seri 179 phosphorylation and 
subsequent activation (Erwin et a l, 2005). Moreover, additional work using 
myristoylation-deficient and membrane-targeted eNOS chimera, showed that association 
to the plasma membrane is a requirement for eNOS S-nitrosylation (Erwin et a l, 2005; 
Erwin et a l, 2006). In viti^o evidence suggests that S-nitrosylation dampens eNOS
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activity and even though the cysteines implicated are part of the zinc-tetrathiolate involved 
in dimer assembly, mutational studies precluded the role S-nitrosylation in eNOS 
monomerization (Erwin et a l, 2005). The dynamic nature of eNOS suggests that in 
addition to acylation and phosphorylation, S-nitiosylation also serves to regulate eNOS 
function both spatially and temporally. This finding exemplifies the importance of NO 
signaling mechanisms in controlling vascular homeostasis.
1.7.3 Subcellular Localization
Each NOS isoform engages in unique protein-protein interactions that assemble 
macromolecular NO-signaling complexes. eNOS was originally isolated from detergent 
solubilized bovine aortic endothelial cells (BAECs) and was found to be predominantly 
associated with particulate subcellular membrane fractions (Pollock et a l, 1991). 
Dependent on the cell type and/or mode of stimulation, eNOS has been found to reside in 
various subcellular compartments, including cytosol, nucleus, mitochondria, Golgi (TGN) 
and plasmalemma.
Plasma Membrane
eNOS is localized to small (50-100 nm) cholesterol- and sphingolipid-rich 
invaginations of the plasma membrane, termed caveolae. In addition to endothelial cells, 
caveolae can be found on adipocytes, fibroblasts and smooth muscle cells (for review see 
(Anderson, 1998; Parton & Simons, 1995)). Caveolae appear to be sequestration points 
for cell signaling molecules such as receptors, protein kinases, channels, transporters, G- 
proteins and eNOS. The major structural components of caveolae are a family of 21-24
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kDa transmembrane proteins designated caveolin-1, caveolin-2 and caveolin-3. Caveolins 
serve as a scaffolding site for the organization and concentration of specific proteins 
within the caveolar pocket. eNOS has been shown to associate exclusively with caveolin- 
1 in endothelial cells and caveolin-3 in cardiac myocytes. The 20 amino acid scaffolding 
domain of caveolin-1 (82-101) has been defined as the interaction motif responsible for 
docking to eNOS (Garcia-Cardena et a l, 1997). The influential role of caveolin-1 in 
vascular physiology was revealed by the phenotype of caveolin-1 knockout mice (Drab et 
a l, 2001). These mice exhibited profound vascular dysfunction and thickening of alveolar 
septa as a consequence of increased endothelial cell proliferation and fibrosis. The 
phenotypic characteristics of these mice apparently results fi om mislocalization and thus, 
dysregulation of eNOS protein (Drab et a l, 2001).
Golgi
The post-translational fatty-acid modifications, /v'-myristoylation and S- 
palmitoylation, serve to ‘home’ eNOS to the Golgi complex and caveolae (Sessa et a l, 
1995). In both intact blood vessels and cultured endothelial cells, the relative amounts of 
eNOS at the plasma membrane versus Golgi vary depending on the tissue, species and, in 
the case of cultured cells, confluency (Andries et a l, 1998; Govers & Rabelinlc, 2001; 
O'Brien et a l, 1995). Acylation-deficient eNOS lacks both Golgi and plasma membrane 
association and its mislocalization results in attenuated NO release in response to agonistic 
stimuli. Disruption of the Golgi complex of endothelial cells by Brefeldin A, inliibits 
eNOS activity and prevents plasmalemmal association (Stanboli & Morin, 1994). This 
suggests that eNOS at the Golgi undergoes modifications critical for its plasma membrane
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association. Indeed the presence of palmitoyltransferase at the Golgi complex (Schmidt & 
Catterall, 1987) provides an attractive model, whereby depalmitoylated/active eNOS 
cycles from the plasma membrane to the Golgi, where it is repalmitoylated and 
ti'anslocates back to the plasma membrane (Feron et a l, 1998; Sowa et a l, 1999).
The notion that both caveolin-1 and eNOS reside within Golgi membranes 
suggested a possible interaction between the two proteins. However, Govers et a l 
obseiwed segregation of eNOS- and caveolin-1-containing Golgi structures upon treatment 
of endothelial cells with the microtubule-depolarizing agent, nocodazole (Govers et a l,
2002), This implies that caveolin-1 does not regulate eNOS fimction at the Golgi, as it 
does not reside within the same subcompartment. The extent of VEGF-mediated 
phosphorylation on Seri 177 was found to be similar in Golgi and caveolar eNOS, 
demonstrating two separate pools of active enzyme (Fulton et a l, 2002). The precise 
subcellular localization of eNOS within endothelial cells is suggestive of a dynamic and 
intricate trafficking pattern for this protein. NO released in the Golgi area may serve as 
both an autocrine (endothelial) and paracrine (smooth muscle) effector.
Mitochondria
The existence of a distinct mitochondrial NOS (mtNOS) is an area of great interest 
and controversy. Bates and colleagues used immunohistochemical techniques to 
demonstrate the presence of a NOS-like protein in mitochondria isolated from some rat 
tissues (Bates et a l, 1995, 1996). The role o f NO in the regulation of mitochondrial 
respiration has been well elucidated (see (Brown, 2001)). NO at nanomolar 
concentrations has been shown to compete with oxygen for binding to cytoclirome c
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oxidase (Brown, 1995). At low concentrations of NO (iiM), the reaction with cytochrome 
c oxidase is reversible and leads to attenuation of mitochondrial respiration. At higher 
concentrations (p,M), NO and some derivatives (such as peroxynitrite (ONOO ), nitrogen 
dioxide (NO%) and nitiosothiols (RSNO)), cause irreversible inhibition of the 
mitochondrial respiratoiy chain and permeability tiansition, ultimately leading to 
apoptotic cell death. A more recent study revealed that NO, acting via cyclic GMP, 
triggers mitochondrial biogenesis (Nisoli et ah, 2003). An attractive possibility is that 
levels of NO within the mitochondria are regulated by the organelle itself. Although 
several groups have argued against mtNOS being eNOS, nNOS or iNOS, this may vary 
for different cell types. Notably, reasonable evidence supports the presence of 
mitochondrial-associated eNOS in endothelial cells. Studies have shown that NOS 
activity co-purifies with mitochondria isolated from endothelial cells and experiments 
using immunogold electron microscopy and/or western blotting have revealed that eNOS 
protein associates with purified mitochondria (Bates et a l, 1995, 1996; Gao et a l, 2004; 
Lacza et a l, 2001). There is some inconsistency among published reports regarding 
whether eNOS resides in the matrix (Lacza et a l,  2001), inner (Giulivi et a l, 1998) or 
outer mitochondrial membrane (Heinrich et a l, 1998). In a study to try and settle the 
controversy, Gao and colleagues convincingly showed that eNOS is tethered to the 
cytoplasmic face of the outer mitochondrial membrane, where it is basally active and 
activity increases in response to calcium transients (Gao et a l, 2004). Furthermore, they 
suggested that the ‘zip-code’ directing eNOS to the outer mitochondrial membrane is the 
pentabasic sequence (RRKRK) (amino acids 628-633 of bovine eNOS) within the
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autoinhibitory loop of eNOS (Gao et a l, 2004). The central role, targets and regulation of 
mitochondrial eNOS await further elucidation.
Nucleus
In an immunohistochemical study of eNOS, caveolin-1 and Flk-l/KDR (VEGF 
receptor), it was found that upon stimulation with the potent mitogen VEGF, all three 
proteins translocate into the nucleus from the plasma membrane (Feng et a l, 1999). 
Additionally, cell fractionation and immunoblotting studies, revealed that after 60 min of 
VEGF treatment, the levels of all three proteins within the caveolar pockets declined 
progressively but increased within the nucleus (Feng et a l, 1999). The specific role of 
nuclear eNOS-derived NO and the mechanisms involved in eNOS regulation within the 
nucleus are unknown. Potentially, NO may influence transcription factor activation as 
observed for the early growth response gene, c-fos (Idriss et a l, 1999; Peunova & 
Enikolopov, 1995).
1.7.4 Protein-Protein Interactions of eNOS
All three NO synthase isoforms are under tight control by both tianscriptional and 
post-translational mechanisms. An added level of complexity for eNOS regulation 
involves interactions with other signaling molecules, and structural proteins. Despite 
evidence showing important protein-protein interactions for all three NOSs, the regulatory 
aspects of eNOS and its binding partners have been explored most extensively.
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1.7.4.1 Negative Regulatory Proteins
Caveolin
The subcellular localization of eNOS to caveolae is known to occur directly 
through its interactions with caveolin-1. Caveolin-1 (cav-1) is abundant in the 
endothelium and consists of N- and C-terminal cytosolic domains separated by a 33- 
residue membrane-spanning region. In the resting state, eNOS is directly tethered to 
caveolin-1, leading to tonic inhibition of NO synthesis (Feron et a l, 1998; Garcia-Cardena 
et a l, 1997). Consensus binding motifs were identified within both proteins: amino acid 
residues 82-101 of the C-teiminal region of caveolin-1 (termed the scaffolding domain) 
(Ju et a l, 1997) interact with a caveolin-binding peptide region found in the oxygenase 
domain of eNOS (bovine isoform: amino acids 350-358) (Feron et a l, 1998; Garcia- 
Cardena et a l, 1997), The scaffolding domain of caveolin-1 is also responsible for the 
attachment of a number of other signal proteins including phosphatidylinositol 3-kinase, 
G-proteins and the Src family of proteins (Okamoto et a l, 1998; Shaul & Anderson,
1998). Additionally, the reductase domain of eNOS has been shown to associate with 
regions of the N-terminus of caveolin-1 (Ghosh et a l, 1998).
NOS Interacting Protein (NOSIP)
The NOS interacting protein (NOSIP) was identified as a 34 kDa protein using a 
yeast two-hybrid screen (Dedio et a l, 2001). The interaction of eNOS with NOSIP occurs 
via the C-terminal region of the eNOS oxygenase domain (amino acids 366-486) and has 
been observed both in vitj-o and in vivo (Dedio et a l, 2001). Stimulation of cells with 
calcium ionophore has no effect on the NOSIP-eNOS association. In viU'o experiments
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suggest that NOSIP does not affect eNOS catalysis in vitro but when coexpressed with 
eNOS in cells, NOSIP attenuates ionomycin-induced NO release (Dedio et ah, 2001). 
Although the mechanics and the true fimction of the NOSIP-eNOS interaction are unclear, 
evidence suggests that NOSIP interferes with the binding of eNOS to the caveolar 
pockets, promoting eNOS relocalization to alternative intracellular compartments (Dedio 
et ah, 2001).
NOS Traffic Inducer (NOSTRIN)
Also identified in a yeast two-hybrid screen, the NOS traffic inducer (NOSTRIN) 
is a 58 IcDa protein comprised of an N-terminal cdcl5 domain and a C-terminal SH3 
domain (Zimmermann et ah, 2002). NOSTRIN is highly expressed in vascularized 
tissues such as placenta, kidney, lung and heart as well as in human microvascular 
(HMVEC) and umbilical vein (HUVEC) endothelial cells. In vivo studies identified 
amino acids 433-506 of the NOSTRIN SH3 domain as the primary site of eNOS- 
NOSTRIN complex formation (Zimmermann et a l, 2002). These observations were 
paralleled in viti'o (Zimmermann et a l, 2002). NOSTRIN- associated eNOS translocates 
from the plasma membrane to intracellular compartments. Conversely, a cdcl5 deletion 
mutant of NOSTRIN (NOSTRINAcdc 15) confers correct localization to the plasma 
membrane and Golgi compartments, suggesting a pivotal role for the cdcl5 domain in 
eNOS trafficking away from the PM to inti*acellular vesicular stiuctures. Ultimately, 
NOSTRIN-mediated relocalization attenuates Ca^^-induced NO release (Zimmermann et 
a l, 2002),
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Intracellular domains o f  G-Protein Coupled Receptors
Work by Marrero and colleagues, has shown that the G-protein coupled C-terminal 
intracellular domain 4 (ID4) of various G-protein coupled receptors (GPCRs), including 
the bradykinin 2 (B2), angiotensin II (Ang II) and endothelin-1 (ET-1) receptors, 
negatively regulates eNOS activity in vitro (Marrero et a l, 1999). Further studies 
revealed that ID4 interferes with flavin-to-heme electron transfer, suggesting a mechanism 
for eNOS inhibition (Golser et a l, 2000). The physiological implication of the eNOS- 
GPCR association is uncertain.
1.7.4.2 Positive Regulatory Proteins
Calmodulin
Calmodulin is a ubiquitous intracellular receptor for Ca"^  ^ that plays a pivotal role 
in electron transfer and catalytic activity when reversibly bound to either eNOS or nNOS. 
The precise molecular interactions of CaM required for the activation of the cNOSs is not 
yet clear. The stiucture of CaM is defined by 4 helix-loop-helix (hlh) calcium binding 
motifs called EF hands, found in pairs in the N- and C-terminal lobes of CaM (Tjandra,
1999). Each of the four EF hands (named sites I, II, III and IV) has the ability to bind one 
Ca***^  ion; sites III and IV are located in the C-tenninal domain and have a 10-fold greater 
affinity for Ca^^ than sites I and II in the N-terminus (Ikura et a l, 1983). Typically, 
activation of target proteins by CaM requires the occupancy of all four Ca^^ binding sites 
(Fig. 1.14). The binding of C a^ results in a reorientation of CaM’s protein stmcture, 
changing it from a somewhat flat hydrophilic molecular surface in Ca^’^ -free CaM, to a 
dumbbell-shaped hydrophobic stiucture after C a^ binding. This structural alteration of
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CaM exposes residues that engage in the specific interactions with target proteins. A 
schematic model that depicts hypothesized steps in eNOS activation by staged Ca^^/CaM 
binding is shown in Figure. 1.15.
Heat Shock Protein 90 (Hsp90)
Heat shock protein 90 (Hsp90) is an intracellular chaperone involved in the 
trafficking and regulation of a variety of signaling proteins including Src and its family 
members, Raf and mitogen activated protein kinase kinase (MAPKK/MEK) (Pratt, 1997). 
Previously, it was shown that eNOS coprecipitates with a 90 kDa tyrosine-phosphorylated 
protein that was identified as Hsp90 (Garcia-Cardena et a l, 1998; Venema et a l, 1996). In 
endothelial cells, external stimuli such as VEGF, histamine, estrogen and shear stress 
promote association of eNOS and Hsp90, contributing to activation of eNOS (Garcia- 
Cardena et a l, 1998). The eNOS-Hsp90 association is an absolute requirement for Akt- 
mediated stimulation of eNOS (Brouet et al., 2001). The cun*ent dogma is that in response 
to external stimuli, such as VEGF, Hsp90, along with calcium bound Calmodulin dismpt 
the inliibitory eNOS-caveolin-1 complex is disrupted, allowing Ca^/CaM to bind eNOS 
and reveal a docking site for Akt-dependent phosphorylation of eNOS. The net effect of 
Akt phosphorylation is an enhanced electron flux from the reductase domain to the 
oxygenase domain of eNOS and thus accelerated production of NO. Hsp90 serves (1) as a 
scaffolding site between eNOS and Akt and (2) to stabilize both calmodulin binding and 
phosphorylation of Seri 177 (Fontana et a l, 2002).
S-nitrosylation o f Hsp-90
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S-nitrosylation of Hsp90 has been shown to exacerbate the intiinsic ATPase 
activity of the Hsp90 enzyme (Martinez-Ruiz et al., 2005). The specific cysteine modified 
was mapped to Cys 597 located in the C-terminal domain of Hsp90, the region implicated 
in the eNOS-Hsp90 interaction. Cys 597 nitrosylation dampens eNOS activity and it was 
suggested that a conformational change in the Hsp90 structure and subsequent disruption 
of the eNOS-Hsp90 complex, might account for this (Martinez-Ruiz et ah, 2005). 
Mechanistically, this finding shows an elegant autoregulation of eNOS activity by eNOS- 
derived NO. This feedback mechanism could allow for endothelial protection from 
overwhelming amounts of NO.
Dynamin-2
Dynamins are a large family of GTPase proteins originally isolated from bovine 
brain. Functionally, dynamins are involved in scission of clathrin-coated pits from the 
plasma membrane during endocytosis. There are three dynamin isoforms that are 
differentially expressed in various cell types. Dynamin I is predominantly found in 
neurons, dynamin II is ubiquitously expressed in many cell types and dynamin III is 
restricted to testis, brain, lung and heart (for review see (Praefcke & McMahon, 2004)). 
Dynamin II is targeted to Golgi membranes and colocalizes with caveolin. At the neck of 
caveolae, dynamin is involved in vesicular fission from the plasma membrane and 
subsequent internalization of caveolar membranes.
Cao and colleagues observed that eNOS and dynamin II reside in the same 
membrane compartments, suggesting a possible interaction between the proteins (Cao et 
al., 2003). They went on to confirm the eNOS-dynamin II association both in vivo and in
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vitro and showed that dynamin II potentiates eNOS catalysis. In vitro studies showed that 
dynamin II has an affinity for eNOS in the nanomolar range (K^ -'27 nM) (Cao et a l, 
2001). In the presence of elevated Ca^ the dynamin mediated increase in eNOS activity is 
heightened, suggesting regulation by intracellular signals. To date, the physiological 
implications of the eNOS-dynamin complex remain elusive.
S-niti^osylation o f dynamin
Dynamin has been implicated as a target for S-nitrosylation. The S-nitrosylation 
site on dynamin is Cys 607, located in the pleckstrin-homology (PH) domain and 
conserved among dynamin family members (Wang et a l, 2006). eNOS and dynamin 
exist as a complex at caveolar pockets and this interaction is thought to localize dynamin 
to the plasma membrane (Cao et a l, 2001). S-nitrosylation of Cys 607 may facilitate the 
assembly of dynamin complexes to enable (32-adi'energic and EOF receptor internalization 
and GTPase activity (Wang et a l , 2006).
The eNOS-Caveolin/CaM Cycle
The binding of eNOS to caveolin-1 has been shown to inhibit eNOS activity. This 
inhibition may be explained by a competitive interaction between calmodulin and 
caveolin-1 for binding to eNOS, suggesting a dynamic regulation of the enzyme by 
intracellular calcium concentrations. As a consequence of agonist-induced increases in 
intracellular calcium levels, calmodulin-binding disrupts the eNOS/caveolin-1 interaction 
and completely reverses the inhibitory effect of caveolin-1 by allowing inter-domain 
electron flux from the reductase to the oxygenase domain of eNOS. The eNOS/CaM
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complex apparently produces NO until intracellular calcium levels drop to a concentration 
at which the lobes of calmodulin revert to their uncompacted form and the eNOS-CaM 
complex dissociates, resulting in the reformation of the eNOS-caveolin complex (Michel 
et a l, 1997; Michel et a l, 1997). The precise details of the sequence of events involved in 
the recycling of eNOS are unclear, however experiments have shown that prolonged 
agonist activation leads to eNOS depalmitoylation, translocation from the caveolae to the 
cytosol, phosphorylation and eventually reassociation of the eNOS-caveolin complex 
(Garcia-Cardena et a l, 1996).
The identity of the intracellular compartment to which eNOS tianslocates after 
dissociation from caveolin-1, as yet, unknown. It is likely that some of the 
depalmitoylated eNOS is confined to non-caveolar regions of the plasma membrane 
(Shaul et a l, 1996). Other possible targets are the trans-Golgi system and intracellular 
vesicles derived from caveolae. The interaction of eNOS with caveolae is facilitated by, 
but not dependent on, acylation (Feron et a l, 1998); myristoylation targets eNOS to the 
plasma membrane and when combined with palmitoylation, eNOS is targeted to caveolae. 
As a result, agonist induced depalmitoylation does not reverse the tonic inhibition of 
eNOS by caveolin-1. Instead, it is proposed that palmitoylation may serve a role in the 
stabilization of the eNOS-caveolin complex upon reformation.
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Figure 1.14. Crystal Structure of Human Calmodulin based on X-ray Diffraction Studies.
Structure taken from the protein data bank (PDB ID: ICLL) and modified using the molecular 
simulation program Insight II. Clearly illustrated are the EF-hands (yellow), calcium-binding 
motifs.
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Figure 1.15. Four-Step model of eNOS activation by Ca /CaM. (1) In a resting 
cell (100 nM Ca^^), CaM exists with two Ca^  ^ ions bound to the C-lobe, the C-lobe 
is therefore compacted and primed for binding to eNOS. (2) The compacted C-lobc 
interacts with the CaM-binding site of eNOS, but the enzyme remains inactive. (3) 
A stimulus-evoked increase in intracellular Ca^  ^ (s i pM) causes the binding of 
Ca“^  to the two remaining EF-hands of CaM-causing compaction of the N-lobe. 
However, eNOS remains inactive. (4) Binding of the compacted N-lobe of CaM to 
eNOS elicits full activation.
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CHAPTER 2
2.0 AIMS AND OBJECTIVES
In the vasculature, endothelium-derived NO provides raoment-to-moment control 
of blood flow, blood pressure, extravasation of cells and expression of pro-inflammatory 
mediators. While these and other actions of NO are known to result from specific 
chemical modifications of protein targets, the exact molecular mechanisms involved 
remain elusive.
Efficient signal transduction events are dependent on correct localization and 
assembly of signaling proteins within discrete subcellular microdomains. The existence of 
multimeric protein complexes imposes spatial and temporal confinement to signaling 
systems, allowing tight regulation of the cell’s biochemical, physiological and signaling 
properties. This paradigm certainly holds true for the NOS family of enzymes. The 
fundamental importance of the subcellular organization of NOSs within cells was best 
exemplified in a study by Barouch et al, who showed that in cardiac myocytes eNOS and 
nNOS co-exist at distinct subcellular compartments, the plasma membrane and 
sarcoplasmic reticulum respectively, yet the NO produced by each iso form has 
independent and opposing effects on cardiac function as exemplified in Figure 2.1 
(Barouch et a l, 2002). Spatial confinement of eNOS and nNOS within cardiomyocytes, 
can couple NO to discrete signaling pathways that regulate diverse cardiac functions 
within the same cell. Indeed the intiacellular concentration of NO and NO-derived 
species at specific sites may be a key determinant of the pathways responsible for 
downstream signaling. Mechanistically, NO acts predominantly via two independent
pathways: protein S-nitrosothiol formation and activation of sGC, leading to intracellular 
cGMP accumulation. The subcellular confinement of NOSs at distinct organelles 
presumably dictates the specific protein-protein interactions that NOS can achieve with 
other signaling effectors and additionally determine which of the alternative reactions of 
NO can be efficiently carried out.
The importance of cell signaling complexes has been most extensively studied in 
the context of receptor-dependent protein phosphorylation cascades, revealing that 
spatially and temporally restricted modifications are an integral part of signaling in all 
mammalian systems. An analogous “cascade” for S-nitrosylation of proteins within NOS- 
containing multimeric protein complexes is anticipated, but has not been explored. The 
prevailing model for NO signaling holds that NO travels within (autocrine) or between 
(paracrine) cells via simple random diffusion, reacting with target proteins en route. This 
dogma fails to addi ess key issues relating to the apparent specificity of NO addition to a 
discrete subset of cysteine residues in proteins. We hypothesize that proximity-based 
transfer of NO to specific protein cysteine residues is a key determinant of which proteins 
become modified by NO. To address this possibility, we have adapted a system for on- 
demand localization of eNOS to distinct subcellular loci, including the cytosol, plasma 
membrane, nucleus, Golgi and mitochondria. Tliese studies, coupled with proteomic- 
based approaches for SNO-protein detection, should provide a powerful tool to elucidate 
fundamental molecular mechatiisms governing NO reaction specificity. Additionally, we 
aim to address critical questions relating to an infened physiological role for eNOS 
localization to the outer mitochondrial membrane, specifically on cNOS’s capacity for NO 
synthesis, susceptibility to undergo posttianslational modifications, identity of interacting
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proteins and potential for selective targeting of NO to mitochondrial proteins. A key 
question is whether NO has differing effects on mitochondrial functions when the NO is 
produced by eNOS on the outer mitochondrial membrane versus eNOS in the cytosol or 
elsewhere.
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CHAPTER 3 
DESIGN OF VECTORS FOR IDENTIFICATION AND 
CHARACTERIZATION OF eNOS SIGNALING COMPLEXES
3.0 Introduction
eNOS is a central regulator of cardiovascular homeostasis with established roles 
in vasorelaxation, angiogenesis, regulation of cardiac contractility and platelet 
aggregation (reviewed by (Loscalzo & Welch, 1995)), The production of NO by eNOS is 
a highly-regulated event and occurs in response to various physiological stimuli (for 
review see (Dudzinski et a l, 2006; Sessa, 2005)). Principally, eNOS is characterized as a 
Ca^VCaM-dependent enzyme, yet extensive work has demonstrated additional modes of 
eNOS regulation, including phosphorylation, protein-protein interactions and acylation 
(Fleming & Busse, 2003; Fulton et a l, 2001; Kone, 2000). Fatty acid modifications of 
eNOS, specifically myristoylation of glycine 2 and dual-palmitoylation at cysteines 15 
and 26, dictate the subcellular organization of eNOS and hence, the function of signaling 
complexes within the vascular endothelium (Sessa et a l, 1992), Assembly of eNOS into 
specific signaling domains, places cognate target proteins in close proximity and is likely 
to serve a fundamental role in enabling efficient NO signaling.
In both intact vessels and cultured endothelial cells, eNOS is confined to the 
caveolar pockets and lipid-rafts of the plasma membrane, in addition to the cw/medial 
Golgi membrane (Garcia-Cardena et a l, 1996; Liu et a l, 1996). Biochemical studies 
illustrated that myristoylation-deficient eNOS is a cytosolic and catalytically competent 
enzyme, but in comparison to native eNOS, displays attenuated NO release, an
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observation attributed to inefficient Seri 179 phosphorylation (Fulton et a l, 2002; 
Gonzalez et a l, 2002). Although eNOS regulation and fimction has been best 
characterized at the Golgi and plasma membranes, it has been demonstrated that eNOS 
can translocate into the nucleus (Feng et a l, 1999), as well as dock onto the 
mitochondrial outer membrane (Gao et a l, 2004). The functional consequence of eNOS 
inside the nucleus has not been properly characterized, but recent work suggests that the 
nuclear environment is catalytically unfavorable for NO production by eNOS (Jagnandan 
et a l, 2005). The identification of eNOS on the outer surface of the mitochondria raises 
questions concerning the regulation of eNOS and functional consequence of 
mitochondrial eNOS-derived NO. Recent findings have shown that eNOS plays a key 
role in mitochondrial biogenesis via NO-mediated modification of nuclear proteins 
(Nisoli et a l, 2004a; Nisoli et a l, 2003; Nisoli et a l, 2004b; Nisoli et a l, 2004c; Nisoli 
et a l, 2005). Mechanistically, it remains unknown whether the source of this NO is 
nuclear or mitochondrial eNOS.
Subcellular localization of eNOS is a key determinant of the precise role 
subserved by eNOS-derived NO in vascular homeostasis. To rigorously address the 
functional and regulatory role of eNOS at distinct subcellular organelles and identify 
novel protein interactors, we developed eNOS chimera that contain specific “zip codes” 
that deliver eNOS to the nucleus, plasma membrane (both caveolar and non-caveolar), 
cytosol, Golgi and the sub-precincts of the mitochondria. Additionally, we devised a 
novel technique that enables small molecule-triggered, on-demand translocation of eNOS 
to desired cellular organelles. The latter is the focus of Chapter III. Herein is a summai*y 
of the molecular biological approaches applied to develop targeting vectors that enable
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eNOS-targeting to desired subcellular structures providing a tool to assess eNOS fimction 
at these loci.
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3.1 Materials and Methods 
3,L I Materials.
Mouse monoclonal antibodies against GM130 and eNOS were from BD 
Biosciences (San Diego, CA). Rabbit polyclonal anti-eNOS antibody (Ab) was from 
Upstate Biosciences (Charlottesville, VA), rabbit polyclonal anti-FKBP Ab was from 
Affinity Bioreagents (Golden, CO), anti-MnSOD Ab was from Stressgen (Ann Arbor, 
MI) and Rabbit polyclonal anti-actin Ab was from Sigma (St.Louis, MO). pcDNA3- 
eNOS and pcDNA3-CD8-eNOS were gifts from Dr. David Fulton (Medical College of 
Georgia, GA). pRc/CMV-EGFP-Tom5 and pEGFP-golgin97 (pFB128) were obtained 
from Dr. Mihara (Kyushu University, Japan) and Dr. Barr (Max-Planck Institute, 
Germany), respectively. Restriction enzymes and all other molecular biology reagents 
were from Fermentas Inc. (Hanover, MD) and New England Biolabs Inc. (Beverly, MA). 
Tris-HCl, paraformaldehyde and all other chemicals were obtained from Sigma, unless 
otherwise stated.
3.1.2 Cell Culture Conditions and Transfection.
The immortalized human epithelial kidney cell line, HEK293T, and the monkey 
fibroblast cell line, C0S7, were grown in high glucose Dulbecco’s modified Eagle’s 
media (DMEM) (Invitrogen, Carlsbad, CA) supplemented with 10% (v/v) fetal bovine 
serum (FBS), penicillin (100 units/ml)/streptomycin (100 ng/ml), L-glutamine (2 mM) 
and fungizone (2.5 pg/ml) (complete DMEM) at 37°C in a humidified atmosphere of 5% 
CO2 . For transfection, both HEK293T and COS7 cells were grown in serum-fr ee media 
for 24 h prior to transfection at an approximate density of 1 x 10  ^ cells/well in a 6-well
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plate. Transfections were carried out using FuGENE 6  according to the manufacturer’s 
instructions (Roche Diagnostics, Indianapolis, IN). Low serum OptiMEM media (97 |xl) 
(Invitrogen) was added to the appropriate number of sterile 0.7 ml tubes. Subsequently 3 
pi of FuGENE 6  reagent was added directly to the OptiMEM, and the 
OptiMEM/FuGENE 6  mixture was allowed to stand at RT for 5 min. The desired cDNA 
was added (1.0 pg), and tubes were gently tapped to mix contents then incubated at RT 
for 25 min. The mixture was added to the cells drop-wise and evenly dispersed. Cells 
were returned to the incubator for 6 - 8  h, after which the transfection media was removed 
and replaced with complete DMEM.
3.1.3 DNA Primers and Sequencing
Synthesis of all nucleotide primers was performed by either Invitrogen or 
GeneLink (Hawthorne, NY). All plasmid consti'ucts were confirmed by sequencing 
using GENEWIZ Sequencing Services (North Brunswick, NJ).
3.1.4 Generation o f Subcellular Localization Plasmids
Constructs ChemicallnducedDimerization (CID)
Table 2.1 shows a summary of the localization signals used to move eNOS to the 
various subcellular compartments. Vector PC4 M-F2E (ARIAD Pharmaceuticals, Inc. 
Pharmaceuticals, Inc., Cambridge, MA) is a chimeric fusion protein containing an N- 
terminal myristoylation signal, two copies of FKBP, followed by a hemagglutinin-tag 
(HA) and expression is under the control of the human cytomegalovirus (CMV) 
enhancer/promoter. To tianslocate the FKBP-FKBP frision protein to distinct subcellular
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loci, the myristoylation sequence was removed by digestion using EcoR I  and Xba I  and 
replacement with an oligonucleotide encoding the desired peptides, as described below.
Membrane Targeted Constructs -  PC4M-F2E
The PC4M-F2E vector (ARIAD Pharmaceuticals, Inc.) encodes a fusion protein 
containing an N-terminal myiistoylation signal that directs two FKBP modules to the 
cytoplasmic face of cellular membranes (e.g. plasma and Golgi membranes).
Mitochondria-targeted Constmcts
Mitochondria contain multiple compartments including the, outer membrane, 
inner membrane and matrix. Our experiments sought to localize eNOS, constitutively or 
on-demand using CID, to each of these three mitochondrial compartments.
Outer Mitochondrial Membrane Construct - pC 4M-Tom5
Several studies have shown that the yeast Tom5 (translocase of outer membrane 
5) cDNA sequence targets GFP fusion proteins to the mitochondrial outer membrane. 
However, fusion proteins must contain Tom5 fused to their C-termini, rather than their 
N-termini (Horie et a l, 2002, 2003). To direct FKBP to the outer mitochondrial 
membrane, the localization sequence of PC4 M-F2E was first removed to prevent 
mislocalization (new plasmid was named PC4 M-F2E’). Next, the Tom5 cDNA was 
amplified using pRc/CMV-EGFP-Tom5 as a template and cloned into the Spe I/BamH I  
site of PC4 M-F2E’, replacing the HA-tag (PC4M-F2E ' -Tom5). Tom5 prhners: (sense) 5’- 
GGACTAGTATGTTTGGTCTACCTCAACAG-3’. (antisense) 5’-CGGGATCCTTAT
75
TTCCATTGCTTTTTCAC-3’. To enable fusion peptide immunoprécipitation, the Mlu 
UXba I  fragment was replaced with a PCR amplified Mlu I/Xba I  fragment of PC4EN-FI 
lacking an NLS sequence but containing the HA-tag: (sense) 5’-
CGACGCGTTCGAGCTCGCCCCGTTACAT-3’. (antisense) 5 '-GCTCTAGAACTAG 
AAGGTCCTCCCAGGCTG. The final expression plasmid was teimed pC4M-Toni5 .
Inner Mitochondrial Matrix Construct- PC4M-C0 X
The mitochondrial targeting sequence from subunit VIII of human cytochrome c 
oxidase (Cox (Su VIII)) has been used to localize fusion proteins to the mitochondrial 
matrix. Tlie Cox (Su VIII) cDNA targeting sequence was synthesized by PCR in 
annealing buffer (10 nM Tris-HCl, pH 7.5, 100 mM NaCl, 1 mM EDTA) using the 
following cycle: 95°C for 3 min, 25°C for 90 min. The Cox (Su VIII) primers used were: 
(sense) 5 ’ -AATTCATGTCCGTCCTGACGCCGCTGCTGCTGCGGGGCTTGACAGG 
CTCGGC CCGGCGGCTCCCAGTGCCGCGCGCCAAGATCCATTCGTTGT-3’, (anti­
sense) 5’-CTAGACAACGAATGGATCTTGGCGCGCGGCACTGGGAGCCGCCGGG 
CCGAGCCTGTCAAGCCCCGCAGC AGC AGCGGCGTCAGGACGG ACATG-3 '. As 
a means to track FKBP localization intracellularly GFP was cloned onto the C-tenninus 
of the PC4 M-C0 X vector, to yield PC4 M-C0 X-GFP (Cox-FKBP-FKBP-GFP).
Nucleus-targeted Construct - PC4EN-FI
PC4EN-FI (ARIAD Pharmaceuticals, Inc.) contains an N-terminal HA-tag, 
followed by a nuclear localization signal from SV40 large T-antigen and a single copy of
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FKBP. Expression is under the control of the CMV enhancer/promoter. This plasmid 
was used as provided by ARIAD Pharmaceuticals.
Golgi Complex-Targeted Construct -  PC4EN-GRIP
The GRIP domain is a conserved amino acid targeting sequence found in a family 
of coiled-coil peripheral Golgi proteins, including golgin-97. Several groups have found 
that GRIP containing proteins are recruited to the tubulovesicular structures of the ti'ans- 
Golgi network (TGN), GFP studies revealed that the GRIP domain is both necessary and 
sufficient for Golgi-targeting in animal cells (Munro & Nichols, 1999). The GRIP 
domain (-51 amino acids) of golgin-97 was amplified by PCR using pFB128 as template 
and cloned, in frame, into the Spe I  site of PC4 EN-FI: (sense) 5 ’-GGACTAGTATGGT 
C ACGAAT A AC ACTG-3 ’, (antisense) 5 ’ -GGACT AGTGGACC ATGGT ATCCG AGG 
G-3’. The amplified sequence encodes the entire GRIP domain -  MVTNNTDLTD'^AREI 
NLEYLK HVVLKFMSCR'eSEAFHLIKA'VsVLLNFSQE E. The existing nuclear 
localization sequence (NLS) of PC4EN-FI was removed by digestion using Mlu UXba I  
and replaced with a PCR amplified Mlu I/Xba I  fr agment of PC4EN-F1, devoid of an NLS 
sequence, but containing the HA-tag: (sense) 5’-CG ACGCGTTCGAGCTCGCCCCGT 
TACAT-3% (antisense) 5’-GCTCTAGAACTAG AAGGTCCTCCCAGGCTG.
3.1.5 Generation of eNOS Fusion Proteins for CID-Based Assays.
Standard molecular cloning techniques were used to manipulate DNA. The 
mammalian expression vectors, pcDNA3-eN0S and pcDNA3-CD8-eNOS, were used to 
construct pcDNA3-eN0S-GFP, pcDNA3-FRAP-eN0S and pcDNA3-FRAP-eN0S-GFP.
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To generate pcDNA3-eN0S-GFP, a region of eNOS known to contain a unique Xho I  
site was PCR amplified up to the eNOS stop codon; (sense) 5 TCCCGCGGCG 
GGGCCACATGTTTGTCTG-3’, (antisense) 5’-CTAGCTAGCGGGGCCGGGGGGT 
GTCTGGGC-3’. Primers were designed to introduce Sac II  and an Nhe I  sites on the 5’ 
and 3’ flanks, respectively (bold and underlined bases represent restriction sites). The 
PCR product (termed Xho I  fragment) was then cloned into the Sac II/Nhe I  site of the 
pQBI-25 GFP expression vector (Qbiogene, Carlsbad, CA). Subsequently, the Xho I  
fragment, fused N-terminally to the GFP cDNA sequence, was amplified with the 
following primers: (sense) 5 ’-CCGCTCGAGCGGGGCCACATGTTTGTCTG-3 ’, 
(antisense) 5 -GCTCTAGAT TACTAGTGGATCCTCAGTTG-3 '. The product of this 
PCR reaction was then cloned, in-frame, into the Xho I/Xba I  site of pcDNA3-eN0S 
yielding pcDNA3-eN0S-GFP. To generate pcDNA3-FRAP-eN0S and pcDNA3-FRAP- 
eNOS-GFP, FRAP was amplified using pC4 -RhE as template (ARIAD Pharmaceuticals, 
Inc. Pharmaceuticals, Inc.) and cloned into the Hind III/Not I  ûtQ of pcDNA3-CD8-eNOS 
to generate pcDNA3-FRAP-eNOS: (sense) 5 '-CCCAAGCTTATGATCCTCTGGCAT 
GAGA-3 ’, (antisense) 5 ’-AAATATGCGGCCGCACTAGTCTTTTGAGATTC-3 ’.
Subsequently, GFP was cloned into pcDNA3-FRAP-eNOS, from the pcDNA3-eN0S- 
GFP plasmid using Xba I/Xho I  restriction enzymes.
3.1.6 Organelle-Restricted eNOS Constructs
Cytosolic eNOS—pcDNA 3- G2A eNOS
A cytosol expressed form of eNOS, in which the glycine at position 2 is mutated 
to alanine (G2AeNOS) (Liu & Sessa, 1994), was created by site-directed mutagenesis
7«
using the QuickChange XL Site-Directed Mutagenesis Kit from Stratagene (La Jolla, 
CA). The primers used were: (sense) 5’-CGTCCGGCCCCAGCGCCATGGCCAACTT 
GAAGAGTGT-3’, (antisense) 5’-ACACTCTTCAAGTTGGCCATGGGCGCTGGGGC 
CGGACG-3 ’. These mutagenic primers, in addition to substituting glycine 2 for alanine 
(nucleotide in red), also introduced a new Nco I  site (bold and underlined) that was used 
to identify positive clones. A polymerase chain reaction was setup, using pcDNA3- 
eNOS (WT) as template and P/wTurbo DNA polymerase (Stratagene). The PCR- 
amplified product was transformed into XL 10-Gold ultracompetent cells (Stratagene) and 
grown on LB agar plates containing 50 j.ig/ml ampicillin. Screening of positive clones 
was done by restriction digest using Nco I  confirmed by sequencing.
Outer Mitochondrial Membrane-Targeted eNOS Construct—pcDNA3-eNOS-Tom5
The eNOS Xho /-fragment was amplified using primers containing a 5’ Xba I  site 
and 3’ Sac II site: (sense) 5 '-GCTCTAGACGGGGCCACATGTTTGTCTG-3'. 
(antisense) 5 '-TTCÇÇGCGGGGGGCCGGGGGGTGTCTGGGC-3 '. The product of 
this PCR was purified from a 1% agarose gel and ligated into the Xba I/Sac II site of 
pRc/CMV-EGFP-Tom5 (ligation removes the EGFP module and replaces it with the 
eNOS Xho I  fragment). The Xho I  fragment-Tom5 fusion was amplified and cloned into 
the Xho I/Xba I  site of pcDNA3-G2AeNOS, using the following primers: (sense) 5’- 
CCGCTCGAGCGGGGCCACATGTTTGTCTG-3 '. (antisense) 5’-GCTCTAGATTAT 
TTCCATTGCTTTTTCAC.
Inner Mitochondrial Membrane-Targeted eNOS Construct—pcDNA3-CytCl-eNOS
7Q
The 59 amino acid subunit Vila of cytochrome-c oxidase (CytCl), targets 
proteins to the imier mitochondrial membrane (Duhl et a l, 1990). Primers were de­
signed to amplify the CytCl fragment using bg20-CytCl vector (a gift from Dr. 
Manffedi, Weill Medical College, NY) as template. The PCR product was cloned onto 
the N-terminus of pcDNA3-CD8-eNOS using Hind /  restriction sites: (sense) 5’-
CCC AAGÇTTATGTTTTC A A ATCT ATCT AAAC-3 ', (antisense) 5’-ATTCTTATGC 
GGCCGCCTGCGGTCATA GCTTC-3’.
Inner Matrix-Targeted eNOS Construct - pcDNA3-Cox-eNOS
Localization to the mitochondrial matrix was accomplished by fusion of the 
targeting sequence derived from human cytochrome-c oxidase (Cox) subunit VIII 
(MSVLTPLLLRGLTGSARRLPVPRAKIHSL) onto the N-terminal domain of CD8 - 
eNOS after digestion with Not I/Hind IIII (removes CD8  targeting peptide from eNOS N- 
terminus). The primers used to amplify Cox were: (sense) 5' CCCAAGCTTA 
TGTCCGTCCGTCCTGACGCCGC-3’, (antisense) 5’-ATTCTTATGCGGCCGCCAA 
CGAATGGATC-3’. The template used for the PCR reaction was PC4 M-C0 X.
Nuclear-Targeted eNOS Constmct - pcDNA3-NLS-eNOS
Nuclear-targeted eNOS was achieved by fusion of three tandem repeats of the 
SV40 nuclear localization sequence (PKKKRKVD) onto the eNOS N-terminus. The 
following primers were used to synthesize the tipartite NLS in annealing buffer (10 nM 
Tris-HCl, pH 7.5, 100 mMNaCl, 1 mM EDTA): (sense) 5 ' - AGCTT ATGGATCC A A A A 
AAGAAGAGAAAGGTAGATCCAAAAAAGAAGAGAAAGGTAGATCCAAAAAA
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GAAGAGAAAGGTAGC-3’, (antisense) 5’-GGCCGCTACCTTTCTCTTCTTTTTTGG 
ATCTACCTTTCTCTTCTTTTTTGGATCTACCTTTCTCTTCTTTTTTGGATCCATA- 
3’.
Golgi-Targeted eNOS Consti^uct - pcDNA3-eNOS-GRIP
Targeting to the tram-QoXgi membrane was achieved by fusion of the GRIP 
domain onto the C-terminus of pcDNA3-G2AeNOS. The GRIP domain was amplified 
using pFB128 as template, with the following primers that introduce 5’ Sac II and 3’ Apa 
I  restriction sites: (sense) 5’-TCCCGCGGATGGTCACGAATAACACTGAC-3\ 
(antisense) 5’-GCGGGCCCGGACCATGGTATCCG-3’. The PCR product was ligated 
into the Sac II/Apa I  site of pRc/CMV-EGFP-Tom5 (this removes the Tom5 sequence 
and replaces it with the GRIP domain). Subsequently the Xho /-fi*agment of eNOS was 
amplified and cloned into the Xba IlSac II  site of pRc/CMV-EGFP-GRIP, followed by a 
second PCR to amplify the Xho 7-ffagment-GRIP domain for fiision onto the pcDNA3- 
G2AeN0S C-terminus via Xho I/Xba I  ligation. Primers used were: (sense) 5’-CC 
GCTCGAGCGGGGCCACATGTTTGTCTG-3(antisense) GCTCTAGAGGACCAT 
GGTATCCG-3’
3.1.7 Immunoblotting
Transfected and untransfected cells were washed twice in ice-cold PBS and lysed 
by addition of ice-cold lysis buffer (50 mM Tris-HCl, pH 7.7, 150 mM NaCl, 1% NP-40, 
1% Sodium Deoxycholate, 1 mM Sodium Vanadate, 50 mM NaF, 10 mM Na4P20?, 2 
mM EDTA, 2 mM PMSF, 1 mg/ml Protease Inhibitor Cocktail (Roche)), directly onto
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the cell monolayer. Cells were scraped with a rubber policeman and insoluble material 
removed by centrifugation at 14,000 rpm for 10 min at 4°C. The supernatant was 
removed and protein content measured using the BioRad Protein Assay using BSA 
standards (BioRad, Hercules, CA). After normalizing for equal protein, samples were 
subjected to SDS-PAGE, followed by tr ansfer of proteins by electroelution (300 mv, 90 
min, 4°C) to nitiocellulose membranes (0.2 pm pore size, Invitrogen). Nonspecific 
protein binding was blocked by incubating membranes in blocking buffer (Tris-buffered 
saline containing 0.1% Tween 20 (TBST) and 5% nonfat dry milk) at room temperature 
for 2 h. Membranes were washed 3X in TBS and incubated overnight at 4°C with anti- 
eNOS (1:2500) or anti-FKBP (1:1000) in blocking buffer. Membranes were washed 3X 
in TBS and incubated for 90 min at room temperature in blocking buffer containing 
Horseradish peroxidase-conjugated goat-anti-mouse or goat-anti-rabbit secondary 
antibodies (1:3000) (Zymed). LumiGLO chemiliiminescent substrate (Cell Signaling, 
Danvers, MA) or ECL Plus (Amersham, Piscataway, NJ) was used to visualize bound 
primary antibodies, according to the manufacturer’s instructions.
3,1.8 Fluorescence Microscopy
Transfected cells were plated onto sterile uncoated or poly-D-lysine coated 
coverslips in complete DMEM. At approximately 70-80% confluency, the cells were 
fixed for 10 min at room temperature in 4% paraformaldehyde in PBS supplemented with 
0.1% sodium azide and then permeabilized with 0.2% Triton X-100 in PBS for 5 min. In 
some cases, cells were fixed and permeabilized in ice-cold acetone/methanol (1:1) for 10 
min at -20°C. Cells were washed 2X in PBS and 2X in PBS/1% bovine serum albumin
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(BSA) and then blocked in PBS/5% goat serum/1% BSA for 30min at 37°C. 
Subsequently, cells were incubated for 2 h at room temperature in blocking buffer 
containing anti-eNOS (1:300), anti-MnSOD (1:300) or AlexaFluor 488/546 conjugated 
anti-HA (1:500). Alexa-Fluor 488/546 anti-rabbit or anti-mouse (1:1000) secondary 
antibodies (Molecular Probes) were incubated for 1 h at room temperature. Nuclei were 
stained with 4’ -6-Diamidino-2-phenylindole (DAPI) for 5 min at room temperature 
(Molecular Probes). Slides were mounted with VECTASHIELD (Hardset) mounting 
media (Vector Laboratories Burlingame, CA) and cells were visualized with an inverted 
Nikon Eclipse TE2000 microscope (Nikon, Melville, NY). All presented images were 
representative of 30-50 images analyzed from 3 or more independent experiments.
3,L9 Image Deconvolution
Images were distally captured from a Nikon Eclipse TE-2000 inverted epi- 
fluorescence microscope. In general, 15-20 Z-plane optical sections, spaced by 0.1 pm, 
were acquired. The best optical section for each data set is represented in this study. 
Exposure times were set so that the camera was in the linear range for each fluorophore - 
exposure times for all fluorescent images were kept constant. A 63X (NA 1.0) oil- 
immersion lens was used. The data sets were three-dimensionally deconvoluted using 
AutoDeblur (AutoQuant, Silver Spring, MD) and stack images were collapsed to a single 
image using the “best focus” projection. Image analysis was performed with MetaMorph 
(Molecular Devices, Sunnyvale, CA).
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3.2 Results
3.2.1 Targeting eNOS to Subcellular Organelles
Table 3.1 summarizes the localization sequences used in this study to target eNOS 
to distinct subcellular organelles. Expression of plasmids encoding the desired organelle 
targeting peptide fused to either the C- or N-terminus of eNOS, were constructed as 
described in Methods and depicted schematically in Figure 3.1. Detailed experimental 
stiategies for generation of eNOS-GFP, G2AeNOS and organelle restricted eNOS 
chimera are considered below. The subcellular loci chosen for eNOS targeting were 
selected based on literature implicating these as the most relevant to eNOS cell biology, 
regulation and native residence. These primary sites of interest are plasmalemma, trans- 
Golgi membranes, nuclei and mitochondria.
3.2.2 Fusion o f  eNOS with GFP Does Not Interfere with Subcellular Localization.
We initially asked whether we could use GFP as a reporter protein to study eNOS 
localization in living cells. To this end, eNOS was constructed with GFP fiised to its C- 
terminus as depicted in Figure 3.2. To assess the expression of the eNOS-GFP fusion 
protein, COS-7 cells were transiently transfected with expression plasmids for GFP alone 
(Fig. 3.3), eNOS alone (Fig. 3.4) or with full-length eNOS fused in frame with C- 
terminal GFP (Fig. 3.5). Consistent with previously published reports (Liu et a l, 1997), 
cells transfected with GFP alone showed diffuse fluorescence throughout the cell with 
higher concentrations observed at the nucleus (Fig. 3.3). When COS-7 cells were 
transfected with eNOS (WT) and eNOS was determined immunohistochemically, intense 
perinuclear fluorescence was observed as well as a faint fluorescence at the plasma
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Figure 3.2. Generation of eNOS-GFP fusion protein. A. Amplification of the Xho I
fragment using primers engineered to encode an N-terminal Sac II  and C-terminal Nhe I  
site. The gel shows the resulting PCR reaction yielding a band at ~300bp. B. Cloning of 
the resulting Xho I  fragment into the Sac II  and Nhe I  sites of the pQBI-25 GFP vector 
yields the Xho /-GFP fusion which appears at an approximate size of 1007bp. C. Primers 
engineered to give a 5^ Xho I  and 3’ Xba I  site were used to amplify the Xho /-GFP 
fragment and this was gel-purified and cloned into the Xho I/Xba I  site of pcDNA3-eNOS. 
As confirmed by gel electrophoresis and restriction digest, clones 1-10 yielded the correct 
digestion pattern for Xho I/Xba I  digest of pcDNA3-eNOS-GFP. D. To further confirm 
the construction of pcDNA3-eN0S-GFP, primers to the 5’ and 3’ flanks of eNOS and 
GFP respectively were used to amplify eNOS-GFP (~4335bp). Positive clones were 
further verified by sequencing, expression and immunohistochemistry.
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Figure 3.4. Subcellular distribution of wild-type eNOS. COS-7 cells were 
transfected with pcDNA3-eNOS (WT), fixed and probed with anti-eNOS antibody. The 
figure illustrates the cellular localization of eNOS to the Golgi apparatus (filled arrow 
head) as well as hot-spots on the plasma membrane (open arrow heads).
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membrane (Fig. 3.4). To detennine the subcellular distribution of eNOS-GFP, COS-7 
cells were transiently transfected with pcDNA3-eNOS-GFP and counter stained with a 
Golgi marker protein, GM130. The cells revealed an intense co-localization of eNOS- 
GFP with the Golgi marker (Fig. 3.5), a similar observation to that made by Sowa et al 
(Sowa et a l, 1999). Additionally, there was notable staining at the plasma membrane of 
some cells consistent with reports showing that eNOS resides in caveolae and interacts 
with caveolin-1 in the plasmalemma (Fig. 3.5) (Garcia-Cardena et a l, 1996; Shaul et a l, 
1996).
The use of GFP as a means to track eNOS within cells is advantageous from a 
methodological point of view -  this approach does not rely on antibody specificity, is 
unaffected by the harsh potentially disruptive biochemical procedures inherent in slide 
preparations and it additionally allows for in vivo tracking of eNOS. The findings clearly 
illustrate that eNOS-GFP localizes to the same cellular compartments as wild type eNOS. 
Since cell cycle status and cell confluency at the time of transfection may affect the 
overall subcellulai- distribution of the fusion protein within cells, the conduct of all 
studies routinely used cells seeded at an identical density and transfected when they 
reached 60-70% confluency. Based on my findings and those previously published (Liu 
et a l, 1997; Sowa et al., 1999), tagging of eNOS with GFP at the C-terminus results in an 
intracellular localization that is indistinguishable to that of native eNOS (WT).
3.2.3 Generation o f eNOS Targeting Constructs
eNOS (WT), or a cytosolic mutant of eNOS (G2AeNOS) that cannot undergo 
myristoylation, were used to generate eNOS fusion proteins intended to selectively target
q?
the plasma membrane, Golgi complex, mitochondrial sub-precincts and the nucleus (Fig. 
3.1).
Mutation o f Glycine-2 converts eNOS from a membrane-associated to a cytosolic protein.
Previous in vitro studies have shown that eNOS retains full catalytic activity in 
the absence of myristic acid incoi*poration at Gly 2. Yet, when expressed in cultured 
cells, G2AeN0S does not exhibit the native plasmalemmal and Golgi localization and, as 
a consequence, demonstrates an impaired ability to release NO in response to agonistic 
stimuli and undergoes reduced phosphorylation at Seri 179 (Fulton et a l, 2002; Gonzalez 
et al., 2002; Lin et al., 2000). Considering non-native localization of G2AeN0S, we 
used the G2A mutant to generate chimera that were intended to target the Golgi 
apparatus, nucleus and mitochondrial loci.
G2AeNOS was generated by site-directed mutagenesis of pcDNA3-eN0S (WT). 
Figure 3.6A shows the 5'-termini of an oligonucleotide encoding eNOS (WT). Primers 
for mutagenesis were designed to substitute glycine 2 with alanine, as well as 
incorporating an Nco I  restiiction site to rapidly screen positive clones (Fig. 3.6A). 
Notably, the inclusion of a novel Nco I  site into the native eNOS (WT) sequence yields 
an additional restriction fragment at 300 bp. Screening of 6 clones for cleavage by Nco I  
suggested that clones 3, 4 and 5 were positive G2AeN0S clones (Fig. 3.6B). To further 
confirm this interpretation, all three clones were sequenced. Immunohistochemical 
preparations of COS-7 cells transfected with pcDNA3-G2AeNOS confirmed the 
expression of myi'istoylation-deficient eNOS and demonstrated cytosolic localization, as 
previously described (Fig. 3.7) (Sessa et a l, 1993).
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Figure 3.6. Generation of myristoylation deficient eNOS. A. Shows the N- 
terminal primer sequences used in site-dircctcd mutagenesis reactions to generate 
G2AcNOS. The G2A Nco I primer allows for mutagenesis of glycine 2 to alanine, 
but additionally adds bases that generate an Nco I site for facile identification of 
G2AeN0S positive clones. B. Illustrates the Nco I digestion pattern of 6 G2AcNOS 
clones. Positive clones yield a band at 300 bp (red arrow) that is absent in negative 
clones. X indicates negative clone and ^  indicates positive clone.
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Membrane-Targeted eNOS - pcDNA3-CDS-eNOS
Fusion proteins consisting of eNOS with N-terminal fusion of the hydrophobic 
transmembrane domain of the T-cell surface glycoprotein, CDS, has previously been 
characterized in COS-7 cells (Gonzalez et a l, 2002; Prabhakar et a l, 2000). The CDS 
chimera of eNOS does not undergo myristoylation but nonetheless undergoes 
palmitoylation and localizes to the caveolar pockets of the plasma membrane and the 
Golgi apparatus (Gonzalez et a l, 2002) (Fig. 3.8). pcDNA3-CDS-eN0S was used as an 
auxiliary vector to enable facile cloning of targeting peptides or FRAP onto the eNOS N- 
terminus via the Not I/Hind III restriction sites.
Direct Targeting o f eNOS to the Nucleus -  pcDNA3-NLS-eNOS
Using three tandem-repeats of the SV40 nuclear localization signal (NLS) 
(PKKKRKVD), eNOS was directed exclusively into the nucleus, as deteiinined by 
comparison with DAPI counterstaining (Fig. 3.9).
Direct Targeting o f eNOS to the Outer Mitochondrial Membrane using TomS -  pcDNA3- 
eNOS-TomS
The structure of the mitochondria and its compartments is illustrated in Figure 
3.10. Localization sequences were designed to target the outer and inner membranes in 
addition to the matrix of the mitochondria.
Several studies have elucidated die requirements for localization of proteins to the 
mitochondrial outer membrane (Horie C et al, 2002, Mihara K, 2000, Kaufman T et al, 
2003). Horie et al identified the 51 amino acid targeting peptide that directs Tom5 to
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Figure 3.10. Basic structure of the mitochondria. Targeting sequences have been 
fused to eNOS in an attempt to direct eNOS to the outer membrane, inner membrane 
and the mitochondrial matrix.
QQ
mammalian mitochondiia by using yeast Tom5 as a model and gi*een fluorescent protein 
as a reporter. They revealed the absolute requirement for both an N-terminal 
transmembrane segment (TMS) and a C terminal-segment (C) for localization of GFP to 
the mitochondiia. Moreover, when the localization sequence was fused N-terminally to 
GFP, mislocalization to the ER resulted (Fig. 3.11) (Horie et a l, 2002). Thus, an 
important point to consider when constructing a vector that targets eNOS to the outer 
mitochondria is that the Tom5 localization sequence must be introduced on the C- 
terminus of eNOS.
Molecular manipulation of G2AeNOS to introduce a C-terminal Tom5 sequence 
yielded a vector that enables direct targeting of eNOS to mitochondria, in accord with a 
localization on the cytosolic face (Horie et a l, 2002) (Fig. 3.12).
pcDNA3-Cox-eNOS targets the Mitochondrial Matrix
To generate an eNOS fusion protein that selectively targets to the inner 
mitochondrial matrix, the fragment encoding the N-terminal 31 amino acids of the 
precursor of subunit VIII of cytochrome c oxidase was synthesized by PCR as described 
in Methods. The sequence was fused in-frame to the N-terminus of G2AeN0S to 
generate pcDNA3-Cox-eNOS. The desired cellular localization of Cox-eNOS when 
expressed in COS-7 cells was confirmed by immunohistochemistry (Fig. 3.13).
Attempts to direct eNOS into the inner mitochondrial membrane — pcDNA3~Cyt-eNOS
Subunit Vila of cytochrome-c oxidase (CytCl) is a small (59 amino acids) protein 
that resides within the inner mitochondrial membrane (Duhl et a l, 1990). The CytCl
100
Cytosolic Domain
1 - 2 7
TMS C Segment
28 - 45 46 - 50
TomS GFP
Localization
Mitochondrial
ATM GFP
AC OFF
Cytosolic
Cytosolic
2 3 50
TomS TM-GFP GFP Endoplasmic Reticulum/  \  MKTLK
(Adapted from Horie et ai. 2002)
Figure 3.11 Schematic illustration of GFP-TomS fusions and their intracellular 
localization. The above figure illustrates the importance of C-terminal fusion of Tom5 
for mitochondrial localization. Abbreviations: GFP, green fluorescent protein; AC, C- 
segment deletion; TMS, transmembrane segment.
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sequence was fused in-ffame onto the N-terminus of eNOS to potentially target eNOS 
into the inner mitochondrial membrane. Expression of CytCl-eNOS was robust in COS- 
7 eells but immunohistochemical preparations nonetheless revealed a laek of specific 
colocalization at the inner membrane protein MnSOD (Fig. 3.14).
The GRIP domain targets eNOS to the trans-Golgi membrane - pcDNA3-eNOS-GRIP
The GRIP domain is a conseiwed 42 amino acid targeting sequence found in a 
family of coiled-coil peripheral Golgi proteins, including p230, golgin-97 and golgin-245 
(Barr, 1999). Studies revealed that the GRIP domain is both necessary and sufficient for 
Golgi-targeting of proteins in mammalian cells (Barr, 1999; Luke et a l, 2003).
To determine whether eNOS fused N-terminally to the GRIP domain of golgin-97 
would localize eNOS to Golgi membranes, the vector harboring pcDNA3-eN0S-GRIP 
was transfected into COS-7 cells and the intracellular distribution of eNOS determined by 
immunohistochemistry. Results show that cells expressing eNOS-GRIP co-localize with 
the Golgi marker GM130 (Fig.3.15).
3,2.4 Chemical Induced Dimerization (CID)
Translocation of proteins to distinct subcellular compartments can, in addition to 
direct targeting, potentially be achieved using small molecule triggered dimerization of 
FRAP/mTOR (mammalian target of rapamycin) and FKBP (FK506 binding protein) 
fusion proteins. Chapter III describes the application of this technology for control of 
eNOS trafficking within cells. Herein, I provide a description of the expression plasmids 
developed for on-demand targeting of eNOS to desired cellular organelles using CID.
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Designing Vectors fo r  CID~based Techniques
FRAP-FKBP interactions have had broad utility as a system for establishing 
conditional protein interactions, following treatment with rapamycin or its analogs (eg. 
AP21967). The aim of this research was to use CID to link eNOS-fusion proteins to 
target peptides, captive in the subcellular compartment of interest for analysis of local 
eNOS function. To this end, cells will be engineered to express plasmids encoding eNOS 
fusion proteins with an N-terminal FRAP-domain. When transfected into cells that 
additionally express FKBP-protein domains fused to specific “homing-sequences” that 
target a desired subcellular locus, this construct would predictably enable rapalog- 
induced targeting to distinct subcellular organelles. The CID system should allow us to 
determine the impact of eNOS localization within endothelial cells on (1) the capacity for 
NO synthesis, (2) the susceptibility of eNOS to undergo posttranslational modifications
(e.g. phosphorylation), (3) the identity of novel eNOS-interacting proteins and (4) the
\
specificity of NO addition to Cys residues in protein targets (S-nitrosylation),
CID can potentially enable assessment of the changing phosphoiylation status of 
eNOS after selective translocation to distinct subcellular compartments. It is well 
established that eNOS becomes active following transient increases in intracellular 
calcium due to three critical events- binding of Ca^^/calmodulin, dissociation of eNOS 
from the inhibitory eNOS-caveolin-1 complex and displacement of the 45 amino acid 
autoinhibitory loop contained within the FMN-binding domain. These events expose 
essential regulatory sites on eNOS for kinase- and phosphatase-mediated 
phosphoregulation. While these processes are operative for eNOS at the plasmalemma 
and Golgi, activity and regulation of eNOS at other subcellular loci is unknown. Toward
107
this end there is a need to assess locns-dependent changes in eNOS activity and 
regulation; potentially enabled by a combination of cell based assays, phospho-specific 
antibodies and eNOS mutagenesis.
An overview of the expression cassettes used for small-molecule triggered 
translocation of eNOS to distinct subcellular loei is shown in Figure 3.16. Expression of 
each of the fusion proteins was assessed in COS-7 cells using western blotting and 
immunohistochemistry. Immunoblot analysis of transfected COS-7 cell lysates showed 
robust expression of both FRAP-eNOS and targeted-FKBP proteins at the predicted 
molecular weights (Fig. 3.17).
FRAP was PCR amplified using pC4 -RnE (ARIAD) as a template and fused onto 
the 5’-termini of eNOS and eNOS-GFP encoding plasmids, respectively. Presumably, 
fusion of FRAP on to the N-terminus of eNOS would disrupt native subcellular targeting 
of eNOS, given that glycine 2 is no longer available at the N-terminus (following 
methionine cleavage) for myristoylation. Indeed, immunohistochemical analysis 
confirmed a diffuse cellular distribution of FRAP-eNOS when expressed in cells (Fig. 
3.18). A modular depiction of the FKBP expression plasmids is illustrated in Figure 
3.19. The location of FKBP, key restriction sites, epitope tags and localization 
sequences is depicted schematically.
Cellular Membranes - PC4M-F2E
Vector PC4 M-F2E (ARIAD) is a chimeric fusion protein comprised of an N- 
terminal myristoylation signal followed by two copies of FKBP. To target the FKBP 
modules to distinct subcellular loci, the EcoR UXba I  fragment can be removed by
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Figure 3.17. Expression analysis of CID-based constructs as assessed 
from transfected COS-7 cell lysates. COS-7 cells were transfected with the 
indicated constructs and cell lysates were prepared and analyzed by SDS- 
PAGE and immunoblotting with an anti-eNOS Ab (1:2500) and an anti- 
FKBP Ab (1:1000).
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restriction digest and replaced with the desired localization signal flanked by appropriate 
restriction sites. The PC4M-F2E vector itself, due to the presence of the c-Src 
myristoylation sequence, targets FKBP to the cytoplasmic face of cellular membranes 
(Fig. 3.20).
Nucleus -  PC4EN-FI
Using a single copy of the SV40 large T-antigen (Fig. 3.16), It was determined 
that one FKBP module was sufficient for selective targeting to the nucleus as confirmed 
by immunohistochemistry and colocalization with the nuclear marker, DAPI (Fig. 3.21).
Outer Mitochondrial Membrane - pC 4M-Tom5
The PC4M-F2E vector was modified to include the outer mitochondrial membrane 
targeting sequence, replacing the HA-tag. Additionally, the myiistoylation sequence that 
directs FKBP to the plasma membrane was removed to prevent membrane localization. 
To enable facile immunoprécipitation of complexes, the HA-tag was reintroduced onto 
the N-tenninal segment of the FKBP-Tom5 fusion protein. The final vector was named 
pC4M-Tom5  and its subcellular distribution to mitochondria was confirmed by 
immunohistochemistry (Fig. 3.22).
Inner Matrix o f  the Mitochondria -  PC4M-C0 X
The Cox (Su VIII) sequence was PCR synthesized and fused in-ffame to the 5’- 
terminus of two FKBP modules to generate PC4 M-C0 X and a GFP encoding 
oligonucleotide was fused to the 3’-terminus (PC4M-C0 X-GFP) to track subcellular
i n
expression of the cognate fusion protein. The image obtained in Figure 3.23 shows the 
association of Cox-FKBP-FKBP-GFP protein in COS-7 cells with typical ‘rod-like’ 
mitochondrial structures. The merge panel shows perfect co-localization of pC^M-Cox- 
GFP with the cotransfected pRC/CMV-EGFP-Tom5 construct. These findings confirm 
the correct synthesis and subcellular localization of PC4 M-C0 X-GFP in mitochondria, 
allowing its utility in proposed experiments.
Trans-Golgi Network — PC4EN-GRIP
A GRIP domain-encoding sequence was amplified from pFB128 and fused to an 
FKBP-encoding oligonucleotide in the PC4EN-FI vector using Spe I  (Fig. 3.19). The 
original nuclear localization signal (NLS) was removed to prevent nuclear localization 
and the resulting construct was named PC4EN-GRIP. Wlien expressed in COS-7 cells, 
localization of FKBP to the Golgi complex was confirmed by concentration of FKBP in a 
perinuclear pattern and colocalization with the transfected GFP-GRIP frision protein, 
pFB128 (Fig. 3.24).
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3.3 Discussion
Endothelial NO synthesis must occur at an appropriate rate and tempo for 
vascular homeostasis. The amount of NO released by eNOS is tightly regulated by the 
interplay of several distinct protein-protein interactions, in addition to post-translational 
modifications (principally acylation and phosphorylation) and temporal changes in 
intracellular Ca"^  ^concentration (Fulton et al., 2001). Given the important and pervasive 
role of eNOS-derived NO in the cardiovascular system, it is not surprising that eNOS 
must be correctly localized to specific subcellular regions of endothelial cells for efficient 
release of NO upon activation by agonistic stimuli (Fulton et a l, 2001). Moreover, the 
ability of eNOS to translocate from compartment-to-compartment may be central to 
eNOS activation and deactivation.
The presence of eNOS has been reported within plasma membrane caveolae and 
also decorating the perinuclear/Golgi region, both in vivo (isolated blood vessels) and in 
vitro (endothelial cells in culture) (Busconi & Michel, 1993; Garcia-Cardena et a l, 1996; 
Liu et a l, 1996; Sessa et a l, 1992; Shaul et a l, 1996). Extensive work has elucidated the 
absolute requirement of eNOS (as well as iiNOS and iNOS) localization to specific 
cellular compartments to allow for maximal activation (for review see (Oess et a l, 
2006)). Such ‘active’ eNOS-rich locales suggest free access to essential cofactors (e.g. 
BH4, FAD, FMN), substrates (e.g. L-arginine, NADPH) and upstream activators (e.g. 
Ca^VCaM, kinases/phosphatases). Targeting of eNOS to specific signaling domains 
within the intracellular milieu is likely to be pivotal for efficient NO production protein 
targeting, to achieve “correct” ensuing biological effects.
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The impact of eNOS translocation and localization in endothelial cells in culture 
has been extensively studied. Comparison of subconfluent and confluent populations of 
cultured endothelial cells, revealed that eNOS activity is greater in confluent cells, where 
increased activity coirelates with a greater pool of plasma membrane eNOS (Covers et 
a l, 2002). Other studies, using palmitoylation-deficient mutants of eNOS, showed a lack 
of eNOS at the plasma membrane (Garcia-Cardena et a l, 1996; Liu et a l, 1996; Shaul et 
a l, 1996) and impaired NO release from intact cells, yet enzymatic activity of mutants 
and wild type eNOS were comparable in viti^o (Liu et al., 1996). Based on these 
observations, it is evident that proximity to the plasma membrane is important for 
efficient eNOS derived-NO synthesis (Shaul, 2002). More recently, eNOS has been 
shown to shuttle into the nucleus (Feng et a l, 1999) and dock onto the outer 
mitochondrial membrane (Gao et a l, 2004). Regulation of eNOS at these alternate sites 
has been tackled by targeting myristoylation-deflcient eNOS (G2AeNOS) to several 
intracellular organelles, including the plasma membrane, cw-Golgi membrane, trans- 
Golgi membrane, nucleus, outer mitochondrial membrane and the mitochondrial matrix 
(Church & Fulton, 2006; Deraklishan & Gross, 2006; Fulton et a l, 2004; Fulton et al., 
2002; Jagnandan et a l, 2005). In accord with earlier observations, targeting of eNOS to 
the plasma membrane confirmed this locale as the preeminent location for NO synthesis 
in endothelial cells (Fulton et a l, 2004). Furthermore, Golgi-resident eNOS was shown 
to be active, albeit its activity was significantly lower than plasma membrane-associated 
eNOS (Fulton et a l, 2004). Targeting eNOS to either the nucleus or the matrix of the 
mitochondria revealed that neither of these cellular compartments are capable of 
efficiently supporting eNOS activity (Jagnandan et a l, 2005). In contrast, eNOS docked
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onto the outer mitochondrial membrane exhibited basal and agonist-induced NO 
synthesis comparable to that of native eNOS (Derakhshan & Gross, 2006). Basal activity 
of targeted eNOS chimera in their appropriate cellular locales, as described above, is 
summarized in Table 3.2.
Although accumulating evidence suggests that localization of eNOS has an 
overwhelming effect on eNOS activity, the molecular mechanism’s governing eNOS 
regulation and fimction at different compartments remains poorly understood. Based on 
the knowledge that the substrate and cofactor requirements for both eNOS and iNOS are 
virtually identical, using iNOS-fusion proteins that target the subcellular compartments 
described above, Jagnandan and Fulton isolated Ca^VCaM as the prevailing mediator of 
eNOS function in various subcellular loci (Jagnandan et a l, 2005). Moreover, further 
investigations showed that the degree of phosphorylation of key serine residues (Ser617, 
635 and 1179) parallels the ability of targeted eNOS to produce NO -  increased 
phosphoiylation at each of these residues is concomitant with increased eNOS activity 
(Church & Fulton, 2006). Phosphorylation on Ser617, Ser635 and Seri 179 reduces the 
Ca'^VCaM dependence of eNOS (McCabe et a l, 2000; Michell et a l, 2002), accounting 
for observed differences in eNOS activity at distinct compartments (Church & Fulton, 
2006).
Even though Ca^VCaM and phosphorylation tightly regulate eNOS function at 
alternative subcellular loci, eNOS’s promiscuous nature allows for intricate and diverse 
protein-protein interactions that influence both eNOS function and intracellular targeting 
(Covers & Rabelink, 2001; Kone, 2000). The most widely studied is the spatial 
organization of eNOS within the caveolar pockets of the plasma membrane, tlirough
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eNOSs interaction with the scaffolding protein caveolin-1 (Feron et a l, 1996; Garcia- 
Cardena et a l, 1997; Ghosh et a l, 1998). The direct interaction between eNOS and 
caveolin-1 leads to inhibition of eNOS enzymatic activity, further exemplified by 
increased eNOS activity in caveolin-1 knockout mice (Drab et a l, 2001). Caveolae are 
microdomains enriched in signaling proteins and localization of eNOS within the 
caveolae brings eNOS into close proximity to its upstream activators, Ca^/CaM, Akt and 
Hsp90 and its downstream target, sGC (Shaul, 2002). However, eNOS also interacts 
with NOSIP, NOSTRIN, dynamin and the cytosolic face of GPCRs, resulting in an 
attenuated eNOS-derived NO production (Kone, 2000; Oess et a l, 2006). In the case of 
NOSTRIN, association with eNOS results in vesicular internalization and trafficking of 
eNOS away fi'om the plasma membrane to intracellular vesicular structures, consistent 
with a decrease in eNOS activity (Zimmermann et a l, 2002).
Studies to date have primarily focused on the protein-protein interactions 
involving native eNOS at the plasma membrane caveolae. The protein-protein interactors 
of eNOS at the cis- and trans-GoXgi membranes, nucleus, mitochondrial matrix and outer 
mitochondrial membrane, remain elusive.
The main focus of the work presented in this thesis is to systematically test the 
hypothesis that the subcellular sites of eNOS localization in endothelial cells determines 
the capacity for NO synthesis, the susceptibility of eNOS to post-translational 
modifications, the identity of eNOS-interacting proteins and the effective channeling of 
NO-reactivity to protein targets. Vectors were developed for both direct targeting of 
eNOS, where a localization peptide is fused directly onto the eNOS N- or C-tenninus and 
chemical-induced dimerization, to achieve on-demand translocation of eNOS to the
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desired subcellular loci. Wliile, to date, direct targeting has been the only method used 
to study organelle-restricted eNOS (Church & Fulton, 2006; Fulton et a l, 2004; Fulton et 
a l, 2002; Gonzalez et a l, 2002; Jagnandan et a l, 2005), we sought to develop a 
conditional approach, for association of the proteins FRAP and FKBP in response to Rap, 
that would provide an unprecedented tool to investigate NO signaling in diverse 
biological systems.
To define the chemical and biological consequences of eNOS redistribution 
within endothelial cells, we generated fusion proteins that specifically target eNOS to the 
plasma membrane, trans Golgi membrane, cytosol, nucleus and mitochondiial 
subprecincts. The work presented in this chapter describes the methods used to generate 
targeting peptides for organelle-restricted eNOS, in addition to expression cassettes used 
to achieve on-demand translocation of cytosolic eNOS to desired subcellular loci. To 
determine whether eNOS and FKBP chimera target their intended destinations, COS-7 
cells were transfected with the desired constructs and localization analyzed 
immunohistochemically. Targeting of both eNOS and FKBP to the plasma membrane, 
cytosol, Golgi, nucleus and mitochondria was confirmed by co-localization with relevant 
subcellular organelle markers.
For chemical induced dimerization experiments, FRAP was fused onto the eNOS 
N-terminus. Given that native eNOS requires myristoylation of glycine 2 for membrane 
localization and subsequent palmitoylation, positioning FRAP onto the N-terminus 
eliminated native eNOS localization (plasma membrane and Golgi) and resulted in a 
predominantly cytosolic protein. Thus, all experiments utilizing on-demand translocation 
of eNOS would result in a comparison between cytosolic eNOS and eNOS resident at
194
distinct subcellular organelles. Chapter 4 describes the development of chemical induced 
dimerization to control eNOS translocation in cells.
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CHAPTER 4
DEVELOPMENT OF A SYSTEM FOR ON-DEMAND TRANSLOCATION OF 
eNOS TO DESIRED SUBCELLULAR LOCI
4.0 Introduction
A growing body of literature demonstrates that eNOS undergoes dynamic 
subcellular trafficking in endothelial cells. Indeed, posttranslational protein 
modifications and protein-protein interactions have been implicated in eNOS 
translocation between plasmalemma (caveolae), Golgi, mitochondria and possibly nuclei. 
Although it is likely that regulation of eNOS and targets of NO signaling differ at these 
alternative subcellular loci, rigorous assessment of these predictions has been limited by 
the lack of a suitable approach. To overcome this limitation, we adapted an inducible 
protein heterodimerization system to achieve rapid and complete tianslocation of eNOS 
to desired subcellular organelles in cells.
Chemical Induced Dimerization (CID)
Specific protein-protein interactions are a key component of almost all biological 
networks. A subset of protein-protein interactions is dimerization -  a physical interaction 
composed of two protein modules, either identical or non-identical. Dimerization is a 
powerful and variable biological control mechanism that governs many cellular processes 
as exemplified by activation of cell surface receptors, transcription factors, vesicle fusion 
and numerous other classes of both intra- and extra-cellular signaling events (Klemm et 
aL, 1998). Wlien proteins dimerize, they are brought into proximity with one another.
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This can permit essential proteimprotein interplay leading to regulation of vital 
downstream signal transduction events (Clemons, 1999). Methods that allow 
manipulation of such processes can provide powerful tools for the control and 
understanding of complex cellular events. In the last decade, induced-dimerization, often 
refeiTed to as induced-proximity, has emerged as a versatile approach to gain control over 
intracellular processes.
A chemical inducer of dimerization (CID) or ‘dimerizer’, is a low-molecular- 
weight, cell-permeable, organic molecule used to specifically induce the assembly of two 
protein targets, often resulting in a highly specific biological response (Schreiber & 
Crabtree, 1995). CID has been used in gene therapy (Berger et a l, 2003; Clackson, 
2000; Richard & Elan, 2003), for the regulation of gene expression (Amara et a l, 1997), 
to modulate cell membrane receptor signaling (Muthuswamy et a l, 1999; Spencer et al, 
1993), to selectively antagonize cellular processes (Briesewitz et a l, 1999) and in the 
search for novel biocatalysts (Firestine et a l, 2000), To date, the most widely used 
dimerizer systems have involved the immunophilin FKBP (FK506 binding protein) and 
its ligands. FKBP is a 12-kDa cytosolic protein that acts as the initial intracellular target 
for the naturally occurring small-molecule immunosuppressants, FK506 and rapamycin. 
The role of rapamycin as a dimerizer has been well established. Rapamycin is equipped 
with two binding surfaces that each recognize a unique protein module. This allows the 
dmg to simultaneously associate with FKBP and a -100 amino acid portion of the protein 
kinase FRAP, termed the FKBP rapamycin binding (FRB) domain (Figuie 4.1). The 
ultimate result of this union is inhibition of FRAP activity (Clemons, 1999; Pollock & 
Clackson, 2002; Rollins et a l, 2000).
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Figure 4.1. Structure of the rapamycin-iinked FRAP-FKBP complex. This 
figure represents the 3D crystal structure of the ternary complex formed between 
FRAP, FKBP and rapamycin. The interaction between the two proteins, FRAP 
and FKBP, is the basis of the chemical induced dimerization technique.
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The FRAP/FKBP/Rapamycin Ternary Complex
Elucidation of the interactions between FRAP, FKBP and rapamycin has revealed 
a system whereby intracellular signaling events can be regulated. Cells have been 
engineered to express chimeric proteins comprising a signaling domain fused to either 
FKBP or FRAP; the addition of dimerizer crosslinks the proteins and initiates signaling. 
However, the use of rapamycin as an in vivo inducer of dimerization is potentially 
complicated due to interactions with endogenous FKBP (Clackson et a l, 1998; Pollock & 
Clackson, 2002). To overcome this problem, a steric ‘bump’ has been tailored into 
rapamycin, thus prohibiting interactions with endogenous FKBP and/or FRAP. 
Additionally, a genetic modification on FRAP, specifically the incoiporation of a single 
point mutation T2098L (Figure 4.2), permits tlie system to respond to a wide range of 
rapamycin analogs, also referred to as “rapalogs” (such as A21967) (Pollock & Clackson, 
2002; Rollins et a l, 2000).
Small Molecule Triggered Translocation o f  eNOS
Based on the FRAP-Rap-FKBP technology described above, we sought to 
develop a novel teclmique for regulating intmcellular trafficking of eNOS. This 
engineered system utilizes dual expression vectors, one encoding the 93 amino acid Frb 
domain of mTOR/FRAP fused to eNOS, and a second encoding FKBP 12 fused to an 
organelle targeting peptide. We hypothesized that conditional heterodimerization of the 
eNOS fusion protein with the targeting peptide can be achieved upon treatment with a 
biologically inert rapamycin analog (or rapalog), taking advantage of the two high- 
affmity binding faces of rapamycin for efficient tethering of FRAP to FKBP 12. Using
no
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Figure 4.2. Closeup of the FRAP-Rap-FKBP interaction. Upper panel, shows 
the ternary complex and its interaction with specific amino acids within both 
FKBP and FRAP. Lower panel, is a magnified version showing the point 
mutation T2098L allowing the system to respond to a range of rapalogs.
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this system and various targeting peptides, we engineered cells to undergo small 
molecule triggered translocation of eNOS from cytosol to mitochondrial subprecincts 
(outer membrane and matrix), plasmalemma, Golgi and the nucleus (Figure 4.3). 
Characteristics of this system and functional consequences of eNOS translocation to 
organelles are described in this chapter, with special focus on eNOS at the outer 
mitochondrial membrane.
Physiological Modulation o f  eNOS by its Autoinhihitory Domain
Relevant to the molecular mechanism of eNOS activation by phosphorylation, our 
group previously identified two autoinliibitory conhol elements in eNOS -  one is a 45 
amino acid insertion in the FMN-binding module (ACEl) that includes S635 (Salerno et 
a l, 1997) and the other is a 42 amino acid extension of the C-terminus (ACE2) that 
includes SI 179 (Lane & Gross, 2002; Roman et a l, 2000). Deletion of either 
autoinhihitory domain in their entirety results in enzymes that are phenotypically 
indistinguishable from each other and from phosphorylation mimics of their cognate Ser 
residues (i.e., increased NO synthesis, accelerated interflavin electron flux and reduced 
calcium-dependence for activation) (Lane & Gross, 2002; Nishida & Ortiz de 
Montellano, 1999; Roman et a l, 2000). Accordingly, phosphorylation of S635 and 
SI 179 are thought to activate eNOS by disinhibition of interacting autoinhihitory control 
elements, removing baniers to electron flux and productive Ca^VCaM binding by eNOS 
(Lane & Gross, 2002).
The Role o f NO in Mitochondrial Function and Dysfunction
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Mitochondria are the microscopic (0.5-10 p.m) energy factories in our cells. They 
are responsible for generating almost all of our energy, and consume 90% of our oxygen 
intake. They additionally contribute to the regulation of cellular metabolism in a 
fundamental way and execute intrinsic programmed cell death (apoptosis).
Since the discovery of NO as a signaling molecule in the late 1980’s, extensive 
information has amassed suggesting that NO and other free radicals play a central role in 
mitochondrial biology. Indeed, mitochondria possess several hemoproteins (e.g. 
cytochrome c oxidase), cysteine-containing proteins and low molecular weight thiols 
(e.g. glutathione) that are bona fide  targets for reaction with NO and its congeners. Most 
extensively studied, are the effects of NO in the control of mitochondrial respiration both 
in vivo and in vitro (see review by (Brown, 2001)). NO competes with O2 for heme- 
binding in cytochrome c oxidase and thereby suppresses mitochondrial respiration 
(Brown, 1999) (Figure 4.4). Low physiological concentiations of NO have been 
implicated in the moment-to-moment regulation of cellular respiration (Brown, 1999). 
At higher concentrations, NO additionally interacts with iron sulfiir centers in complexes 
II and III of the respiratory chain, irreversibly blocking respiration and ATP synthesis. 
NO interacts with mitochondrial superoxide to produce ONOO' which can open 
Pandora’s box, leading to damage of complexes I, II, IV and V, aconitase, creatine 
kinase, mitochondrial DNA, calcium release, mitochondrial permeability transition 
(MPT) and apoptosis (Figure 4.5).
The presence of a NOS isofoim at the mitochondria has sparked immense interest 
in its fimctions. To date, several studies have identified eNOS at the mitochondria, 
reportedly in the matrix (Lacza et ah, 2001), the imier membrane (Giulivi et a l, 1998)
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and on the outer surface of the mitochondria (Heinrich et a l, 1998). Recent findings 
have suggested that eNOS docks onto the outer mitochondrial membrane via its C- 
terminal pentabasic, RRKRK, motif (Gao et a l, 2004). The regulation of eNOS activity 
on the outer face of the mitochondria and targets of the NO on and within mitochondria, 
remain unknown. We sought to fill this void by targeting eNOS to the outer membrane 
of the mitochondria to enable definitive studies of the impact on eNOS function and 
regulation, as well as identification of novel eNOS-derived mitochondrial protein-targets.
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Figure 4.4. Crystal Structure of Cytochrome Oxidase containing the heme centers a and ag and two copper 
centers C u a  and C u b * The reduced forms of the cytochrome as heme-iron coupled with Cub constitute the 
oxygen binding site for which NO competes.
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Figure. 4.5. Fates of NO and ONOO at the Mitochondria. NO has been shown to speeifieally and 
reversibly inhibit cellular respiration by binding to Complex IV of the electron transport chain. 
When NO reacts with O2’, it forms ONOO', which attenuates respiration at many levels (complexes I, 
II, III and IV) as well as mitochondrial ATPase. Additionally, ONOO evokes proton leakage 
through the inner mitochondrial membrane.
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4.1 M aterials and Methods
4.1.1 Materials
The rat lung fibroblast cell line (RFL-6) was a generous gift from Dr. Ferid 
Murad (The University of Texas-Houston Medical School, TX). The eNOS monoclonal 
antibody was from BD Biosciences. Phospho-specific antibodies raised against Ser635, 
Serb 17, Ser 116, Thr495 and the polyclonal anti-eNOS, were from Upstate 
Biotechnology. The Seri 179 antibody was from Zymed and the FKBP antibody was 
from Affinity Bioreagents. Unless otherwise stated, all other materials were from Sigma 
and were of the highest obtainable quality.
4.1.2 Cell Culture
HEK293T and COS-7 cells were grown in high-glucose DMEM as described 
earlier. The rat lung fibroblast cells (RFL-6) were grown in Ham’s F-12 media 
supplemented with 10% (v/v) fetal bovine serum (FBS), penicillin (100
units/ml)/streptomycin (100 pg/ml), L-glutamine (2 mM) and fungizone (2.5 ng/ml) at 
37°C in a humidified atmosphere of 5% CO2 .
4.1.3 Isolation o f Mitochondria — Discontinuous Percoll Gradient
Porcine lung tissue (~ 20 grams) was thawed in 4 ml of buffer (0,25 M sucrose, 
0.01 M Tris-HCl, pH 7.5) warmed to 45°C. The buffer was strained through cheesecloth 
several times and the washed tissue was macerated with a tissue-tearer in 10 ml/gram of 
MHH buffer (250 mM Mannitol, 0.5 mM EGTA, 10 mM Hepes, pH 7.4, 0.1% BSA, 2 
mM PMSF and protease inhibitors (Roche)). Lysates were transferred to a doimce
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homogenizer and further homogenized with 50 strokes. The final pH of the cellular 
homogenate was adjusted to pH 7.5. Cellular debris and nuclei were removed by 
centrifugation at 2000 rpm for 10 min at 4°C. The supernatant was removed and 
carefully passed through 2 layers of cheesecloth to remove particulate matter. The flow­
through was centrifuged at 10,000 x g  for 20 min - the supernatant was decanted and the 
pellet was resuspended in MHH buffer, then centrifuged at 100,000 x g for 1 hr. During 
this time, a discontinuous Percoll gradient was east in Beckmann Ultra-Clear centrifuge 
tubes, as depicted below, and allowed to sit undisturbed. The crude mitochondrial pellet 
was resuspended in 3 - 6 ml of 12% Percoll in MMH and layered onto the Percoll 
gradient. The samples were then centrifuged at 31,000 x g in an SW-41Ti swing-out 
rotor for 45 min. The resulting bands between the different Percoll interfaces were 
collected using a syringe, washed in MMH buffer to remove the Percoll and analyzed for 
organelle-specific proteins by immunoblotting.
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4.1.4 Isolation o f  M itochondria — C ontinuous 30% Percoll
This method requires large amounts of starting material but yields relatively large 
amounts of mitochondria, albeit the derived mitochondrial fractions obtained were less 
pure (i.e. contaminated with other cellular organelles) than those obtained using the 
discontinuous Percoll technique. Fifty to one hundred grams of porcine lung tissue was 
thawed in pre-warmed (45°C) buffer (0.25 M sucrose, O.OIM Tris HCl, pH 7.0) using 4 
ml/gram of tissue. The buffer was strained through several layers of cheesecloth, the 
tissue minced with scissors and washed twice in MHH buffer (0.25 M mannitol, 20 mM 
Hepes, pH 7.4). The tissue was homogenized first using a tissue tearer and subsequently 
with 50 strokes of a dounce homogenizer, in 4 ml/gram of MSH buffer (0.25 M mannitol, 
0.75 M sucrose, 20 mM Hepes, pH 7.4) supplemented with 2 mM PMSF. The pH was 
adjusted to pH 7.5 using 1 M Tris-HCl and homogenates were cleared of unbroken cells 
and nuclei by centrifiigation at 600 x g for 10 min at 4°C. The resulting supernatant was 
cleared through 2 layers of cheesecloth and centrifuged at 10,000 x g  for 20 min. The 
resulting crude mitochondrial pellet was washed in 3 ml of MSH buffer and repelleted at
10,000 X g  for an additional 20 min. Mitochondrial pellets were resuspended in MEHB 
buffer (0.25 M mannitol, 1 mM EDTA, 25 mM Hepes, pH 7.4, 0.1% (w/v) BSA), loaded 
onto a 30% Percoll gradient (5 volumes of MEHB buffer, 3 volumes of Percoll, 2 
volumes of water) and centrifuged at 95,000 x g for 30 min. The brownish/yellow band, 
corresponding to mitochondria, was carefully extracted and washed twice in MSH buffer 
at 10,000 x g for 10 min. The purified mitochondria were resuspended in MMH (1 ml/ 
10 grams of starting material) and protein content was determined with the BioRad 
Protein Assay relative to BSA standards prepared in MSH buffer.
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4.1.5 Proteinase K  and  K C l treatm ent o f  M itochondria
Mitochondria were isolated using 30% Percoll. For KCl treatments, mitochondria 
were incubated on ice for 30 min in buffer containing 125 mM KCL Mitochondria were 
washed in MSH buffer and collected at 12,000 x g  for 10 min. A second batch of 
mitochondria were treated with proteinase K (50 |xg/ml) from a lOOX stock for 30 min on 
ice. PMSF (2 mM) was added to mitochondria and incubated on ice for a further 10 min. 
Mitochondria were pelleted at 12,000 x g for 10 min. For both KCl and proteinase K 
treated mitochondria, the pellets were carefully resuspended in homogenization buffer (1 
M aminocaproic acid, 50mM Bis-Tris HCl, pH 7.0) and supplemented with 1.25% 
lauiylmaltoside from a 10% stock. The mitochondria were incubated on ice for 15 min 
and centrifuged at 100,000 x g for an additional 15 min. The supernatants were removed 
and analyzed by SDS-PAGE and immunoblotting.
4 .1 .6 Rapalog Treatm ents
Dual-transfected cells were treated with 250 nM rapalog (AP21967) for 0, 3, 5, 
10, 30 and 60 mins. In some cases, cells were incubated in the presence of AP21967 for 
16 hrs. Cells were then washed free of excess rapalog with two successive PBS washes.
4.1 .7  Im m unofluorescence  M icroscopy
Dual ti'ansfected cells were plated onto sterile uncoated or poly-D-lysine coated 
coverslips in complete DMEM. After growth to approximately 70-80% confluency cells 
were treated with AP21967 for the desired time and then fixed for 10 min at room 
temperature in 4% paraformaldehyde in PBS, supplemented with 0.1% sodium azide.
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followed by permeabilization in 0.2% Triton X-100 in PBS for 5 min. Cells were rinsed 
twice in PBS, twice in PBS/1 % bovine serum albumin (BSA) and then blocked in 
PBS/5% goat serum/1 % BSA for 30min at 37°C. Subsequently, cells were incubated 
with anti-eNOS Ab (1:300) for 2 h at room temperature in blocking buffer. Cells were 
rinsed as before and Alexa-Fluor 488 anti-mouse secondary antibody (1:500; Molecular 
Probes) was added for 1 lii’ at room temperature. Nuclei were stained with 4’-6- 
Diamidino-2-phenylindole (DAPI) for 5 min at room temperature (Invitrogen). Slides 
were mounted with VECTASHIELD (Hardset) mounting media (Vector Laboratories, 
Burlingame, CA) and cells were visualized with an inverted Nikon Eclipse TE2000 
microscope (Nikon, Melville, NY). All microscopy images are representative of 50-100 
images analyzed from 5 or more independent experiments.
4.1.8 D ual-transfection o f  H E K 2 9 3 T a n d  CO S-7 cells
HEK293T and COS-7 cells were grown in 12-well plates and serum-starved for 
24 hrs prior to ti'ansfection. Transfections were canied out using 3 pi of FuGENE, 47 pi 
of OptiMEM, 0.5 pg of pcDNA3-FRAP-eNOS and 1.0 pg of the desired localization 
vector (PC4M-F2E, PC4EN-FI, PC4 M-C0 X, pC4M-Tom5  or PC4EN-GRIP). Cells were 
allowed to sit in transfection media for 6  hrs, after which the media was replaced with 
complete DMEM. Volumes were scaled proportionally for transfection of cells grown in 
6 -well plates. Cells were assayed 24 - 48 lirs post-ti ansfection.
4.1.9 D etection o f  N O  using  an R F L -6  Reporter B ioAssay
Sample Preparation
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12-well plates of HEK293T or COS-7 cells, transfected with the desired 
constructs, were washed twice in Locke’s buffer (10 mM HEPES, pH 7.4, 154 mM NaCl, 
5.6 mM KCl, 2 mM CaCli, 1 mM MgClz, 3.6 mM NaHCOs, 5.6 mM glucose, 500 pM 
arginine) and subsequently equilibrated in Locke’s buffer (500 pi) in the presence or 
absence of 3 mM NMA for 30 min. Next, the cells were incubated in 500 pi of Locke’s 
buffer supplemented with superoxide dismutase (SOD, 100 U/ml) ± 3 mM NMA for 5 
min. Desired wells were then incubated with fresh media in the presence or absence of 
A23187 (5 pg/ml) for 20 min (400 pi). At this time, RFL-6 cells were washed twice in 
Locke’s buffer containing 300 pM 3-isobutyl 1-methylxanthine (IBMX) and equilibrated 
in the same buffer for 20 min (500 pi). Five min before tiansferring the conditioned 
media from either HEK293T or COS-7 cells, RFL-6 cells were incubated in Locke’s 
buffer with 300 pM IBMX and 100 U/ml SOD. The RFL-6 media was aspirated off, 
HEK293T or COS-7 cell-conditioned media (400 pi) was tiansferred to the RFL-6 
monolayer and incubated for 4 min at RT. The media was rapidly removed and cGMP 
production was quenched within seconds by addition of 109 pi of 0.1 N HCl and 
incubation for 20 min at RT. After this time, HEK293T or COS-7 cells were lysed on 
ice, by the addition of RIPA buffer and lysates were prepared for protein quantification 
and eNOS expression analysis. RFL-6 cells were harvested by scraping with a rubber 
policeman and the resulting lysates cleared of insoluble material by centrifiigation at 
3,500 rpm for 10 min. The supernatants were transferred into 0.7 ml microfuge tubes and 
lyophilized in a speed-vac for 4-6 his. The lyophilized samples were resuspended in 109 
pi of enzyme immunoassay buffer (EIA) and stored at -80°C until analyzed for cGMP 
content.
1 4 1
Acétylation o f Samples fo r  cGMP Quantification
Acétylation improves the sensitivity of the ELISA assay for detection of cGMP. 
To acetylate cGMP, each sample was diluted in EIA buffer to a final volume of 500 pi. 
cGMP standards, ranging from 0.02 -  3 pmol/ml, were additionally acetylated. 
Acétylation was carried out as follows: 100 pi of 4 M KOH was added to each 500 pi 
sample or standard individually, followed in quick succession by the addition of 25 pi of 
acetic anhydride. Tubes were vortexed for 15 sec and acétylation reactions were stopped 
by the addition of 25 pi of 4 M KOH. Samples were vortexed for an additional 2 sec and 
placed on ice until analysis by ELISA.
cGMP Quantification by Enzyme-Linked Immuno-Sorbent Assay (ELISA)
Samples were assayed using a Cyclic GMP EIA Kit (Cayman). Fifty microliters 
of acetylated samples and standards were loaded into 96-well plates. Each plate 
contained two blank wells, two non-specific binding wells, two maximum binding wells 
and a total activity well. Standards were assayed in duplicate and samples in triplicate. 
Plates were prepared by the addition of cGMP acetylcholine esterase tracer and cGMP 
antiserum to the appropriate wells and incubated at 4°C for 18 hrs in the dark. After five 
washes with wash buffer, plates were developed by the addition of Ellman’s Reagent for 
90 min in the dark with shaking at room temperature. Developed plates were read at 405 
nm using a VersaMax Spectrophotometer (Molecular Devices, Sunnyvale, CA). cGMP 
amounts were expressed as pmol of cGMP per mg of protein.
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4.1.10 Im m unoprécipita tion a n d  Im m unob lo tting
Immunoprécipitation
Dual-transfected and vehicle or AP21967-treated cells were rinsed twice in PBS 
and incubated with either A23187 (5 pg/ml) or VEGF (50 ng/ml) for 5 min at 37°C in 5% 
CO2 . Cells were then washed twice in ice-cold PBS and lysed on ice by the addition of a 
modified-RIPA buffer (50 mM Tris-HCl, pH 7.7, 150 mM NaCl, 1% NP-40, 1% sodium 
deoxycholate, 1 mM sodium vanadate, 50 mM NaF, 10 mM Na4 P2 0 7 , 2 mM EDTA, 2 
mM PMSF, 1 mg/ml protease inhibitor cocktail). Cells were scraped with a rubber 
policeman and lysates were transferred to a 2 ml Dounce homogenizer. Cells were 
homogenized with 50 stiokes and lysates were subsequently rotated at 4°C for 30 min. 
Insoluble material was removed by centrifugation at 14,000 ipm for 10 min. Protein 
amounts were quantified using the Bio-Rad Protein Assay kit (BioRad) using bovine 
serum albumin standards. Seventy pi of the cmde lysate was retained for analysis as the 
“pre-IP” sample. Supernatants were transfened to silanized 1.7 ml microfuge tubes, 40 
pi of a 1:1 suspension of hemagglutinin (HA)-conjugated agarose beads was added to 
each tube and rocked overnight at 4°C. The beads were pelleted at 5,000 ipm for 5 min 
and washed 4X in RIPA buffer. After the final wash, bound proteins were eluted with 30 
-  40 pi of SDS-PAGE loading buffer at 95°C for 10 mins. The beads were pelleted at
13,000 rpm for 10 min and the supernatant was transferred to a fiesh eppendorf tube and 
stored at -20°C prior to analysis by immunoblotting.
Immunoblotting
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Western blots were earned out as described earlier, with minor modifications. 
Lysates of dual-transfected cells treated with AP21967 or vehicle (60 min), were 
analyzed for total eNOS using a monoclonal eNOS antibody (1:2500; clone 3, BD 
Biosciences). Additionally phospho-modification of eNOS serine and threonine residues 
were assessed with phospho-specific antibodies raised to the individual phosphorylation 
sites of eNOS: SeiT179 (1:1000), Ser635 (1:2000), Ser617 (1:1000), Ser116 (1:1000) and 
Thr495 (1:1000). When immunoblotting for phospho-eNOS, milk was substituted with 
5% BSA in all blocking and antibody-dilution buffers. For immunoprécipitation (IP) 
samples, 20 pi of the IP samples was loaded onto a 4-12% SDS-PAGE gel (eNOS WB) 
and a 1/20 dilution of the IP samples was loaded onto a 10-20% SDS-PAGE gel (FKBP 
WB). Proteins were transferred to nitrocellulose at 300 mA for 120 min and membranes 
were blotted for eNOS using a polyclonal eNOS antibody (1:1000). The efficiency of 
capture by anti-HA agarose beads was determined by western blotting for FKBP 
(1:1000).
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4.2 Results
4.2.1 Purification o f  M itochondria using  a D iscontinuous Percoll Gradient
Porcine lung mitochondria were isolated as described in the Methods. Figure 
4.6A illustiates the position of mitochondria isolated from porcine lungs on a 
discontinuous Percoll gradient, following centrifugation. By inspection, the mitochondria 
appeared to accumulate predominantly at the interface of the 12 to 26% and 26 to 40% 
layers. Bands 1-3 were carefully removed by puncturing the side of the tube with a 
syi'inge fitted with a 22-gauge needle. Purity of the mitochondria was assessed by 
immunoblotting for common organelle markers. Figure 4.6B shows western blots for 
calnexin (ER marker), GM130 (Golgi marker), Na'^/K’^ ATPase (plasma membrane 
marker) and porin (mitochondrial marker) from starting lysates, crude mitochondria and 
Percoll gradient bands 1 to 3. It is evident that band 2 contains the “purest” mitochondria 
and, unless stated otherwise, all subsequent experiments were performed using 
mitochondria isolated in this way.
4.2.2 Im m unoprécipita tion o f  eN O S and  P hospho-eN O S fro m  Isolated  M itochondria
We sought to determine whether eNOS and phospho-eNOS could be found in 
isolated mitochondria. Prior literature showed that eNOS can associate with the 
cytoplasmic face of the outer mitochondrial membrane (Gao et (lA, 2004; Reiner et a l, 
2001), via an unidentified proteinase K-cleavable protein (Gao et a l, 2004). Therefore, 
we investigated whether eNOS and phospho-eNOS Seri 179 were present in 
mitochondria isolated from porcine lungs. While eNOS was present in too low 
abundance to be detected by western blotting in mitochondria as isolated.
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Figure 4.6. Isolation of pure mitochondria using a discontinuous percoll gradient Pig lungs were 
used as the source of mitochondria. A. The percoll gradient was set up as shown in i. and crude 
mitochondria were loaded on top of the 12% layer. After centrifugation bands 1 to 3 where removed using 
a syringe (ii). B. Isolated bands, crude mitochondria and a sample of the original lysate were loaded onto 
a 4-12% SDS-PAGE gel and transferred onto nitrocellulose. Proteins were probed with the indicated 
antibodies (a-Calnexin 1:1000, a-GM130 1:250, a-NaVK^ ATPase 1:5000 and a-Porin 1:1000) to assess 
the relative purity of the mitochondrial preparations from the three bands.
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immunoprécipitation of eNOS showed that both eNOS and eNOS phosphorylated at 
SeiT 179 have a mitochondrial presence (Fig. 4.7A). Although the mitochondrial protein 
porin has been reported to interact with eNOS, this was not confhined in eNOS IP 
experiments (Fig. 4.7A). Additional immunoprécipitation experiments, confirmed the 
presence of eNOS (Fig. 4.7B), eNOS Seri 179 (Fig. 4.7C) and Akt-1 (Fig. 4.7D) at the 
mitochondria, Akt-1 is significant for its recognized ability to phosphorylate eNOS on 
Seri 179 (Dimmeler et a l, 1999; Fulton et a l, 1999). Reciprocal immunoprécipitation 
with a phospho-eNOS Seri 179 antibody provided support for the presence of phospho- 
eNOS on the mitochondria (Fig. 4.7C). Although we detected high levels of Akt-1 in 
isolated mitochondria, evidence for direct association with eNOS was not supported by 
co-IP experiments (Fig. 4.7C). Nonetheless, the abundance of Akt-1 in isolated 
mitochondria, coupled with Akt’s Icnown functions elsewhere in the cell, suggests a 
possible role in phosphorylation of eNOS Seri 179.
4.2.3 Expression o f  eN O S on the Outer M itochondrial M em brane
Purification of mitochondria using 30% Percoll yielded approximately 10 mg of 
“pure” mitochondria from 20 grams of starting tissue. Upon treatment with 125 mM 
KCl, the association of eNOS with the mitochondria was reduced by approximately 44%, 
as assessed by densitometry (Fig. 4.8). Wlien Proteinase K was used to selectively cleave 
proteins on the outer surface of the mitochondria, there was a complete loss of bound 
eNOS (Fig. 4.8), supporting prior observations that eNOS docks to the outer 
mitochondrial surface (Gao et a l, 2004).
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Figure 4.7. Immunoprécipitation of eNOS and Phospho-eNOS Seri 179 from 
the mitochondrial fraction of porcine lungs. Mitochondria were isolated from pig 
lungs as described in Methods. eNOS was immunoprccipitatcd from purified 
mitochondria and immunoblotted for eNOS, phospho-eNOS Seri 179 and Porin (A). 
B, C and D show cNOS IPs and immunoblots for total eNOS, eNOS Scrl 179 and 
Akt, respectively. Additionally, phosphorylated cNOS was immunoprecipitatcd 
using a polyclonal phospho-eNOS Seri 179 Ab and immunoblotted for eNOS (C). 
Immunoblots are representative of three separate experiments.
1 50
Figure 4.8. Treatment of porcine lung mitochondria with high salt 
and proteinase-K. Mitochondria were isolated from pig lungs using 
30% Percoll and treated with either 125 mM KCl or Proteinase K (50 
pg/ml). Proteins from crude mitochondria, pure mitochondria or pure 
mitochondria treated with either 125 mM KCl or Proteinase K, were 
separated on a 4-12% SDS-PAGE gel. After transfer of proteins onto 
nitrocellulose, membranes were probed with an anti-cNOS antibody 
(1:2500).
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4.2.4 Generation a n d  Characterization o f  eN O S chim era, F R A P -eN O S a n d  Targeting  
Vectors
As myristoylated eNOS tends to associate predominantly with the plasma 
membrane, the myristoylation deficient mutant eNOS, G2AeN0S, was used as a template 
to generate fusion proteins that directly target the outer mitochondrial membrane (Tom5), 
the imier mitochondrial membrane (Cytochrome Oxidase) and the mitochondrial matrix 
(Cytoclirome Oxidase Subunit VIII) (Fig. 4.9A). For rapalog-induced dimerization 
experiments, FRAP was cloned into the CD8 site of CD8-eN0S and CD8-eN0S-GFP. 
Vectors were developed for targeting to the mitochondrial membranes (Fig. 4.9B), Golgi, 
cellular membranes and the nucleus (Fig. 4.10).
4.2.5 Activity  o f  M itochondria l eN O S
To determine the relevance of mitochondrial localization to eNOS function in 
intact cells, HEK293T cells were tiansfected with empty vector, eNOS (WT), eNOS- 
Tom5 or Cox-eNOS and NO release was assayed indirectly via cGMP ELISA. Cells 
were subsequently lysed and blotted for eNOS to confirm that equal amounts of eNOS 
enzyme were present (Fig. 4.11 graph inset). As shown in Figure 4.11, both eNOS (WT) 
and eNOS-Tom5 on the cytoplasmic face of the outer mitochondrial membrane, exhibited 
significant basal activity -  null activities of empty vector controls were subtracted as 
blank values. As shown, a modest increase in basal activity was observed for eNOS- 
Tom5 compared to eNOS (WT), but this did not achieve statistical significance. In 
contrast, eNOS in the mitochondrial matrix produced substantially less basal NO than 
either eNOS (WT) or eNOS-Tom5 (Fig. 4.11). This may be due to insufficient calcium-
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Figure 4.11. eNOS Activity at the Mitochondria. A. eNOS (WT), eNOS- 
Tom5 and Cox-cNOS were transfected into HEK293T cells and the activity 
of each assessed by cGMP ELISA in the presence or absence of A23187. 
Control samples were incubated in 3 mM NMA for 30 min prior to A23187 
addition and cGMP levels were subtracted as blank values. B. Shows 
western blots, confirming comparable levels of expression of each NOS 
construct. Samples were assayed in triplicate and are presented as means ± 
SEM. The depicted experiment is representative of four independent 
experiments.
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calmodulin in the matrix microenvironment for full support of basal eNOS activity. 
Indeed, Fulton and colleagues have reported similar results for the mitochondrial Cox- 
eNOS (Jagnandaii et a l, 2005), Elevation of intracellular calcium levels by stimulation 
with A23187, evoked NO release from eNOS (WT), eNOS-Tom5 and Cox-eNOS to 
equivalent levels (Fig. 4.11). This finding indicates that despite apparent differences in 
basal activity, eNOS is fully-activatable when resident on or in the mitochondria.
Localization of eNOS to cellular membranes occurs tlirough acylation and, 
potentially, via membrane interactions with polybasic residues, such as the RRICRK 
motif in the eNOS reductase domain. Post-translational regulation of eNOS ensures 
correct targeting to cellular domains that allow efficient coupling to second messengers. 
The inability of Cox-eNOS to support basal activity suggests that the mitochondrial 
matrix provides limited support for NO production in the absence of a Ca^^ agonist 
stimulus such as A23187. However, eNOS exposed to the cytosol on the outer 
mitochondrial face shows basal activity comparable to WT. Presumably its location here 
enables efficient Ca^VCaM binding to support eNOS activity. eNOS docked on the outer 
mitochondrial membrane would predictably be exposed to the “intracellular soup” of 
signaling molecules, such as kinases and phosphatases that enable constitutive regulation.
4,2.6 O n-dem and Translocation o f  eN O S to D istinct Subcellu lar Loci
Kinetics o f  eNOS Translocation to Distinct Subcellular Compartments
A new technology using an engineered system for on-demand translocation of 
eNOS to distinct subcellular loci, including mitochondria, was developed based on the 
constructs summarized in Figures 4.9B and 4.10. The system relies on the fact that
rapamycin and its analogs (rapalogs) possess two distinct high-affinity protein-binding 
surfaces that can effectively bridge FKBP12 and FRAP domain-containing proteins. 
Studies utilize FRAP-eNOS along with a family of desired FKBP-fusion expression 
plasmids whose translation products would predictably target eNOS to intended 
organelles and sub-organelles following rapalog treatment. The specificity of rapalog- 
induced FRAP-eNOS tianslocation was determined by each of two techniques: 
immunoprécipitation of cell lysates, taking advantage of the N-terminal HA-tag of the 
FKBP-fusion proteins, and immunohistochemical analysis of transfected cells.
Immunoprécipitation
COS-7 cells were dual-transfected with FRAP-eNOS and HA-FKBP-fusion 
peptides targeting distinct cellular compartments. After overnight growth, cells were 
treated with rapalog for 0, 3, 5, 10, 30 and 60 min, followed by rapid lysis. The lysates 
were then incubated overnight with an HA antibody coupled to agarose and immuno- 
captured HA-FKBP was evaluated for its association with eNOS by imraunoblotting. 
Figure 4.12A shows the kinetics of eNOS translocation to cellular membranes, the outer 
mitochondrial membrane, nucleus, mitochondrial matrix and Golgi. The results 
demonstrate that within 10 min of rapalog exposure there is already significant 
association of FRAP-eNOS to each of the subcellular organelles studied (Fig 4.12A 
highlighted box). Figure 4.I2B shows the loading control for the immunoprécipitation 
reactions, as assessed by immunoblotting for FKBP. Results confirm equivalent 
expression of HA-FKBP at all time points evaluated in Fig. 4.12A and demonstrate rapid 
on-demand translocation of eNOS to intended organelles.
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Figure 4.12. Kinetics of FRAP-eNOS translocation to distinct subcellular 
compartments as determined by immunoprécipitation. Cells were dual­
transfected, treated with AP21967 for the indicated times, lysates were 
prepared and immunoprecipitated using anti-HA-conjugated agarose beads. 
Samples were eluted, electroblotted and probed for A. eNOS (1:1000) and B. 
FKBP (1:000).
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Immunohistochemistiy
The time coui'se of FRAP-eNOS translocation from the cytosol to intended 
subcellular loci was further determined by immunohistochemistry. COS-7 cells grown 
on glass coverslips and dually-transfected with FRAP-eNOS and each of the organelle 
targeting FKBP-fiision proteins, were treated with rapalog at time “0” and then fixed at 
the indicated times (Fig. 4.13 -  Fig. 4.17). The results show efficient translocation to the 
nucleus occurs within 60 min (Fig. 4.13), to the outer mitochondrial surface (Fig. 4.14) 
and cellular membranes (Fig. 4.15) within 10 min and to the Golgi apparatus within 24 
hrs (Fig. 4.16). In conti*ast, it appears that FRAP-eNOS does not enter the mitochondrial 
matrix even after 24 hrs of rapalog treated (Fig. 4.17).
4,2 .7  Activity  o f  eN O S on the O uter M itochondria l M em brane
As supported by my earlier presented findings, the cytoplasmic face of the 
mitochondrial outer membrane appears to be a physiological destination for eNOS in 
endothelial cells (Gao et a l, 2004). In experiments assessing the kinetics of FRAP-eNOS 
translocation, approximately 50% of the cells showed eNOS associated to the 
mitochondrial outer membrane at 10 min (Fig. 4.14). At 60 min, greater than 90% of 
cells showed FRAP-eNOS localized to the mitochondria. In all subsequent experiments 
utilizing rapalog-induced trafficking of eNOS, cells were incubated in rapalog-containing 
media for 2 hrs prior to experimentation. To determine the extent to which FRAP-eNOS 
activity may be altered upon trafficking from the cytosol to the outer mitochondrial 
membrane, activity assays were performed on cells dual-transfected with FRAP-eNOS 
and FKBP-Tom5, and incubated in the absence or presence of rapalog (2 his). Figure
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4.18 shows basal and A23187-evokedNO bioactivity from culture medium of tiansfected 
cells, as detected by cGMP accumulation in RFL-6 reporter cells. Notably, the 
association of FRAP-eNOS with mitochondria did not result in any change in basal 
activity (Fig. 4.18 light blue bars). Upon stimulation with A23187, activity of cytosolic 
eNOS increased approximately five-fold over basal levels. In contrast, there was an 
approximate three-fold increase in mitochondrial eNOS activity after treatment with 
A23187. This result suggests a 40% reduction in A23187-evoked NO release when 
eNOS migrates to the mitochondiial outer membrane from the cytosol (Fig. 4.18 black 
bars). The graph inset is an immunoblot analysis confirming equivalent levels of FRAP- 
eNOS protein in these activity assays.
4,2,8 R egulation o f  eN O S A ctivity  on the O uter Surface  o f  the M itochondria
The initial discoveiy that eNOS is a Ca'^VCaM-dependent enzyme, was followed 
by immense interest in elucidating other mechanisms by which eNOS may be regulated. 
To date, much work has focused on characterizing the function and regulation of eNOS at 
its predominant subcellular sites, the Golgi and plasma membrane. The importance of 
Ca'^VCaM-binding, phosphorylation and the intimate relationships with protein binding 
partners, on the regulation of eNOS function is well appreciated. Recently, the field 
expanded when mitochondria were identified as a new cellular target for eNOS 
translocation. Studies suggest that a pool of trafficking eNOS docks onto the cytosolic 
face of the outer mitochondrial membrane via the pentabasic RRKRK motif in the 
autoinliibitory control element present in the FMN-binding domain of eNOS. Despite 
evidence for the existence of mitochondrial eNOS, regulation of eNOS function at this
165
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Figure 4.18. Determination of eNOS activity following translocation to the 
mitochondrial outer membrane. Cells transiently expressing FRAP-eNOS and 
pC4M-Tom5, were incubated in rapalog or vehicle for 2 hrs and stimulated with 
A23187 for 20 min. Activity was measured indirectly via cGMP accumulation in 
RFL-6 reporter cells. The inset shows equal expression of eNOS in each of the 
transient cell lines used in the experiment. The graph is representative of four 
separate experiments, each carried out in triplicate ± SEM. The asterisk indicates 
a significant decrease in A23187-evoked eNOS activity following CID-elicited 
translocation of eNOS from cytosol to the outer mitochondrial membrane, as 
assessed by using an unpaired t test with a two-tail P value (p > 0.0050).
166
site remains unstudied. To begin to address this question, we took advantage of the small 
molecule tiiggered heterodimerization of FRAP, RAP and FKBP. Cells were transfected 
with FRAP-eNOS and FKBP-Tom5 constructs, then treated with A23187 or VEGF in the 
presence or absence of rapalog. Cell lysates were analyzed using phosplio-specific 
antibodies against established phospho-regulatory sites of eNOS: Thr495, Ser635 and 
Seri 179.
The specificity of the Seri 179. antibody was tested on bovine aortic endothelial 
cells (BAEC) lysates in the presence or absence o f VEGF and calf intestinal phosphatase 
(CIP). Figure 4.19 shows that in the absence of CIP, VEGF phosphorylates eNOS on 
Seri 179 with peak phosphorylation at 5 min. When the lysates were pretreated with CIP 
to remove the phosphate groups, the signal was abolished demonstrating the specificity of 
the phopho-Serl 179 antibody. '
To determine the impact of A23187- and VEGF-mediated phosphorylation on 
eNOS localized to the outer mitochondrial face, cells were transfected with FRAP-eNOS 
and pC4M-Tom5, pretreated with either AP21967 or vehicle for 2 hours and treated with 
either A23187 (1 ^iM) or VEGF (50 ng/ml) for 5 min. Cells were lysed, proteins were 
separated by SDS-PAGE and then transferred onto nitrocellulose and probed using site- 
directed phospho-eNOS antibodies. Probing of these blots with anti-phospho-eNOS 
antibodies showed that eNOS phosphorylation on Thr495 and Ser635 does not change 
regardless of the stimulus applied (A23187 and VEGF) or the subcellular organelle where 
eNOS is resident (cytosol vs mitochondria). Basal phosphorylation on Seri 179 of eNOS 
was detectable at low levels both in the presence (mitochondrial) and absence (cytosolic) 
of rapalog. As shown in Fig. 4.20 and summarized in Fig. 4.21 stimulation with A23187
167
resulted in a marked increase in SeiT 179 phosphorylation on eNOS in the cytosol (~ 50% 
over basal) and when docked on the mitochondria (~ 60% over basal). Further 
experiments demonstrated that there was additionally a modest increase in A23187- 
elicited phosphorylation of Ser635 and this was evident for both cytosolic and 
mitochondrial eNOS.
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0VEGF 50ng/ml
Time (min)
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eNOS Ser1179
Total eNOS
-CIP
eNOS Ser1179 
Total eNOS
+ CIP
Actin
Figure 4.19. Time course of VEGF-induced phosphorylation of eNOS 
Seri 179 in bovine aortic endothelial cells. The phospho-cNOS Scrll79 
antibody detected a time-dependent phosphorylation of Seri 179 in response to 
50 ng/ml VEGF. Maximal phosphorylation was detected at 5 min of VEGF 
stimulation. When samples were treated with CIP, the ability of the phospho- 
antibody to recognize Seri 179 phosphorylation was abolished.
A.
Thr495
Ser635
Ser1179
Total eNOS
Actin
Rapalog
A23187
VEGF
147 kDa 
147 kDa 
147 kDa 
147 kDa
45 kDa
B.
IP: HA 
IB: FKBP
IB: eNOS
30 kDa
148 kDa
Figure 4.20. Detection of changes in eNOS phosphorylation status in 
response to A23187 or VEGF. Cells were treated as indicated in A. 
Incubations with rapalog and A23187 or VEGF were for 2 hrs and 5 min 
respectively. A. Lysates were analyzed for basal and stimulus-evoked levels 
of phosphorylation on Thr495, Ser635 and Seri 179, as well as total eNOS and 
actin as a loading control. B. A portion of the lysates was immuno­
precipitated using anti-HA conjugated agarose beads and immunoblotted for 
eNOS and FKBP.
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A23187
Seri 179
Ser635
Cytosolic
Mitochondria
I I Cytosolic 
Mitochondria
0) 40
c  30
Ser1179 Ser635
Figure 4.21. Densitometric analysis of A23187-mediated phosphorylation of cytosolic 
and mitochondrial eNOS on Serines 635 and 1179. Cells were co-transfected with FRAP- 
eNOS and pC4M-Tom5 and pre-treated with rapalog or vehicle for 2 hours, prior to A23187 
stimulation. Incubations in A23187 were carried out for 5 min, lysates were prepared and 
immunoblotted using phospho-eNOS antibodies to Ser635 (1:2000) and Seri 179 (1:1000). 
The graph illustrates the percentage ehange in phosphorylation relative to basal levels of 
phospho-modified eNOS.
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4.3 Discussion
The work presented herein describes a novel strategy designed to address the 
significance of eNOS localization on eNOS activity and phosphorylation status, with 
emphasis on the outer mitochondrial membrane. The assay relies on the ability of FRAP 
and FKBP to conditionally bind in the presence of rapamycin or rapalog (collectively 
abbreviated as Rap). Rapamycin is a small immunosuppressive molecule that binds to 
FKBP (Wiederrecht et a l, 1991). Mutagenesis studies have allowed the development of 
non-immunosuppressive rapalogs that are biologically inert, yet can still interact with 
FRAP and FKBP. Upon binding of FKBP to Rap, FRAP can bind and form a stable 
trimeric FRAP-Rap-FKBP complex (Brown et a l ,  1994; Sabatini et a l, 1994). This 
three-way interaction only occurs in the presence of Rap. We have fused FKBP to 
distinct subcellular organelle targeting peptides, and FRAP onto eNOS (FRAP-eNOS), 
resulting in mislocalization of native eNOS to the cytosol. Addition of Rap causes rapid 
translocation of FRAP-eNOS to desired organelles, providing a powerful tool that allows 
us to study cytosolic eNOS (-Rap) and organelle targeted eNOS (+Rap) within the same 
cells.
The present studies additionally provide in vivo evidence demonstrating the 
presence of eNOS on the cytoplasmic face of the outer mitochondrial membrane. In viti^o 
experiments assessing the activity and regulation of eNOS targeted to the outer 
mitochondrial membrane revealed, for the first time, that this pool of eNOS is 
functionally active and undergoes phosphorylation on serines 635 and 1179 in response 
to A23187 and to a lesser extent, VEGF.
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Within endothelial cells, the dynamic nature of eNOS results in spatial 
confinement to distinct cellular compartments ensuring the fidelity of NO signaling to 
neighboring and distant targets. Native eNOS localizes to the plasma membrane and the 
cw/medial-Golgi complex both in intact blood vessels and cells in culture (Garcia- 
Cardena et a l, 1996; Liu et a l, 1996; O'Brien et a l, 1995; Shaul et a l, 1996; Sowa et a l, 
1999). Extensive work has addressed the consequence of eNOS targeting to the Golgi 
and plasma membrane with specific emphasis on eNOS activity and regulation (Fulton et 
a l, 2004; Fulton et a l, 2002). At non-caveolar regions of the plasma membrane, eNOS 
is phosphorylated on serine 1179 (Seri 179) and exhibits high basal activity. In contiast, 
eNOS docked to the cw-Golgi membrane is insensitive to calcium fluxes from 
transmembrane channels, but exhibits full activity upon Akt-mediated phosphorylation of 
Seri 179 (Fulton et a l, 2004).
Specific protein-protein interactions are vital to ensure the fidelity of signal 
transduction events within all eukaryotic cells. Often dimerization of key proteins, either 
by endogenous factors or exogenous compounds, regulates essential cellular processes by 
virtue of recruitment and activation of signaling modalities. Potentially, any cellular 
process can be regulated by associating key components using synthetically developed 
molecules. These molecules are called dimerizers and contain motifs that specifically 
bind to high affinity sites within proteins.
The small-molecule immunosuppressant, rapamycin, allows for an interesting 
tliree-way relationship between the immunophilin FKBP and protein kinase FRAP. 
Rapamycin exerts its immunosuppressive effects tluough association with FKBP which 
in turn inhibits FRAP kinase activity (Brown et a l, 1994). Heterodimerization reactions.
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such as rapamycin-mediated association of FRAP and FKBP, opened the field for the 
development of a new class of molecules known as the chemical inducers of dimerization 
(CIDs). Elucidation of this mechanism resulted in the development of a collection of 
non-immunosuppressive compounds, mutagenically engineered to bind in response to 
specific CIDs. Amongst these are biologically inert mutants of FRAP and FKBP. If we 
consider two proteins, protein X and protein Y, we can fiise FRAP onto X and FKBP 
onto Y and by the addition of a non-reactive rapamycin analog (AP21967), induce 
association of Proteins X and Y. To this end, several groups have successfully adapted 
the use of FRAP and FKBP heterodimerization to study signal transduction (Pruschy et 
a l,  1994; Spencer et a l, 1993), cell death (Belshaw et a l, 1996; Spencer et a l, 1996) 
and transcriptional activation (Belshaw et a l, 1996; Ho et a l, 1996; Rivera et a l, 1996) 
in cells. In the present study we provide the first evidence for the use of FRAP/FKBP 
heterodimerization technology to specifically traffic proteins, in this case eNOS, to 
distinct subcellular organelles.
Extensive work has been carried out to characterize eNOS function, regulation 
and activity at intracellular domains in both endothelial and non-endothelial cell systems 
(Church & Fulton, 2006; Erwin et a l, 2006; Fulton et a l, 2004; Fulton et a l, 2002; 
Garcia-Cardena et a l, 1996; Gonzalez et a l, 2002; Jagnandan et a l, 2005; Prabhakar et 
a l, 2000; Zhang et a l, 2006). In each of the above cited publications, experiments were 
carried out on organelle-restricted eNOS via fusion of targeting-peptides directly onto the 
eNOS C- or N-terminus. In the current study we describe a small molecule triggered 
approach for on-demand targeting of cytosolic eNOS to distinct subcellular 
compartments. The advantage of this novel CID-based approach over the prior eNOS
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targeting approach, is that CID-induced eNOS translocation allows characterization of 
eNOS function, regulation and activity in the same cells, before and after the addition of 
AP21967, providing for well-controlled experimentation.
The work presented establishes the use of AP21967 to trigger rapid (typically 
within 10 min) FRAP-eNOS relocation from the cytosol to specific subcellular 
compartments, including the outer mitochondrial membrane, the nucleus, cellular 
membranes and the trans-Golgi network. In contrast, trafficking of eNOS to the 
mitochondrial matrix, as deteimined immunohistochemically, was absent even when cells 
were treated with AP21967 for 24 hours. Considering the finding that within 10 minutes 
there is significant association of FRAP-eNOS with Cox-FKBP, as assessed by 
immunoprécipitation, it is plausible that FRAP-eNOS and Cox-FKBP associate in 
response to AP21967, not at the mitochondrial matrix but at a location external to the 
mitochondrial membranes. This would suggest that AP21967, either through binding to 
FRAP-eNOS or Cox-FKBP individually, induces translocation of Cox-FKBP from the 
mitochondria to an extramitochondrial location, a finding supported by the 
immunohistochemical data presented here. To reconcile these observations, we 
considered each of the localization peptides individually. The GRIP domain, Tom5, c- 
Src N-myristoylation sequence and the SV40 NLS, all anchor FKBP to specific cellular 
membranes (see Table 1.1). Conversely, Cox leaves a freely diffusible fusion protein 
within the matiix of the mitochondria that upon addition of AP21967, preferentially 
leaves the matrix than FRAP-eNOS enters the mitochondria. This could be attributed to 
the size of the respective fusion proteins: FRAP-eNOS is a 145 kDa protein whereas 
Cox-FKBP is approximately 24 kDa in size. Presumably, it is more facile for a small
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non-native mitochondrial protein (Cox-FKBP) to leave the mitochondria than for a large 
non-native protein (FRAP-eNOS) to enter upon stimulation with AP21967.
Wliile caveolar and Golgi membranes are recognized as the primary sites of 
eNOS in endothelial cells, additional evidence suggests that eNOS translocates to and 
regulates mitochondrial function (Gao et a l, 2004). A focus of this work was to 
elucidate the mechanisms involved in the regulation and actions of mitochondrial eNOS.
Mitochondi'ia are dynamic organelles, which undergo numerous fusion and fission 
events. These processes yield variations in mitochondrial size, number and mass, and are 
governed by physiological and pathophysiological stimuli. The mitochondrion is the 
cell’s powerhouse, generating energy (ATP) via election transport through protein 
complexes anchored to the inner mitochondrial membrane. The bioenergetic properties 
of mitochondria have been well studied and their role in cell survival is pivotal (see 
review by (Brown, 1999)).
Cytochrome c oxidase (complex IV) is the terminal complex of the mitochondrial 
respiratory chain and is responsible for consumption of almost all cellular oxygen. NO 
tonically inhibits cytochrome oxidase either through binding to reduced heme « 3  or by 
binding to oxidized Cub and excluding O2 from the enzyme (Ghafourifar & Cadenas, 
2005). Either binding event would lead to inliibition of cellular respiration. The 
physiological interaction of NO with cytochrome c oxidase is further substantiated by the 
finding that inhibition of NOS increases basal mitochondrial respiration (Loke et a l, 
1999). Regulation of respiration by NO-mediated inhibition of cytochrome oxidase 
provides an elegant control mechanism for moment-to-moment regulation of oxygen 
consumption in vivo. The proximity of endothelial cells to circulating blood nutrients
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provides a constant source of arginine that sustains mitochondrial NOS activity. The low 
levels of NO produced under normal physiological conditions, apparently compete with 
O2 for binding to cytochiome oxidase, leading to reversible attenuation of cellular 
respiration. As a consequence the cells demand for O2 is decreased, potentially allowing 
diffusion of free O2 to hypoxic cells deeper within a given tissue (Thomas et a l, 2001).
Mitochondria are the cell’s richest source of superoxide and reports indicate that 
2-5% of the O2 that enters the respiratory chain is converted to superoxide (Chow, 2001). 
In turn, superoxide can react with NO yielding highly reactive ONOO" resulting in 
oxidative protein modifications and potentially, intiacellular havoc. The topological 
location of eNOS on the outer membrane of the mitochondria keeps the source of NO 
away from the pool of superoxide in the mitochondrial matrix, a spatially favorable 
scenario. The physical separation of eNOS from the respiratory chain and mitochondrial 
superoxide is likely to be vital for reversible regulation of mitochondrial activities by NO 
in endothelial cells.
We speculate that ordered phosphorylation/dephosphorylation occurs as eNOS 
translocates through distinct subcellular loci, propagated by changes in protein-protein 
interactions. In support of this view, eNOS activation by agonists normally arises from 
two concomitant and essential Ca^VCaM binding-induced events: (1) displacement of 
inhibitory interactions with caveolin-1, resulting in eNOS release from caveolar pockets 
(Feron et a l, 1998), and (2) rearrangement of the 45 amino acid FMN autoinhibitory 
domain peptide of eNOS (Salerno et a l, 1997) resulting in enzyme activation and 
exposure of regulatory sites to kinase phosphorylation (Ser635). Phosphorylation at 
Ser635 has been shown to decrease calcium-dependence, and can thereby sustain eNOS
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activity even when intracellular C a^  falls to basal resting levels. Phosphorylation of 
Seri 179 on the C-tenninal auto inhibitory domain also results in reduced dependence of 
Ca"^ for activity and can impact on subsequent regulatory processes.
The work presented suggests that eNOS binds to the mitochondrial membrane via 
a Proteinase K-cleavable partner, an observation consistent with that made by Gao and 
colleagues (Gao et a l, 2004). The localization of eNOS to the mitochondrial cytoplasmic 
face allows for basal and A23187-evoked activity, comparable to that of cytosolic eNOS. 
Additionally, stimulation with Ca^^-elevating agents and VEGF results in 
phosphorylation at serines 635 and 1179. A number of external stimuli have been shown 
to increase eNOS phosphoiylation and activation through a panoply of kinases, including 
PKC, Akt, PKA, AMPK, and CAMK. For example, an A kt- and PKA-dependent 
mechanism mediates increased phosphorylation of Seri 179 in native bovine eNOS, 
without affecting phosphorylation at Thr495. This finding was mimicked in our 
experiments looking at mitochondrial eNOS. In addition to Seri 179, PKA has also been 
shown to phosphorylate Ser635. Oui* work was consistent with these findings, suggesting 
that eNOS docked onto the outer surface of the mitochondria undergoes phosphorylation 
on serine 635 and 1179, possibly via PKA in response to Ca^^-elevating agents.
The proposed interaction of eNOS with the outer mitochondrial membrane occurs 
via its poly-basic RRKRK motif. The Ca^^-dependent cNOSs contain a C-terminal 45 
amino acid insertion peptide that functions as an autoinhibitory domain and includes the 
RRKRK sequence. The current model for regulation of eNOS by its autoinhibitory 
domain suggests that the autoinhibitory peptide in the FMN-binding domain of eNOS 
docks to a site adjacent to the CaM-binding domain, possibly via RRKRK, and sterically
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impedes CaM binding and hence, enzyme activity. The location of key phosphorylation 
sites within the eNOS sequence, Ser635 (in the CaM-binding domain) and Seri 179 
(eNOS C-terminus) apparently provides a mechanism for disinhibition of the auto­
inhibited enzyme. It is thought that autoinhibition of eNOS activity through its 
autoinhibitory domain masks Ser635 and Seri 179, preventing access of the kinases 
normally associated with their phosphorylation (Lane & Gross, 2002; Salerno et a l, 
1997). Upon transient increases in intracellular Ca^^, CaM binds to eNOS, displacing the 
autoinhibitory loop by virtue of domain overlap and elicits enzyme activity. In turn, this 
structural reorganization exposes the RRKRK motif as well as Ser635 and Seri 179, 
allowing for phosphorylation, which peipetuates activity by impairing the reformation of 
the autoinhibited enzyme. Considering the finding of Gao et al that eNOS, via RRKRK, 
docks onto the mitochondrial outer membrane, it is no surprise that our findings show 
both basal and stimulus-evoked phosphoiylation of eNOS on the outer surface of the 
mitochondria. Docking onto the cytoplasmic face of the mitochondria, would 
presumably keep eNOS in its active fonn by exposing critical phosphoiylation sites for 
access by available kinases and phosphatases. Tethering onto the outer mitochondiial 
surface would additionally limit autoinhibition of eNOS activity. The simplified 
schematic in Fig. 4.18 illustrates the proposed chain of events leading to eNOS activation 
and regulation at the mitochondiia, considering both published findings and novel 
findings made in this study.
The experimental finding that VEGF does not efficiently elicit phosphorylation of 
eNOS Seri 179 on eNOS in the cytosol or on the outer mitochondrial membrane, suggests 
that VEGF preferentially leads to activation of eNOS at the plasma membrane, rather
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eNOS within the intracellular milieu. Considering the location of the VEGF receptor at 
the plasma membrane, this hypothesis seems plausible. In contrast, A23187 broadly 
releases intracellular calcium stores, resulting in ubiquitous activation of eNOS and Ca^^- 
sensitive kinases and phosphatases that may elicit eNOS phosphorylation and activation 
more broadly.
Taken together our findings show that eNOS docked on the outer mitochondrial 
membrane is basally active and basally phosphorylated on both Ser635 and Seri 179, sites 
that are known to elicit eNOS activation. Additionally, A23187 markedly increases both 
activity and phosphorylation of eNOS when on the mitochondria, as has been shown 
previously for eNOS at the plasma membrane and Golgi. Importantly, we have 
established a novel technique based on chemical induced dimerization of FRAP and 
FKBP fusion proteins for on-demand translocation of eNOS and other proteins to distinct 
subcellular organelles. In future, tins tool will allow for more definitive assessment of 
eNOS activity, regulation and the fate of eNOS-derived NO in alternative subcellular 
compartments.
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Figure. 4.22. Summary illustration of eNOS regulation at the mitochondria. This figures shows 
the proposed chain of events that regulate eNOS function on the outer mitochondrial membrane. 
Activation of eNOS by Ca VCaM exposes serines 635 and 1179 as well as the polybasic RRKRK 
motif, which in turn docks eNOS onto the outer surface of the mitochondria. Phosphorylation of 
eNOS on Ser635 and Seri 179 activates eNOS and the NO released may influence mitochondrial 
function via inhibition of components of the electron transport chain (ETC).
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CHAPTER 5
SNOSID, A PROTEOMIC METHOD FOR IDENTIFICATION OF CYSTEINE S- 
NITROSYLATION SITES IN COMPLEX PROTEIN MIXTURES
5.0 Introduction
NO is an atypical biosignaling molecule in that its actions depend on covalent 
modifications of proteins, rather than traditional “Lock-and-Key” protein interactions. 
This fundamental difference has major consequences for NO-mediated signaling: (i) the 
chemical reactivity of NO determines its biological actions (ii) diverse competing 
reactions of NO (and NO-derived species) occur within biological systems and (iii) the 
chemistries carried out by NO and its congeners, are impacted by the changing 
intracellular microenvironment. Preferred reactions of NO and NO-derived species are 
schematized in Figure 5.1. This diversity of chemical reactions governs the ensuing 
biological consequences of NO. Thus, the inclusion of NOS isoforms within spatially- 
restricted signaling complexes is likely to have evolved for regulation of activity and to 
facilitate the appropriate chemical targeting of NO to specific effector proteins.
From a chemist’s perspective, covalent addition of NO (and NO-derived species) 
to a thiol group sulfur is termed S-nitrosation. However, with the discoveiy that NO 
addition is a generic protein modification that confers physiological regulation of diverse 
protein functions, akin to O-phosphorylation, the term S-nitrosylation has emerged as a 
more apt descriptor (Stamler et a l, 2001). Like O-phosphoiylation, S-nitrosylation is 
stimulus-evoked (Gow et a l, 2002), precisely-targeted (Sun et al, 2001), spatio- 
temporally restiicted (Fang et al, 2000) and may contribute to a cell’s flexibility in
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responding to a continually changing extracellular milieu (for reviews, see (Gaston et al, 
2003; Hess et a l, 2005; Lane et al, 2001; Martinez-Ruiz & Lamas, 2004)). Thus, S- 
nitrosylation fulfills essential criteria to function as a bona fide cell signaling modality.
Whereas reversible S-nitrosylation has been reported for over a hundred distinct 
proteins, contributing to NO-mediated signaling in mammalian cells, fewer than thirty 
protein Cys modification sites have been specified (Hess et al, 2005), In each case, the 
specification of a NO-targeted Cys residue has been a laborious task, usually involving an 
iterative combination of mutagenesis and mass spectrometiy (MS)-based approaches. 
Despite the importance and ubiquity of S-nitrosylation in cell signaling, a method has not 
been described for unbiased identification of SNO-Cys (where NO is covalently attached 
to sulfur) modification sites in proteins. Moreover, the accumulated inventoiy of SNO- 
Cys sites in the published literature was insufficient to enable a compelling elucidation of 
the molecular “rules” that provide a basis for preferential addition of NO (or NO-derived 
species) to particular protein Cys residues. Given this knowledge gap, we sought to 
develop a method that enables unbiased and high-throughput identification of SNO-Cys 
sites on NO-regulated target proteins in biological samples. In this chapter, we describe 
SNOSID (SNO-Site Identification), a method that meets these needs for unbiased SNO- 
Cys site identification in complex protein mixtures.
SNOSID is an extension of the biotin-switch method, originally described by 
Jaffrey and colleagues (Jafffey et al, 2001). The initial step in this procedure involves 
blocking free (umnodified) thiols within a protein mixture using the thiol-specific 
methylthiolating agent, methanethiosulfonate (MMTS) -  MMTS does not react with 
nitrosothiols or preexisting disulfide bonds. Subsequently, S-NO bonds are selectively
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Figure 5.1. Favored redox reactions of NO and NO-derived species. NO can
undergo reduction and oxidation reactions to produce biologically active nitroxyl (NO ) 
and nitrosonium (NO ) anion, respectively. NO, its congeners NO and N O \ and higher 
oxides of NO (N0%), eaeh earry out distinet protein ehemistries as exemplified in the 
sehematic. This reaction diversity helps to rationalize the often conflicting effects of NO 
on biological systems. Abbreviations: O N O O , peroxynitrite; NO2, nitrogen dioxide; 
N2O3, dinitrogen trioxide; RS-NO, nitrosothiol; M-NO, metal-nitrosyl adducts; NH2OH, 
hydroxylamine; RR’N-NO, N-nitroso eompound; RONO, alkyl nitrites; N2O, nitrous 
oxide.
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reduced to free thiols at each former SNO-Cys site. Newly produced free thiols are 
reaeted with N-[6-(biotinamido)hexyl]-3’-(2’-pyridyldithio)-propionamide (biotin- 
HPDP), a sulfhydryl-specific biotinylating reagent. The resulting biotinylated proteins 
are then captured on immobilized avidin and selectively released from avidin by 
reduction of the disulfide linker.
In additional cell cultine studies, CID-diiven tianslocation will be combined with 
SNOSID methodology in an attempt to elucidate the impact of eNOS subcellular 
residence on protein S-nitrosylation. Our aim is to provide a direct test of the prevailing 
dogma that NO signaling occurs by simple random diffusion with homogeneous levels of 
NO throughout the cell. As an alternative, we hypothesize that NO gradients exist within 
the same cell, concentrated around eNOS (and other NOS isofomis) -  proximity to eNOS 
should be a major determinant of which proteins preferentially undergo S-nitrosylation. 
Since eNOS is a low output enzyme (~ 3 NO/sec) (Brovkovych et al, 1999) and only 
transiently activated, it is reasonable to think that NO is consumed by spatially-restricted 
reactions within the endothelial cell, rather than diffiising cell distances away for distal 
paracrine actions. A combination of CID and SNOSID should provide a powerful tool to 
inventory locally S-nitrosylated proteins, when eNOS is resident at differing cellular 
compartments.
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5.1 Materials and Methods
5.1.1 Materials
Rat cerebellum was purchased from Pel-Freez (Rogers, AR). Nanospray capillary 
emitters (15 /<m) were purchased from New Objective (Woburn, MA) and capillary LC 
columns (CIS resin, 75 pim diameter, 150 mm length) were from Agilent Technologies 
(Santa Clara, CA). HPLC grade Acetonitrile was from J.T Baker Chemicals (Philipsburg, 
NJ). All other chemicals, unless otherwise stated, were purchased from Sigma Chemicals 
(St. Louis, MO) and were of the highest purity available.
5.1.2 Cell Culture and Transfections
COS-7 cells were grown in T-75 flasks and maintained in complete DMEM. 
Cells were serum-starved for 24 hrs and transfections were carried out using FiiGENE 6 
reagent (Roche) with 3 j.ig of pcDNA3-FRAP-eN0S and 6 pg of pC^M-TomS per T-75. 
After 36 lirs, cells were treated with vehicle or rapalog (AP21967) for 2 hrs, followed by 
incubation in the presence or absence of A23187 (5 pg/ml) for 30 min. Control reactions 
were pre-incubated with 3 mM NMA for 2 hrs. Cells were washed twice with phosphate 
buffered saline (PBS), scraped in 5 ml of PBS and pooled together. Cell pellets were 
recovered after centiifugation at 3,500 rpm for 10 min, snap frozen in liquid nitrogen and 
stored at -80°C until the day of analysis.
5.1.3 The SNOSID method for SNO-peptide isolation
One gram of rat cerebellar tissue was homogenized in 10 ml of iced lysis buffer 
(20 mM Tris-HCl (pH 7.6), 1 mM EDTA, 150 mM NaCl, 0.4% triton-X 100, 0.1 mM
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neocuproine and protease inhibitor cocktail) using a glass pestle and 10 strokes in a 
Dounce homogenizer. Some lysates were subjected to transnitrosation by incubation 
with desired concentrations of GSNO for 30 min at 37® C -  conti'ol samples were either 
untreated, or incubated under identical conditions with 5 mM dithiothreitol (DTT) to 
promote denitrosylation. Proteins were precipitated by addition of two volumes of iced 
acetone. Samples were then centrifuged at 2000 x g for 15 min and the supernatant was 
discarded. Protein pellets were resuspended in blocking buffer (20 mM Tris-HCl, pH 7.7, 
2.5% SDS, 20 mM MMTS, 1 mM EDTA and 0.1 mM neocuproine) at a final protein 
concentiation of 0.8-1.0 mg/ml and incubated for 30 min at 50°C. Proteins were 
precipitated free of MMTS by addition of 2 volumes of iced-acetone and then pelleted by 
centrifugation; this acetone-precipitation procedure was repeated two times for more 
complete removal of MMTS. Proteins were then solubilized and biotinylated by a 1 hr 
incubation at room temperature in 5 ml of re-suspension buffer (20 mM Tris, pH 7.6, 1% 
SDS, 1 mM EDTA, 0.1 mM neocuproine, 4 mM ascorbate and 0.2 mM Biotin-HPDP. 
Biotinylated-proteins were precipitated with iced-acetone, pelleted and solubilized in 5 
ml incubation buffer (20 mM Tris-HCl, pH 7.7, 1 mM EDTA and 0.5 % Triton X-100), 
followed by digestion with 1:100 DEPC-treated trypsin (Sigma) at room temperature for 
16 h. Digestion was terminated by addition of 1 mM PMSF and the resulting peptide 
mixture was incubated with 100 pi streptavidin-agarose beads (Sigma) at room 
temperature for 1 h. The streptavidin beads were washed five times in 1 ml of wash 
buffer (incubation buffer, additionally containing 600 mM NaCl), followed by five 1 ml 
washes in buffer containing 5 mM ammonium bicarbonate and 20% acetonitrile. 
Streptavidin-bound peptides were eluted with 150 pi of 100 mM (3-mercaptoethanol
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(ME) and concentrated in a Speed-Vac (to diminish sample loss and thiol oxidation, 
complete drying of samples was avoided). Trifluoroacetic acid (TEA) was added to the 
concentiated peptide solution to achieve a final concentration of 0 .1% for analysis by 
nanoLC-MS/MS.
5.1.4 SNO Quantitation hy Saville-Griess Assay
SNO-protein levels in cerebellar lysates were quantified by using the Saville- 
Griess assay, as described by Eu and colleagues (Eu et al, 2000). Briefly, untreated and 
GSNO-treated cerebellar lysates were prepared by precipitation in iced acetone, followed 
by dissolution in incubation buffer, as described above for SNO peptide analysis. 
Mercury displacement of NO from SNO proteins was elicited by 10 min of incubation 
with 100 pM HgCh. Nitrite levels were determined colorimetrically after reaction with 
100 pi of working Griess reagent (1:1 mixture of 1% sulfanilamide and 0.1% 7V-(1- 
naphthyl) ethylenediamine in 5% O-phosphoric acid) and quantified in a microtiter plate 
spectrophotometer (ThermoMax; Molecular Devices) at A540, relative to sodium nitrite 
standard.
5.1.5 Western Blot Method for SNO-protein Detection
Cell pellets from vehicle and rapalog treated samples were resuspended in HEN 
buffer (250 mM HEPES, 1 mM EDTA, 0.1 mM Neocuproine, Protease Inhibitors) 
supplemented with 1% Triton X-100. After centrifiigation at 5000 rpm for 15 min, 
supernatants were tiansferred to flesh tubes and proteins were precipitated out with two
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volumes of ice-cold acetone. Samples were then centrifuged at 3000 rpm for 5 min and 
the supernatant discarded. Protein pellets were resuspended in HEN blocking buffer (250 
mM HEPES, 1 mM EDTA, 0.1 mM Neocuproine, 2.5% SDS, 20 mM MMTS) and 
incubated for 40 min at 55°C with constant shaking to ensure efficient blocking of free 
thiols. Proteins were precipitated free of MMTS by addition of two volumes of iced- 
acetone and stored at -20°C for 20 min. Proteins were pelleted, washed two additional 
times in acetone and biotinylated in HEN resuspension buffer (250 mM HEPES, 1 mM 
EDTA, 0.1 mM Neocuproine, 1% SDS, 4 mM ascorbate, 1 mM biotin-HPDP) at room 
temperature for 90 min with rotation. Biotinylated proteins were filtered through a 0.4 
pm spin filter to remove excess biotin after which, proteins were precipitated with two 
volumes of iced acetone and recovered by centrifugation at 5000 rpm for 10 min. Protein 
pellets were solubilized in HEN buffer, boiled at 95°C for 10 min in an equal volume of 
non-reducing Tris-glycine SDS-loading buffer (63 mM Tris HCl, pH 6 .8, 10% glycerol, 
2% SDS, 0.0025% Bromophenol Blue), centrifuged at 13000 rpm for an additional 10 
min and the supernatant stored at -20®C. Proteins were resolved by non-reducing SDS- 
PAGE (10-20% Tris-glycine), tiansfened onto nitro-cellulose membranes, washed three 
times in Tris-buffered saline containing 0.1% Tween 20 (TBST) and blocked overnight at 
4®C with blocking buffer (5% BSA in TBST). Membranes were probed with a 
NeutrAvidin-HRP conjugate (1:10000; Pierce, Rockford, IL) at RT for 90 min and 
biotinylation proteins were visualized using ECL Plus (Amersham) and a Stonn Analyzer 
(Amersham). Densitometric analysis of immunoblots was carried out using NIH ImageJ 
Software (http://rsb.info.nih. gov).
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5.1.6 LC-MS/MS analysis
Nanoflow liquid cliromatography-tandem mass spectrometry (nLC-MS/MS) was 
employed to obtain peptide sequence information and identify cognate proteins of origin. 
LC-MS/MS was performed using an 1100 series LC/MSD XCT plus ion trap mass 
spectrometer (Agilent Technologies). Eight microliters of an avidin-eluted peptide 
mixture was injected onto a 0.3 x 5 mm Zorbax 300SB-C18 sample-enrichment column, 
at a flow rate of 10 pL/min. Peptides were resolved on a 3.5 pM particle size, 0.075 x 
150 mm Zorbax 300SB-C18 analytical column, at a flow rate of 0.3 pL/min, with a 
gradient of 15-40% solvent B for 50 min and 40-85% solvent B for 30 min. Mobile phase 
solvent A comprised 0.1% formic acid in 3% acetonitrile and solvent B was 0.1% formic 
acid in 100% acetonitrile. The LC column eluate was introduced into an ion trap mass 
spectrometer via electrospray, using a 15 pm diameter silica emitter needle. Mass spectra 
were acquired in positive-ion mode with automated data-dependent MS/MS on the four 
most intense ions from a precursor MS scan. The fragmentation amplitude was 1.15 V, 
MS scan rates were 8100 m/z per sec, capillary voltage was 1800 and the skimmer 
voltage was 30 V.
5.7.7 Database search o f  MS/MS data fo r peptide sequence identification.
Analysis of MS/MS spectra for peptide identification was performed by protein 
database searching using Spectrum Mill software (Millennium Pharmaceuticals, 
Cambridge, MA). Raw MS/MS spectra were processed to extract MS/MS spectra that 
could be assigned to at least two y- or b-series ions, and only the extracted spectra were 
searched against the SwissProt rodent database. Key search parameters were a minimum
IQO
matched peak intensity of 50%, a precursor mass tolerance of 2.0 Da and a product mass 
tolerance of 0.6 Da. The maximum number of missed cleavages allowed was one. The 
threshold used for peptide identification was a Spectrum Mill score greater than 10.0 and 
SPI% (the percentage of assigned spectrum intensity of total spectrum intensity) greater 
than 70%. Finally, all MS/MS spectra were manually inspected.
5.1.8 Bioinfonnatic analysis o f S-nitrosylation motifs in SNO-Cys flanking residues.
To study the content of information available in a window of residues flanking 
identified SNO-Cys residues, a support vector machine (SVM) was trained with true 
SNO sites and negative SNO sites (this work was done in collaboration with the Weill 
Medical College Institute of Computational Biomedicine). True SNO sites were defined 
as the set of SNO-Cys that were identified in rat cerebellum protein by the LC-MS/MS 
method described herein (listed in Table 1); negative SNO sites were assigned to Cys 
residues in these same SNO-proteins that were not detected by the method. This approach 
eliminates or sti'ongly reduces the risk that a site is considered negative because of low 
protein expression. The data features required to train the SVM were obtained by 
encoding the type of residue, and its relative position to the SNO site. Types of residues 
were encoded as 20 Boolean numbers for each position. Similar results were observed 
using another feature representation derived from amino acid residue physicochemical 
properties (3 decimal features per position, data not shown). We measured perfonnance 
with the FI measure. The FI measure is the harmonic mean of recall (the percentage of 
positive examples that are predicted to be positive) and precision (the percentage of 
predicted positive examples that are truly positive), it is calculated as:
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( \ \ \+ ^recall precision ^ (Joachims, 1999). Leave-one-out precision and recall were
measured using the SVMLight (Joachims, 1999) with the SVM parameters tuned by 
LIB SVM (parameter grid-search) (Chang & Lin, 2001). As a positive contiol, we 
performed the same study for O-phosphorylation sites. The O-phosphorylation (OPH) 
dataset was retrieved from Phospho.ELM (Diella et al., 2004). After selecting for rat and 
mouse sequences, we sampled the OPH sites to create a training set of the same size as 
available for SNO. As negative controls, we considered a random permutation of the 
positive and negative sites for OPH or SNO.
5.1.9 Molecular Modeling o f  the SNO-Cys 3D Microenvironment
Molecular visualization of proteins with known crystal structures was earned out 
using Insight II (Accelrys, Burlington, MA). Protein coordinates where retrieved from 
the Protein Data Bank (PDB; pdb.org) and the three-dimensional microenvironment was 
analyzed to determine the proximity of aromatic rings and acidic and basic residues to the 
Cys sulftir gi'oup, within a 6 A perimeter.
5.1.10 Immunoprécipitation and Iimnunoblotting
Dual-transfected and vehicle or AP21967-treated cells were rinsed twice in PBS 
and lysed on ice by the addition of a modified-RIPA buffer (50 mM Tris-HCl, pH 7.7, 
150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 1 mM sodium vanadate, 50 mM 
NaF, 10 mM Na4P20y, 2 mM EDTA, 2 mM PMSF, 1 mg/ml protease inhibitor cocktail). 
Cells were scraped and ti'ansferred to a 2 ml Dounce homogenizer and homogenized with 
50 strokes. Lysates were subsequently rotated at 4°C for 30 min and insoluble material
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was removed by centrifugation at 14,000 rpm for 10 min. Crude lysates were retained for 
analysis as the “pre-IP” sample. Supernatants were transferred to silanized tubes and 40 
pi of a 1:1 suspension of hemagglutinin (HA)-conjugated agarose beads was added to 
each tube and rocked overnight at 4°C. The beads were pelleted at 5,000 rpm for 5 min 
and washed in RIPA buffer. After the final wash, bound proteins were eluted with 40 pi 
of SDS-loading buffer at 95°C for 10 mins. The beads were pelleted at 13,000 rpm for 
10 min and the supernatant was transferred to a fresh eppendorf tube and stored at -20°C. 
Immunoblots were carried out on Pre-IP and IP samples using a polyclonal anti-eNOS 
Ab (1:1000; Upstate), to determine successftil translocation of FRAP-eNOS to the 
mitochondria, and with anti-FKBP (1:1000; Affinity Bioreagents), to assess the 
efficiency of protein capture by the anti-HA agarose beads.
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5.2 Results
5.2,1 Isolation o f  SNO-Cys-containingpeptides by SNOSID method
We sought to adapt the orthodox biotin-swap method (Jaffrey et al, 2001) to 
enable the unbiased identification of SNO-Cys residues on proteins that undergo 
reversible S-nitiosylation. While the method had effectively been employed for affinity- 
capture and identification of intact SNO-proteins, we reasoned that it could similarly be 
used to capture SNO-Cys-containing peptides in tryptic digests of SNO-proteins. 
Further, for peptides with a suitable m/z and possessing only a single Cys residue, it 
should be possible to utilize high-throughput nLC-MS/MS to elucidate the peptide 
sequence, identify the protein of origin and the exact site of S-nitrosylation. To test this 
possibility, we applied the methodology depicted in Figui'e 5.2 for isolation of SNO- 
peptides and analysis by nLC-MS/MS.
As for the previously used afflnity-puriflcation of SNO-proteins (Jaffrey et al, 
2001), initial steps employed for purification of SNO-peptides were: (1) efficient 
blocking of free protein -SH groups (by methylthiolation with 20 mM MMTS); (2) 
selective reduction of SNO-Cys (using 4 mM ascorbate), thereby generating a new 
population of free thiols at sites where NO had previously been; and (3) covalent addition 
of a thiol-biotin moiety (via mixed disulfide linkage, using 0.2 mM biotin-HPDP) to the 
newly produced free thiols. At this stage, rather than capturing intact SNO-proteins on 
streptavidin-agarose, proteins were subjected to complete trypsinolysis and biotinylated- 
peptides were affinity-captured on streptavidin-agarose, followed by selective elution 
using 100 mM P-mercaptoethanol to cleave the mixed disulfide bond linking the peptide 
Cys- and its biotin-tag. This tandem purification procedure incorporates highly-selective
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Figure 5.2. Schematic of the SNOSID method for identifying protein SNO-Cys 
modification sites. Steps 1-3 of the method are performed essentially as described 
previously for the affinity capture of SNO-proteins using the biotin-sAvap method. 
These include efficient methythiolation of free thiols using S- 
methymethanethiosulfonate (MMTS; step 1), selective reduction of SNO-thiol bonds 
with ascorbate and generation of free thiols at sites of NO modification (step 2) and 
then addition of a biotin to former NO modification sites via mixed disulfide linkage 
with N-[6-(biotinamido)hexyl]-3’-(2’-pyi'idyldithio) propionamide (Biotin-HPDP; 
step 3). Biotinylated proteins are then subjected to trypsinolysis (step 4), resulting 
biotinylated-peptides are affinity-captured on streptavidin-agarose (step 5) and 
eluted as the unmodified peptide with (3-mercaptoethanol (|3-ME), which reduces the 
mixed disulfide bond that links biotin to the former SNO-Cys thiol on streptavidin- 
captured peptides (step 6). Finally, peptides (formerly containing SNO-Cys) are 
resolved by nanoLC and amino acid sequence is analyzed by MS/MS with database 
searching.
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capture and efficient recovery of former SNO-peptides in the umnodified form. Because 
the elution of peptides is done under exceedingly gentle conditions, one would not predict 
significant contamination by peptides that bind streptavidin-agarose either non- 
specifically or specifically via biotin incorporated at a non-thiol site (e.g. decarboxylase 
enzymes, where biotin is covalently bound on a Lys e-amino group).
We sought to test the efficacy of this SNO-peptide purification procedure with 
levels of SNO-proteins that may be found in biological settings. Cerebellum was selected 
as a model system because it is known to be a major repository of nNOS in brain (Bredt 
et al, 1991) and prior studies confirmed the presence of endogenous SNO-proteins in 
brains of wild type mice, but not nNOS-nuliozygous mice (Jaffrey et al, 2001). As an 
initial test of the potential of SNOSID to specify SNO-Cys residues, experiments were 
performed using cerebellum lysates in which SNO-protein levels were modestly enriched 
by treatment with relatively low (physiological) levels of GSNO. Notably, levels of 
GSNO as high as 6-8  pM have been detected in rat cerebellum (Kluge et al, 1997) and 
GSNO is implicated as an effector of mammalian NO/cGMP signaling (Mayer et a l,
1998). A physiological role of GSNO in regulating the extent of protein S-nitiosylation in 
vivo is provided by the increased prevalence of SNO-proteins in mice that are 
nullozygous for S-nitrosoglutathione reductase (GSNOR) an enzyme that selectively 
denitrosylates GSNO (Liu et al, 2004).
To quantify the relationship between GSNO concentration and SNO-protein 
content, rat cerebellum lysates (1 mg/ml protein) were pretieated at 37° C for 30 min in 
the dark with varying concentrations of GSNO, from 0 to 30 pM. SNO-proteins were 
then acetone-precipitated to remove unreacted GSNO and nitrite, and protein SNO
1Q6
content was quantified using the Saville-Griess assay. As shown in Figure 5.3A, total 
SNO content of cerebellum proteins under basal conditions was at the limit of detection 
(0.02 -  0.04 pM), but increased progiessively with GSNO concentration. Notably, when 
treated with 10 pM GSNO, the SNO content of cerebellar proteins rose to «3% of the 
total accessible thiol pool (the accessible thiol pool was measured colorimetrically, based 
on the maximal increase in A410 following reaction with an excess of Ellman’s Reagent; 
5,5'-dithiobis-(2-nitrobenzoic acid), (DTNB). All subsequent experiments aimed at 
specification of protein SNO-Cys modification sites were performed using GSNO 
treatments ranging from 0 - 1 0  pM, which give «0.02% -  3.0% occupancy of available 
protein thiols by NO (Fig. 5.3A).
Figure 5.3B shows base peak chromatograms (BPC) and resolution by nLC of 
peptides captured by SNOSID before and after treatment of cerebellar lysates with 5 pM 
GSNO. Before GSNO treatment, a discernible, but very low abundance of peptide ions 
was detected, consistent with a low endogenous expression of SNO-proteins in rat 
cerebellum (Fig. 5.3B, lower panel). Following GSNO treatment, peptide ions were 
found to increase markedly in both abundance and distribution over the BPC (compare 
upper and lower panels in Fig. 5.3B). The substantive increase in detected ions, 
indicative of enhanced SNO-protein levels, is in accord with a s i  00-fold increase in total 
SNO content of proteins observed following treatment with 5 pM GSNO (shown in Fig. 
5.3A).
5.2.2 Identification o f SNO-Cys by nLC-MS/MS and database searching
MS/MS data from experiments, such as that described in Figure 5.3 was analyzed
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Figure 5.3. Application of the SNOSID method for identification of SNO-Cys sites in rat 
cerebellum, before and after GSNO. Panel A: Quantification of SNO-Cys in rat cerebellum 
proteins as a function of GSNO preti*eatment concentration. Cerebellum lysates were incubated 
with the indicated concentrations of GSNO at 37° C for 30 min in the dark. Proteins were 
precipitated in iced-acetone and the SNO-protein content was measured using the Saville-Griess 
assay. Note that of all thiols found to be accessible to modification by 1 mM DTNB (49±2 |,iM 
thiols/mg protein), 2% underwent S-nitrosylation following treatment with 5 pM GSNO (the 
concentration of GSNO used for SNO-peptide analysis and identification in panel B). Points are 
means ±SEM of tiiplicate determinations. Panel B: NanoLC-MS/MS analysis showing base peak 
chromatograms (BPC) of eluted peptide ions (MS mode) as a function of time. Results depict 
SNOSID analysis of a rat cerebellum lysate, before (lower panel) and after (upper panel) treatment 
with 5 pM GSNO. Note the presence of low levels of peptide ions before GSNO treatment and 
detection of abundant ions after treatment.
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using Spectrum Mill software, which compares observed fragmentation patterns of a 
parent ion with a database of predicted fragmentation patterns from an in silico protein 
digest -  in the present case, a tryptic digest of rodent proteins in the SwissProt database.
Table 5.1 lists 68 putative SNO-Cys-containing tryptic peptides derived from 56 
individual proteins that were identified with high stringency (Spectrum Mill score >10, 
and SPI% > 70%) (Moulder et aL, 2005) in at least 3 of 6 experiments, wherein rat 
cerebellum lysates were treated with 2, 5 or 10 pM  GSNO. It is notable that 
identification of a protein based on the inferred sequence of a single tryptic peptide poses 
a significant methodological challenge. If the peptide is too long or too short, present in 
limiting abundance, or provides weak MS/MS spectra for any reason whatsoever, 
sequence information cannot be convincingly established. This limitation left us unable 
to confidently ascribe much of the peptide-derived MS/MS data to a unique protein 
sequence in the database. Notwithstanding this concern about errors of omission, the 
reliability of identified SNO-peptides in Table 5.1 is compelling. First, approximately 
one-quarter of the listed proteins had been previously reported to undergo modification 
by NO and/or have been shown to have their activity altered as a consequence of NO 
exposure. Second, although Cys is a relatively rare amino acid (2.2% representation in 
predicted ORFs in the rat genome; Fig. 5.4), Table 5.1 reveals that 68/69 (98.6%) of 
identified peptides that exceeded the threshold score and SPI% contained at least one 
Cys. It is unclear why one non-tliiol containing peptide (identified as a tryptic peptide 
from glucosamine-fructose-6-phosphate aminotransferase; GRVNFETNTVLLGGLK, 
not included in Table 5.1) was consistently captured with apparently bofta fide SNO-
IQQ
Table 5.1. Identification of SNO-Cys modification sites by the SNOSID 
method in rat cerebellum proteins after treatment with GSNO (1-10 pM).
MS/MS spectra were searched against the Swiss-Prot rodent database using 
Spectrum Mill software. Listed peptides were found in at least three of six 
independent experiments and had a Spectrum Mill score >10 and SPI% >70 (for 
meaning of scores, see Methods). Peptide Cys residues are highlighted in red -  
note tliat 68/69 peptides that exceeded the threshold Spectrum Mill score and 
SPI% were found to contain at least one Cys.
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P rotein  N am e S w issP r o t . A ccn . # P e p tid e  S e q u e n c e
Tubulin alpha Q6P9V9 AVCMLSNTTAIAEAWAR
AYHEQLSVAEITNACFEPANQMVK
SIQFVDWCPTGFK
Tubulin beta P 6 9 8 9 7 EIVHLQAGQCGNQIGAK
LTTPTYGDLNHLVSATMSGVTTCLR
NMMAACDPR
TAVCDIPPR
Sodlum /potasslum -transporting A T P ase P 0 6 6 8 7 LIIVEGCQR
NLEAVETLGSTSTICSDK
YNTDCVQGLTHSK
ADP/ATP tran slocase  1 Q 05962 EFNGLGDCLTK
GADIMYTGTVDCtTR
GAPDH P 0 4 7 9 7 IVSHASCTTNCLAPLAK
VPTPHVSWDLTCR
Mitochondrial glutam ate carrier 1 Q9D6M3 GVNEDTYSGFLDCAR
MYASMSDCLIK
V esicle-fusing A T P ase P 4 6 4 6 0 VFPPEIVEQMGCK
GILLYGPPGCGK
Plasm a m em brane calcium-transporting A T P ase 2 P 1 1 5 0 S HLDACETMGNATAICSDK
TEC6LLGFVLDLR
Sodiu m -d ep en d en t glutam ate/aspartate transporter 1 P 2 4 9 4 2 NMFPPNLVEACFK
Sodium /calcium  exchan ger 2 P 4 8 7 6 8 LLHVSECMGTVDVR
Sodium -dependent glutam ate/aspartate transporter 2 P 3 1 5 9 6 SADCSVEEEPWK
V acuolar ATP sy n th a se  subunit B, brain isoform P 6 2 8 1 5 GPWLAEDFLDIMGQPINPQCR
T riosephosphate isom erase P 4 8 5 0 0 CLGELICTLNAAK
Pyruvate k inase, isozym es M1/M2 P 1 1 9 8 0 AEGSDVANAVLDGADCIMLSGETAK
S uccin ate sem ia ldehyd e d eh yd rogen ase Q8Bt4P0 DMLCITEETFGPLAPVIK
D -3-phosphoglycerate d eh yd rogen ase 0 0 8 6 5 1 NAGTCLSPAVIVGLLR
Malate d eh yd rogen ase , cytoplasm ic P 1 4 1 5 2 VIWGNPANTNCLTASK
6-phosphofructokinase, type C P 4 7 8 6 0 WECVSSILQVGGTIIGSAR
Creatine k inase P 0 7 3 3 5 NYEFMWNPHLGYILTCPSNLGTGLR
Creatine k inase, sarcom eric mitochondrial P 0 9 6 0 5 LGYILTCPSNLGTGLR
D-beta-hydroxybutyrate d eh yd rogen ase P 2 9 1 4 7 FGVEAFSDCLR
Glutam ate d ecarboxylase 65  KD Q 05683 LCALLYGDSEKPAESGGSVTSR
Ciathrin h eavy  chain P 1 1 4 4 2 IHEGCEEPATHNALAK
Reticuion protein 3 Q8VBU0 SCGSSCAVHDLIFWR
Synaptotagm in-2 P 2 9 1 0 1 LTVCILEAK
N -ethyim aieim ide-sensitive factor attachm ent protein, beta P 2 8 6 6 3 ADPQEAINCLNAAIDIYTDMGR
Syntaxin binding protein 1 P 6 1 7 6 5 AAHVFFTDSCPDALFNELVK
N eurotensin receptor type 2 P 7 0 3 1 0 TCRLLSLVWVASLGLALPMAVIMGQK
Synaphin 1 P 8 4 0 8 7 AALEQPCEGSLTRPK
Neuron specific calcium -binding protein hippocalcin P 8 4 0 7 6 DCPTGILNVDEFK
Visinin-tike protein 1 P 6 2 7 6 2 SDPSIVXiLLQCDIQK
B assoon 0 8 8 7 7 8 DACEPESGPDPSTVR
S H 3 and multiple ankyrin repeat dom ains protein 1 Q9WV48 FLENCQARPPPAGTR
MAGUK p55 subfam ily m em ber 2 Q9WV34 DLELTPTSGTLCGSLSGK
MAP kinase k inase 4 P 4 7 8 0 9 ECDFGISGQLVDSIAK
ADP-ribosyiation factor G T P ase activating protein 1 Q 62848 SPSS DSWTCADASTGR
M itogen-activated protein k inase 3 P 2 1 7 0 8 DLKPSNLLINTTCDLK
G uanine nucieotide-binding protein G (o) alpha P 3 0 0 3 3 LWGDSGIQECFNR
Protein k inase C, gam m a P 6 3 3 1 8 LLNQEEGEYYNVPVADADNCSLLQK
Serine/threonine protein p h osp h atase  2B catalytic subunit P 6 3 3 2 9 FKEPPAYGPMCDILWSDPLEDFGNEK
Serine/threonine-protein k inase PCTAlRE-2 0 3 5 8 3 1 LEHEEGAPCTAIR
4 0 S  ribosom ai protein S 3 P 6 2 9 0 8 GLCAIAQAESLR
14-3-3  protein zeta/delta P 6 3 1 0 2 DICNDVLSLLEK
Peptidyi-prolyl cis-trans isom erase  NiMA-interacting 1 Q9QUR7 SGEEDFESLASQFSDCSSAK
Ubiquitin carboxyl-terminal hydrolase isozym e LI Q 00981 NEAIQAAHDSVAQEGQCR
DJ-1 protein 0 8 8 7 6 7 GLIAAICAGPTALLAHEVGFGCK
Carbonic anhydrase-reiated  protein P 2 8 6 5 1 TIPCFNPNTLLPDPLLR
Poiy(rC)-binding protein 1 P 6 0 3 3 5 LW PATQCGSLIGK
Protein farnesyitransferase beta subunit Q 02293 LVDGCYSFWQAGLLPLLHR
U DP-N-peptide N -acelylgiucosam inyltransferase P 5 6 5 5 8 VMAEANHFIDLSQIPCNGK
Glutathione S -transferase P P 0 4 9 0 6 STCLYGQLPK
Glutathione S-transferase theta 2 P 3 0 7 1 3 GQHLSEQFSQVNCLK
60 kDa h eat sh ock  protein 8 P 6 3 0 3 9 AAVEEGIVLGGGCALLR
Myelin proteoiipid protein P 6 0 2 0 3 TSASIGSLCADAR
Dihydropyrimidinase related protein-2 P 4 7 9 4 2 GLYDGPVCEVSVTPK
Caipain 2, large subunit Q 07009 WNDNCPSWNTVDPEVR
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Figure. 5.4. Predicted abundance of amino acids in proteins from rat. There are 20 
naturally occurring amino acids that are incorporated into proteins. However, the actual 
frequency of incorporation varies for each amino acid. The overall usage of cysteine in rat 
proteins, inferred from all predicted ORFs in the rat genome, is approximately 2 .2% 
(Nakamura et al, 2000), making cysteine the second least prevalent amino acid. The 
percentage abundance was calculated based on values obtained from searching the Codon 
Usage Database (Nakamura et al, 2000).
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peptides. Possible explanations include, that this peptide binds to a co-eluting Cys- 
containing peptide-binding partner or that the peptide was missequenced and actually is 
Cys-containing. This marked enrichment of Cys-containing peptides in putative SNO- 
peptides cannot be explained by chance (which predicts one or more Cys in only 26.4% 
of random 12-mer peptides), but is in accord with the requirement that every SNO- 
peptide must contain at least one Cys. Third, the abundance of peptide signals was 
abolished when ascorbate-mediated reduction of the S-NO bond was omitted from the 
procedure, ruling out the possibility that incomplete blocking of free peptide thiols leads 
to significant misrepresentation as SNO-Cys-containing peptides. Finally, detection of 
peptide ions was suppressed by greater than 95% when SNO-proteins in lysates were 
denitrosylated, by prior treatment with 5 mM DTT.
The 56 identified proteins in Table 5.1 belong to diverse functional categories, 
ranging from metabolic enzymes, to structural proteins, ion channels, transporters, 
receptors and signal transduction proteins. These include proteins involved in glutamate 
transport and metabolism: sodium-dependent glutamate/aspartate transporters 1 and 2, 
glutamate decarboxylase and mitochondrial glutamate carrier 1; proteins involved in 
calcium transport and sensing: sodium/calcium exchanger 2 , plasma membrane calcium- 
transporting ATPase 2, hippocalcin and vicinin-like protein-1; receptors and G-proteins: 
neurotensin receptor type 2 and guanine nucleotide binding protein Go alpha; proteins 
that modulate the phosphorylation status of key synaptic proteins: MAP kinase 3, MAP 
kinase kinase 4, Protein Kinase C-y, PCTAIRE-2 (a cdc-2-related Ser/Thr protein kinase) 
and protein Ser/Tlu* phosphatase 2B (calcineurin); proteins involved in synaptic vesicle 
trafficking/docking/recycling: clathrin heavy chain, syntaxin binding protein 1, N-
ethylmaleimide-sensitive factor (NSF) attachment protein beta, bassoon, vesicle-fusing 
ATPase/NSF, ADP-ribosylation factor 1 GTPase-activation protein, and synaptotagmin- 
2. In many cases, NO has been shown to modulate the activity of systems that utilize 
these proteins, whereas the potential role for S-nitrosylation of a critical protein Cys 
residue was not fully explored. One exception is NSF, which was established in brain to 
undergo physiological S-nitiosylation on the Cys residue that we found herein (Cys263), 
resulting in inhibition of exocytosis (Matsushita et al, 2003) and upregulation of AMP A 
receptor expression (Huang et a l, 2005). Considered together, the identified cerebellar 
SNO-peptides listed in Table 5.1 are consistent with a broad role of S-nitrosylation in 
neuroregulation and highlight specific protein Cys residues that may constitute NO- 
mediated cell signaling mechanisms.
5.2.3 Identification o f endogenous SNO-Cys containing peptides
Using native cerebellar lysates (i.e., lysates not exposed to GSNO), six 
endogenous SNO-Cys sites on four distinct proteins were routinely identified. These are; 
Cys295 and Cys376 in a-tubulin, Cys 12 and Cys239 in |3-tubulin, Cys 149 and Cys 153 
(on the same peptide) in glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and 
Cys504 in dihydropyrimidinase-related protein-2/collapsin response mediator protein-2 
(DRP-2/CRMP-2). The sequences of these SNO-Cys peptides and relative ion count 
intensities from untreated lysates (basal nitrosylation) or those treated with increasing 
amounts of GSNO (2, 5 and 10 |.il) are given in Table 5.2. The discovery of peptides 
derived from these particular proteins provides another validation of the SNOSID
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Protein Name Access # Sequence GSNO (nM)
0 2 5 10
Tubulin alpha Q6P9V9 AVCMLSNTTAIAEAWAR 1.1 3.5 26 139
AYHEQLSVAEITOACFEPANQMVK 5.9 11.4 56.8 100
Tubulin beta P69897 EIVHLQAGQCGNQIGAK 0.09 17.6 88.3 199
LTTPTYGDLNHLVSATMSGVTTCLR 0.16 5.83 12 11
GAPDH P04797 IVSNASCTTNCLAPLAK 0.22 2.2 7.8 17.1
Dihydropyrimidinase related protein-2 P47942 GLYDGPVCEVSVTPK 0.23 5.9 21.3 36.9
Table 5.2. Endogenous SNO-Cys residues in rat eerebellai* proteins, identified by the 
SNOSID method, and progressive increases in ion intensity after GSNO treatment.
Values denote MS ion intensities (ion counts x 10^ )^ of endogenous SNO-peptides 
identified endogenously in rat cerebellum lysates ("0" GSNO treatment) and ion intensity 
increases observed after 30 min exposure of lysates to indicated concentrations of GSNO. 
That these ions indeed derive from endogenous SNO-proteins is supported by their lack of 
detection in lysates that had been pretreated with 5 mM DTT (an NO-acceptor) or when 
ascorbate treatment (for reducing Cys-SNO to Cys-SH) was omitted from the assay 
procedure. Depicted results were obtained using a common brain lysate -  similar results 
were obtained in tluee independent experiments.
method, since a- and (3-tubiilin and GAPDH had previously been established to be 
among the most abundant endogenously-expressed SNO-proteins using a western blot 
approach (Jaffrey et a l, 2001; Yang & Loscalzo, 2000). Of these, the only ambiguous 
SNO-Cys site identification is for the GAPDH peptide, which contains two Cys residues 
and hence does not allow us to distinguish whether Cys 149, Cysl53 or both undergo 
endogenous S-nitrosylation. It is notable that Cys 149 was identified as the only 
endogenous SNO-Cys site on GAPDH (using the combined approaches of mutagenesis 
and MS/MS) -  remarkably this modification was found to elicit specific binding of 
GAPDH to Siahl (an E3 ubiquitin ligase), resulting in tianslocation to the nucleus and 
promotion of apoptosis (Hara et al, 2005).
Additional support for peptides listed in Table 5.2 arising from endogenous SNO- 
proteins is provided by loss of their cognate ion counts when the ascorbate-mediated S- 
NO reduction step was omitted from the SNOSID procedure (preventing biotinylation at 
SNO-Cys sites) and their >90% loss when lysates were incubated with 5 mM DTT 
(promoting protein SNO-Cys-denitrosylation). Figure 5.5 shows the extracted ion 
chromatograph (EIC) of m/z equal to 853.4 and 782.9, which are reconciled as doubly- 
charged SNO-peptides derived from SNO-GAPDH (IVSNASCTTNCLAPLAK residues 
143-159; panel A) and dihydiipyiimidinase-related protein-2 (GLYDGPVCEVSVTPK 
residues 497-511; panel B), respectively. For each of these EIC, a single 
clu'omatographic peak was detected for the given m/z (denoted on Fig. 5.5 by inclusion in 
a dotted box) and was undetected when the ascorbate reduction step was omitted from the 
SNOSID procedure. The amino acid sequences of these peptides were provided by
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Figure 5.5. Identification of endogenous SNO-Cys peptides from untreated brains.
A single chromatographic peak was detected in each of the Extracted Ion 
Chromatographs (EIC) at m/z 853.4 and 782.9, which correspond to the expected m/z 
values for doubly-charged SNO-peptides IVSNASCTTNCLAPLAK from GAPDH 
(residue 143-159, panel A) and GLYDGPVCEVSVTPK from DPR-2 (residue 497-511, 
panel B), respectively. The sequence identities of these two peptides were established 
with confidence by MS/MS spectia, shown below each EIC, in which all major daughter 
ions were assigned to an extensive series of y- and b- ion series. The detection of these 
two peaks was abolished in control experiments wherein the ascorbate reduction step 
was omitted from the SNO-protein isolation procedure.
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MS/MS fragmentation analysis, as depicted below each EIC in Figure. 5.5. Similar 
peptide sequence assignments were made based on MS/MS data representing each of the 
four putative tubulin-derived tryptic peptides listed in Table 5.2. When the biotin-swap 
procedure was performed with intact cerebellar proteins rather than tryptic digests, 
additional peptides were identified from GAPDH (Fang et a l, 2000), a-tubulin (six 
peptides) and (3-tubulin (six peptides), and DRP-1 (one peptide), providing further 
confirmation that these are indeed endogenous SNO proteins.
Each of the six endogenous SNO-peptide ions detected was found to increase 
progiessively in intensity, following exposure of cerebellar lysates to increasing 
concentrations of GSNO (0-10 pM) for 30 min. The extent of increase in apparent S- 
nitrosylation, ranged from 16.9-fold (for a-tubulin) to 2,211-fold (for (3-tubulin). 
Although endogenous ion signal intensities were only a fraction of the maximum 
obseiwed for each putative SNO peptide, their relatively low abundance does not preclude 
significant biological consequences. Indeed, nNOS is discretely distributed in the brain 
(Hope et al, 1991), making it likely that endogenous SNO proteins concentrate at nNOS- 
rich brain loci. The further increases in peptide ions elicited by GSNO treatment would 
predictably coiTespond to brain regions with low expression levels of nNOS that may be 
irrelevant to physiological NO signaling. Future studies will be needed to test whether 
SNO proteins are indeed differentially distributed in brain and are concentr ated at sites of 
nNOS expression.
5.2.4 Primaiy sequence analysis o f SNO-proteins
The identification of a single SNO-Cys-containing peptide in 48 out of 56 SNO- 
proteins listed in Table 5.1, suggests that S-nitrosylation can be highly selective, despite
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our currently limited understanding of how selectivity is achieved (Hess et al., 2005). 
With a sufficient knowledge-bank of the protein Cys residues that are most prone to S- 
nitrosylation, it should be possible to distinguish physicochemical features that explain 
the selectivity of S-nitrosylation.
As a first attempt toward elucidating the basis for the specificity of S- 
nitrosylation, we considered whether Cys-flanking residues in the primary amino acid 
sequence predict the susceptibility for SNO-Cys modification, as previously suggested 
(Stamler et al, 1997). It is well known that the primary sequence of residues flanking O- 
phosphorylation (OPH) sites can effectively predict sites of phosphorylation (Blom et al,
1999). By analogy, we asked whether the primary sequence of Cys-flanking residues is 
associated with the relative propensity of the protein to undergo S-nitrosylation at this 
site. To address this question, we used a machine-learning approach to evaluate the 
presence of patterns with the primary sequence of known SNO-proteins, Training sets of 
equal size were used with the same machine-learning protocol for sequence-based 
prediction of SNO and OPH, with OPH sites serving as a positive contr ol and randomly 
assigned SNO and OPH sites as negative controls (see Methods). Figure 5.6 shows the 
prediction performance (FI measure, see methods) as a function of the wirrdow size (i.e., 
the number of residues on each side of the acceptor residue in the primary sequence). 
The values of F 1 for Serine-OPH datasets are consistent with the notion that the kinase 
physically contacts a stretch of 7-12 residues surrounding the acceptor residue (Blom et 
al, 1999). Using the complete OPH dataset, the machine learning protocol used to 
generate data for Figure 5.6 reaches similar performance for OPH sites as previously 
reported (Blom et a l, 1999). For SNO sites, the FI measure increased slightly with
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Figure 5.6. Evaluation of the primary amino acid sequence of identified SNO- 
peptides for Cys flanking residues that may predict S-nitrosylation. The predictive 
performance of flanking residues for S-nitrosylation (SNO) and 0-phosphorylation 
(OPH) sites are compared. For each window size, 20 random samplings for both Ser 
OPH sites and Cys SNO sites were carried out; for each sampling, 65 positive and 65 
negative samples were chosen to obtain a balanced training set of 130 total sites. They 
were from 57 rat/mouse Ser OPH protein sequences (140 Ser sites) and 56 SNO 
rat/mouse protein sequences (65 Cys sites). The negative samples were extracted from 
the other Ser/Cys residues in the same protein sequences. As controls, the same 
number of samplings was carried out without differentiating if the residue is from an 
OPH/SNO site or not, thus the 65 positive and 65 negative samples were randomly 
assigned. Calculations based on these data are denoted as “random”. The F 1 measure, 
which is the harmonic mean of recall and precision, is plotted against size of window 
of flanking residues analyzed.
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window size to a maximum of 3 and then decreased. Notably, with the current number of 
available training examples for S-niti*osylation, the support vector machine model barely 
outperformed random predictions and accordingly, is not usefi.il for predicting SNO sites 
in other sequences. Despite our inability to define a primary sequence motif that predicts 
S-nitrosylation by GSNO under the conditions used, it is conceivable that the SNO-Cys 
residues considered here comprise a subset, selected for susceptibility of S-NO reduction 
by ascorbate (Zhang et a l, 2005); accordingly a primary sequence SNO motif could be 
predictive for SNO proteins identified by using other methods or NO donors. The 
predictive ability of a suggested 3D acid-base flanking residue motif that predicts Cys S- 
nitrosylation (Perez-Mato et a l, 1999; Stamler et a l, 1997) awaits rigorous evaluation.
5,2.5 S-nitrosylation targets specific redox-sensitive thiols
Since a basis for the specificity of S-nitrosylation could not be found in the 
primary sequence of SNO-peptides, presumably key determinants of NO-targeting are 
encoded in the three-dimensional environment of Cys residues. In this regard, it is 
noteworthy that among the 20 Cys residues present in tubulin (8 Cys in the a-subunit and 
12 Cys in the |3-subunit), 4 were identified as sites of endogenous SNO-modification (a- 
Cys295, a-Cys376, p-Cysl2 and |3-Cys239) and 3 additional Cys (a-Cys347, (3-Cys303 
and P-Cys354) were found to undergo S-nitrosylation following treatment with a low 
concentration of GSNO (5 pM). The crystal structure of the tubulin dimer (PDB 
coordinates, ITUB) reveals that, with the exception of (3-Cysl2, none of the NO-targeted 
Cys residues are present on the protein surface (Nogales et a l, 1999). Moreover, these 
Cys residues have previously been found to be most reactive toward thiol-modifying
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reagents, such as DTNB (Kim et a l, 2004; Roychowdliury et a l, 2000). Thus, whereas 
solvent accessibility of Cys does not seem to predict SNO-modification, a low pKa 
(dictating the propensity to form thiolate anion at physiological pH) may be of primary 
importance. Consideration of this finding and subsequent analysis of protein structure 
microenvironments of Tubulin (PDB ID: ITUB), MAPK (PDB ID: 1NY3), ANT-1 (PDB 
ID: lOKC) and GAPDH (PDB ID: IZNQ) (Fig. 5.7) suggests that the 3D environment of 
Cys residues may be a key determinant of its propensity to undergo S-nitrosylation.
Insight into the basis for reactivity of Cys residues in tubulin that undergo 
endogenous S-nitrosylation in tubulin is provided by consideration of the crystal 
structure. Notably, all identified SNO-Cys are located in an enviromnent of net positive 
charge. Additionally, a-Cys295 and a-Cys347 are positioned within 6 Â of a pair of 
aromatic residues (F296/Y319 and W346/F343, respectively; Fig. 5.7, Panel A) with the 
thiol group apparently pointing toward the aromatic ring edge. Tubulin (3-C376 is 
similarly in close proximity for electrostatic interaction with Y272 and in hydrogen bond 
range with a positive residue, R320 (Fig. 5.7, Panel A). Remarkably, electronegative 
sulflirs of Cys are often observed to engage in apparently favorable electrostatic 
interactions with electropositive hydrogens on aromatic rings -  such interactions can 
contribute to protein stiucture stability, particularly in cases where the Cys resides in a 
hydrophobic protein pocket (Kim et a l, 2004; Reid et a l, 1985). Over 50% of protein 
Cys residues in a database of high-resolution structures were reported to be in close 
proximity to aromatic residues, with Cys-sulfur positioned toward the aromatic ring 
hydrogen atoms and apparently engaged in electiostatic interactions (Reid et a l, 1985).
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Figure 5.7. Analysis of the 3D-microenvironment of some SNO-Cys residues 
identified in this study. Three- dimensional structures for the proteins tubulin, 
MAPK protein, ANT-1 and GAPDH were obtained from the protein databank 
(PDB). Cysteines that were identified as S-NO sites were located and the three- 
dimensional microenvironment is rendered. Panel A: the location of three cysteines 
on tln*ee identified SNO-peptides from a-Tubulin. Panels B, C and D: S-NO sites of 
MAPK, ANT-1 and GAPDH, respectively. Consideration of the thiee-dimensional 
structures of all depicted SNO-peptides, reveals close proximity of cysteine (within 
6 Â) to aromatic and basic residues. Abbreviations: Â, angstroms; ANT-1, adenine 
nucleotide translocator-1; GAPDH, glyceraldehyde phosphate dehydrogenase; 
MAPK, mitogen activated protein kinase.
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Such a configuration was similarly noted for Cys 132 in human argininosuccinate 
synthetase, where this structural feature was implicated as a major contributor to the 
activation of Cys 132 for S-nitrosylation in vivo; in contrast, the four additional Cys 
residues on this protein could not be stably S-nitrosylated (Hao et a l, 2004). Hence, we 
propose that the Cys-aromatic interactions, in conjunction with hydiogen-bonding to 
basic residues, serve as a generic structural motif that render Cys residues susceptible to 
S-nitrosylation. Our failure to observe a-Cys315 and a-Cys316 as predominant sites of 
S-nitrosylation on tubulin would argue against the latter view, given that these Cys 
residues exhibit a structural feature that would predictably promote SNO-modification 
and are among the most susceptible to thiol-modifying reagents (Kim et a l, 2004; 
Roychowdhury et a l, 2000). However, this apparent discrepancy may be reconciled by 
knowledge that S-nitrosylation promotes disulfide bond formation between vicinal thiols 
(Amelle & Stamler, 1995); accordingly, if NO were to add to either a-Cys315 or -316, 
crosslinking of the two residues could ensue making them undetectable by oiu assay.
The importance of thiol reactivity (pKa) for S-nitrosylation is further supported 
by consideration of some Cys residues within proteins listed in Table 5.1 that were 
susceptible to S-nitrosylation by low concentrations of GSNO. Indeed, Cys 160 and 
Cys256 in adenine nucleotide translocator-1 (ANT-1) (Fig. 5.7, Panel C) are known to be 
primary targets for oxidative stress that can undergo disulfide bond formation, resulting 
in formation of the permeability transition pore (McStay et a l, 2002). Cys283 of 
cytosolic creatine kinase and the homologous Cys317 of the sarcomeric mitochondrial 
isoform are active-site thiols for which S-nitrosylation was shown to cause inactivation. 
In the case of DJ-1, the identified SNO-peptide contained two Cys residues; one of them.
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Cys 106, was reported as the primary target for oxidation, leading to DJ-1 relocation to 
the mitochondria and subsequent neuroprotectant activity (Canet-Aviles et a l, 2004; 
Kinumi et a l, 2004). Cys299 of protein farnesyltransferase coordinates the zinc to form 
a “zinc finger” (Park et a l, 1997) and zinc finger thiols are well known to be redox-active 
(Webster et a l, 2001). Cys228 of calcineurin (protein phosphatase 2B) is recognized as 
one of two thiols that are most sensitive to oxidation in this protein (Bogumil et a l, 
2000). Very recently, Cys442 of heat shock protein 60 (Hsp60) was reported to be 
alkylated by a natural electrophilic inhibitor, epolactaene (Nagumo et a l, 2005). 
Together, these findings support the general notion that S-nitrosylation preferentially 
targets reactive protein thiols.
5,2.6 S-nitrosylation o f  proteins from  eNOS-derived NO  -  cytosol vs. mitochondria
Preliminary experiments were performed to test whether the subcellular 
localization of eNOS determines the identity of proteins that are accessible to S- 
nitrosylation. COS-7 cells were dual-transfected with pcDNA3-FRAP-eNOS/pC4M- 
Tom5 and tieated with 250 nM AP21967, in the presence or absence of 3 mM NMA. 
Subsequently, the media was removed and cells were treated with A23187 (5 pg/ml) for 
an additional 30 min.
Both immunoprécipitation (Fig. 5.8A) and immuno-histochemical (Fig. 5.8B) 
studies were performed to test for eNOS translocation from cytosol to the outer 
mitochondrial membrane after 60 min of AP21967 treatment. Expression of both FRAP- 
eNOS and FKBP-FKBP-Tom5 were robust in COS-7 cells, as indicated in the Pre-IP 
lanes (Fig. 5.8A). Immunoprecipitates revealed that only in the presence of AP21967
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does association of FRAP-eNOS with FKBP-FKBP-Tom5 occur (Fig. 5.8A, IP lanes). 
High efficiency capture by the anti-HA agarose beads was established by FKBP 
immunoblot findings (Fig. 5.8A). Immunohistochemical results depicted in Figure 5.8B, 
reveal the exclusive association of eNOS with mitochondria after a 60 min, treatment of 
cells with AP21967.
To test for SNO-protein expression a modified biotin-switch assay was performed 
as described in the Methods, with all steps carried out in the dark and at 4°C. Following 
biotinylation, recovered proteins were boiled in non-reducing SDS-PAGE loading buffer 
and 10 pg of each sample was resolved on a 10-20% Tris-glycine gel. High levels of S- 
nitrosylation were observed in A23187-treated, dual-tiansfected COS-7 cells prior to 
treatment with AP21967 (Fig. 5.9A, lane 1). After AP21967 treatment-evoked 
tianslocation of eNOS to the mitochondria, a similar pattern of S-nitrosylation was 
observed (Fig. 5.9A, lane 3). Careful examination of the blot, both visually and by 
densitometry, revealed that several bands appear to change in S-nitrosylation intensity 
when eNOS is cytosolic or mitochondrial (Fig. 5.9A; red arrow depicts one such change). 
As expected, when AP21967-treated cells were pre-incubated in 3 mM NMA there was a 
significant reduction in the overall levels of detectable S-nitroso proteins (Fig. 5.9A, lane 
2 and Fig. 5.9B). Inliibition of S-nitrosylation by NMA confirms that observed SNO- 
modifications are indeed mediated by eNOS-derived NO.
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Figure. 5.8. Association of FRAP-eNOS to the mitochondria in response to 250 nM 
AP21967. COS-7 cells were duai-transfectcd with pcDNA3-FRAP-eNOS/pC4M-Tom5, 
and were incubated in the presence or absence of AP21967. Lysates and 
immunoprecipitated proteins were immunoblotted using both eNOS and FKBP Abs (each at 
1:1000 dilution). A. Demonstrates that FRAP-eNOS translocates to the mitochondria after 
rapalog treatment. B. Illustrates eNOS (green) immunohistochemical findings after 60 min 
of AP21967 treatment. The experiment shows that within 60 min close to 90% of FRAP- 
eNOS is found at the outer mitochondrial membrane. Immunoblots are representative of six 
independent experiments. Immunohistochemistry findings are representative of 50-100 
images analyzed from 3 or more independent experiments. Nuclei were stained with DAPI 
and false colored red.
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Figure. 5.9. Western blot detection of SNO-proteins from transfected COS-7 treated 
with A23187. COS-7 cells were dual-transfccted with pcDNA3-FRAP-eNOS/pC4M-Tom5, 
incubated in media containing rapalog for 12 hrs, pretreated in the presence or absence of 3 
mM NMA for 120 min and subsequently incubated in A23187 for 30 min. Cells were 
harvested and stored at -20°C prior to analysis of SNO-protein content. The modified 
biotin-switch assay was performed as described in the Methods. A. Western blot results 
using a NeutrAvidin-HRP conjugate (1:10,000) to visualize former SNO-proteins. 
Biotinylation was detected by chemiluminescence using a Storm Gel and Blot Imaging 
System. The red arrow indicates a band that differs significantly between rapalog treated 
and untreated cells. B. Densitometric analysis of each respective lane from the immunoblot 
in A. The red asterisk indicates a peak corresponding to the band indicated by the red 
arrow.
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5.3 Discussion
This chapter describes the development of SNOSID, a method for unbiased 
identification of SNO-Cys residues and their cognate proteins in complex biological 
mixtures. Additionally, in preliminary experiments we exploited SNOSID in 
combination with CID technology to reveal eNOS-mediated S-nitrosylation of proteins in 
COS-7 cells wherein eNOS was either diffusible within the cytosol or docked to the outer 
mitochondrial membrane. The combination of CID and SNOSID is anticipated to provide 
a powerful new approach to identify protein SNO-Cys modification sites in distinct 
eNOS-containing subcellular organelles.
Application of the SNOSID method to rat cerebellum allowed for specification of 
68 SNO-Cys on 56 distinct proteins in ^-nitrosoglutathione-treated (2-10 pM) lysates. In 
addition to enumerating these S-nitrosylation sites, the method revealed endogenous 
SNO-Cys modification sites on cerebellum proteins, including a-tubulin, p-tubulin, 
GAPDH, and dihydropyrimidinase-related protein-2. Whereas these endogenous SNO 
proteins were previously recognized, we extend prior knowledge by specifying the SNO- 
Cys modification sites. Considering all 68 SNO-Cys sites identified, a machine learning 
approach failed to reveal a linear Cys-flanking motif that predicts stable transnitrosation 
by 5-nitrosoglutathione under test conditions, suggesting that undefined 3D structural 
features determine S-nitrosylation specificity. SNOSID provides the first effective tool 
for unbiased elucidation of the SNO proteome, identifying Cys residues that undergo 
reversible S-nitrosylation.
Several laboratories have employed the biotin-switch method in combination with 
ID- or 2D-PAGE and in-gel ti-ypsinolysis, for identification of SNO-proteins by mass
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spectrometry (Foster & Stamler, 2004; Gao et a/., 2005; Kuncewicz et a l, 2004; 
Lindermayr et a l, 2005; Martinez-Ruiz & Lamas, 2004; Rhee et a l, 2005). Our aim was 
to increase the sensitivity and range of detectable proteins and ameliorate the labor of 
identifying SNO-proteins one-by-one from limited amounts of cell protein. We sought to 
learn, not only the identity of the S-nitrosylated proteins, but also the specific cysteine 
residues on which the NO modification occurs. Thus to extend the capability of this 
approach, we introduced a proteolytic digestion step following biotinylation and prior to 
avidin capture. This added step provides for the selective isolation of peptides that 
previously contained SNO-Cys residues, rather than the intact SNO-proteins, as isolated 
in the original method. We then exploit nanoflow liquid chromatography tandem mass 
specti'ometry (nLC-MS/MS) as a high-throughput analytical tool for rigorous peptide 
identification, thereby inventorying the set of SNO-Cys modified peptides and, by 
comparison with sequence databases, their parent protein. The inclusion of an additional 
iiLC step can allow a very highly complex sample to be resolved by ion-exchange 
chromatography into multiple simpler ones, further improving the detection of low- 
abundance peptides by separation from relatively abundant peptides. This approach 
should enable identification of greater numbers of potentially biologically relevant S- 
nitrosothiols.
Utility of the SNOSID approach is demonstrated by our identification of 68 SNO- 
Cys residues in 56 rat cerebellar proteins following treatment with 5"-nitrosoglutathione 
(GSNO). Additionally, we specify six endogenously modified SNO-sites on four 
constitutively-nitrosylated cerebellar proteins. To our knowledge, this is the first 
unbiased and large-scale identification of SNO-Cys residues in proteins. To elucidate the
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environment of a given Cys that potentially makes it prone to NO modification, we 
applied a bioinformatic approach that searches for motifs in flanking sequences of 
identified SNO-Cys sites. Whereas a machine learning algorithm and training protocol 
successfully identified sequence patterns that predict 0-phosphorylation, a linear amino 
acid consensus sequence for S-nitrosylation was not identified -  this finding is in contrast 
to a previous suggestion (Stamler et a l, 1997). Instead, the susceptibility of a protein 
thiol to undergo nitrosylation could be encoded in its 3D microenvironment and 
determined by contextual features that remain to be elucidated. Indeed, studies have 
indicated that cysteines that are located within 6 À of flanking basic and acidic residues 
have a higher propensity to undergo S-nitiosylation and denitrosylation reactions (Hess et 
a l , 2005).
In summary, the SNOSID method described here has enabled an unbiased 
identification of SNO-Cys residues in a biologically complex protein mixture. Results 
confirm the presence of endogenous SNO proteins in rat brain and define Cys targets 
therein. With technical advances in nLC-MS/MS-based detection and procedural 
improvements in SNO-protein recovery and bioinformatics detection, it is likely that the 
number of endogenous SNO-Cys residues identified in brain and other NOS-containing 
tissues will expand significantly. Whereas proximity of a protein Cys to NOS may be a 
determinant of NO-targeting selectivity, as implicated for NMDA receptor subunits (Choi 
et a l, 2000) and Dexras (Fang et a l, 2000), features of the Cys environment are likely to 
be predominant. A large data set of high-resolution staictures of SNO-prone protein Cys 
residues will be invaluable for rigorous definition of physicochemical features that 
reconcile protein S-nitrosylation specificity. Future studies using CID for restriction of
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eNOS to desired subcellular loci are anticipated to extend the utility of SNOSID, by 
allowing for specification of site-dependent protein SNO-targets.
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CHAPTER 6
CONCLUDING REMARKS AND FUTURE DIRECTIONS
6.0 Concluding Remarks
eNOS activity is multifactorial - influenced by changes in intracellular Ca'*'^  
concentrations, protein-protein interactions, posttranslational modifications and 
substrate/co factor availability. The localization of eNOS to distinct subcellular loci 
inspired our investigation of the effects of eNOS-targeting, both upon the 
function/regulation of eNOS itself and of its cognate target proteins. Since so little was 
known about eNOS residing at the outer mitochondrial membrane, a native site of eNOS 
localization that has been implicated in the contiol of cellular functions, there were 
numerous important questions to answer. These include: what is the susceptibility of 
mitochondrial eNOS to posttranslational modifications, protein-protein interactions and 
what are the protein-targets of eNOS-derived NO, specific to this locale. Therefore we 
sought to develop a system that can address these questions by designing expression 
plasmids that can specifically target eNOS to mitochondria and other relevant cellular 
organelles, either directly or on-demand.
The body of this thesis describes the development of tools that enable rigorous 
assessment of the consequences of eNOS localization to the outer mitochondrial 
membrane, the mitochondrial matrix, plasma membrane, cytosol, Golgi and nucleus. Our 
findings present the first indication that eNOS docked onto the outer surface of the 
mitochondria is both active and susceptible to phosphoregulation on key residues -  
namely Seri 179 and Ser635. Moreover, preliminary data suggests that cytosolic eNOS-
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derived NO S-nitrosylates a specific pool of proteins that does not change significantly 
when eNOS translocated to the outer surface of the mitochondria. In a separate study we 
developed SNOSID, a novel approach for unbiased identification of SNO proteins in 
complex protein mixtmes. A combination of CID and SNOSID will allow further 
investigations aimed at mapping the intracellular “SNO-proteome”, when eNOS is 
localized to different subcellular organelles and NO synthesis levels are ratcheted up or 
down.
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6.1 Future Directions
The overall goal of this research was to provide a better understanding of the 
complex molecular details underlying the regulation of eNOS and its cognate target 
proteins at different physiologically relevant subcellular loci, with special emphasis on 
the cytoplasmic-face of the outer mitochondrial membrane. The literature relating to 
these aspects of eNOS is ever increasing, but many questions remain and as our 
knowledge increases, new questions will undoubtedly arise.
Much has been learned during the course of this study, but along the way new 
questions have been provoked. Future research directions for this project could be 
pursued either by direct or on-demand targeting of eNOS, combined with other 
approaches described below.
6.1.1 Does subcellular localization o f  eNOS impact on SNO-proteins formed?
A specific aspect of this research that most requires clarification, is the identity of 
protein targets of NO when eNOS is localized to distinct subcellular loci. We 
hypothesize that proximity to eNOS and the presence of a Cys in a favorable 3- 
dimensional context are major deteiminants of the susceptibility of a given protein to 
undergo S-nitrosylation. Accordingly, targeting of eNOS to the outer membrane of 
mitochondria is anticipated to result in enrichment of SNO-proteins in or adjacent to 
mitochondria vs. alternative subcellular loci. Elucidation of the identity and SNO 
modification sites on these proteins is likely to inform on new activities of NO. Follow 
on studies will be driven by oiu* development of SNOSID for unbiased identification of 
low abundance SNO-proteins in complex biological samples and supported by
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preliminary evidence that mitochondria are a repository of SNO-proteins. The goal of 
these studies is global identification of cellular SNO-proteins and determination of 
whether localization of eNOS to mitochondria preferentially targets NO to thiols on 
mitochondrial proteins. Studies will identity SNO-proteins in COS-7 cells expressing 
eNOS on the outer membrane of mitochondria vs. eNOS in the cytosol compared with 
eNOS-null cells (empty vector), before and after stimulation of NO synthesis. Studies 
will use SNOSID, for SNO-peptide identification (Hao et a l, 2006). Veracity of 
identified SNO-proteins will be based on dampened SNO-protein expression following 
24 h cell pretreatment with 3 mM NMA. Preliminary HPDP-biotin labeling studies 
suggest that protein ID will require upscaling of the cell mass used for these experiments 
in order to provide sufficient protein for LC-MS/MS sequencing of basal and stimulus- 
evoked S-nitrosylated peptides from tryptic digests. These studies are intended to 
identify proteins and specific Cys residues that undergo S-nitrosylation following eNOS 
activation by tieatment with various agonistic stimuli. By titrating varying amounts of 
NMA, we anticipate that levels of NO production and thus NO diffusion will be 
progiessively more restricted to limit NO modifications to proximal targets. Presumably, 
in this way we can identify overlapping subsets of SNO-proteins, in addition to SNO- 
proteins that are unique targets of cytosolic and mitochondrial eNOS. As a positive 
control, cells will be treated with 50 pM GSNO to elicit protein S-nitrosylation by 
transniti'osation, rather than activation of endogenous eNOS -  this control will define the 
set of all cellular proteins that can undergo transnitrosylation. To prevent eNOS 
uncoupling and to achieve optimal NO production, cells will be grown in 10 pM 
sepiapterin, an efficient BH4 precursor.
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6.1.2 Does mitochondrial eNOS-derivedNO mediate mitochondrial biogenesis?
The mitochondi'ia are the cells most important organelle, with regard to energy 
production and intermediary metabolism dictating cell life and death. Generation of new 
mitochondria, referred to as mitochondrial biogenesis^ is a highly regulated event 
requiring synchionous expression of several key tianscription factors (for review see 
(Nisoli & Camiba, 2006)). Recent work has focused on the now accepted role of eNOS- 
derived NO on the regulation of the transcription factors, PG C-la and NRF-1, important 
players during mitochondrial biogenesis. However, key questions remain unanswered 
concerning, the source of the NO for control of mitochondi'ial biogenesis (cytosolic, 
mitochondrial or nuclear eNOS) and the possibly synergistic relationship between NO- 
induced apoptosis and biogenesis (Nisoli & Carraba, 2006). The targeted-eNOS 
expression plasmids developed during the course of this thesis provide a foundation for 
the development of cell lines that will enable elucidation of the role of NO in the de novo 
production of mitochondria. Using nuclear- and mitochondrial-restricted eNOS, in 
addition to the native and cytosolic eNOS proteins, we can begin to unravel the 
mechanisms and pathways that govern mitochondrial biogenesis. Despite the low overall 
level of NO production attributed to nuclear eNOS (Jagnandan et a l, 2005), eNOS 
association with target proteins within nuclear signaling complexes, could provide 
localized concentrations of NO that effectively modify nuclear target proteins and 
transcription factors that impact mitochondrial biogenesis. Since mitochondria have been 
implicated in the pathophysiology of several disease states, including neurodegeneration, 
heart failure and type 2 diabetes (Hansford et a l, 1999; Kopecky et a l, 1995; Lehman et
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a l,  2000), the mechanisms by which NO acts as a mediator of mitochondrial biogenetics 
has important implications for our understanding of multiple disease states.
6.1.3 Do eNOSprotein-protein interactions differ at distinct cellular compartments?
Finally, another key piece of missing information involves the identification of 
eNOS-interacting proteins in alternative subcellular loci. These are proteins that are 
anticipated to impact significantly on the local regulation of NO synthesis. The general 
strategy would involve isolating eNOS from alternative subcellular loci along with its 
cognate binding-proteins, before and after rapalog tieatment, using selective pull-down 
experiments. 2D-gel electiophoresis will help resolve eNOS-associated proteins and MS- 
based sequencing will enable unequivocal protein identification. Furthermore, the effect 
of different agonistic stimuli (e.g. VEGF, bradykinin and ATP) will test the influence of 
subcellular localization of eNOS and its relationship to protein-binding partners, as 
influenced by divergent signaling pathways.
6.1.4 Do regulatory modifications o f  eNOS differ at distinct subcellular compartments?
The dynamic nature of eNOS is highly dependent on post-translational 
modifications that regulate eNOS activity and compartmentalization into signaling 
complexes. Phosphorylation of eNOS on specific Ser/Thr residues is the post- 
translational modification that has received most interest in relation to physiological/ 
pathophysiological regulation of eNOS activity (for review see (Fulton et a l, 2001)).
We hypothesize that receptor-mediated changes in eNOS phosphorylation/ 
dephosphorylation will preferentially be initiated when eNOS is initially resident in cell
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membranes that are in proximity to receptor signaling complexes. Accordingly, 
phosphorylation at activating sites (SI 179, S635) and dephosphorylation at inhibitory 
sites (T497) is anticipated to be most rapid and of largest magnitude when eNOS is 
initially resident in caveolae, compared with other more distal sites. Each subcellular 
locus is likely to endow eNOS with a distinct pattern of phosphorylation at Ser/Thr 
residues under investigation. Future, experiments will assess temporal changes in 
phosphorylation status when eNOS is resident at distinct cellular organelles in response 
to stimuli that are receptor-independent (A23187, ortho vanadate), act via G-protein 
coupled receptors (angiotensin, ATP) or act via tyrosine kinase receptors (VEGF, IGF-1). 
Companion studies, looking for compartment-specific eNOS binding partners (as 
described above), will be performed in attempt to identify relevant kinase/phosphatases 
that contribute to the observed pattern of eNOS modification at different cellular sites.
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